galantamine and Alzheimer Disease

galantamine has been researched along with Alzheimer Disease in 638 studies

Research

Studies (638)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	15 (2.35)	18.2507
2000's	317 (49.69)	29.6817
2010's	236 (36.99)	24.3611
2020's	70 (10.97)	2.80

Authors

Authors	Studies
Bores, GM; Effland, RC; Fink, DM; Huger, FP; Kurys, BE; Rush, DK; Selk, DE	1
Greenblatt, HM; Kryger, G; Lewis, T; Silman, I; Sussman, JL	1
Bartolucci, C; Fels, G; Lamba, D; Perola, E; Pilger, C	1
Ingkaninan, K; Khorana, N; Markmee, S; Prachyawarakorn, V; Ruchirawat, S	1
Decker, M; Lehmann, J; Rommelspacher, H; Schott, Y	1
Ge, H; Lin, C; Ma, L; Peng, W; Song, H; Wang, Z; Wen, H; Zhou, Y	1
Andrisano, V; Banzi, R; Bartolini, M; Bergamini, C; Bolognesi, ML; Cattaneo, A; Cavalli, A; Fato, R; Hrelia, P; Lenaz, G; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tarozzi, A; Tumiatti, V	1
Gaube, F; Heilmann, J; Lehmann, J; Rook, Y; Schepmann, D; Schmidtke, KU; Winckler, T; Wünsch, B	1
de Los Ríos, C; Egea, J; Gálvez, E; García, AG; Iriepa, I; León, R; López, MG; Marco-Contelles, J; Moraleda, I; Romero, A; Samadi, A; Villarroya, M	1
Harding, WW; McAnuff, MA; Pecic, S	1
Alvarez-Pérez, M; Chioua, M; Gandía, L; García, AG; González-Lafuente, L; López, MG; Marco-Contelles, J; Ríos, Cde L; Roda, JM; Romero, A; Samadi, A; Soriano, E; Villarroya, M	1
Al-Rashid, ZF; Hsung, RP	1
Arce, MP; Conde, S; del Barrio, L; Egea, J; García, AG; González-Muñoz, GC; León, R; López, B; López, MG; Martín-de-Saavedra, MD; Pérez, C; Rodríguez-Franco, MI; Romero, A; Villarroya, M	1
Boido, V; Carotti, A; Catto, M; Giangreco, I; Nicolotti, O; Novelli, F; Pisani, L; Sparatore, A; Sparatore, F; Tasso, B; Tonelli, M	1
Ding, K; Huang, L; Jiang, H; Li, X; Luo, Z; Su, T; Wang, X	1
Huang, L; Li, XS; Mao, F; Meng, FC; Qin, F; Shan, WJ	1
Beazely, MA; Mohamed, T; Rao, PP; Vasefi, MS; Yeung, JC	1
Bottegoni, G; Cavalli, A; Daniele, S; Goldoni, L; Martini, C; Melchiorre, C; Piomelli, D; Pizzirani, D; Reggiani, A; Rosini, M; Simoni, E; Tarozzo, G; Trincavelli, ML	1
Carotti, A; Catto, M; Cellamare, S; Leonetti, F; Nicolotti, O; Pesce, P; Pisani, L; Stefanachi, A	1
Hu, XJ; Kong, LY; Li, RS; Wang, XB	1
Bag, S; Foster, M; Ghosh, S; LeVine, H; Schifone, C; Sood, A; Török, B; Török, M; Tulsan, R; Zhou, W	1
Kong, LY; Li, JY; Wang, XB; Xie, SS; Yang, L	1
Jiang, N; Kong, LY; Li, SY; Sun, HB; Wang, KD; Wang, XB; Xie, SS; Yao, HQ	1
Boonyarat, C; Reubroycharoen, P; Thiratmatrakul, S; Tohda, M; Vajragupta, O; Waiwut, P; Yenjai, C	1
Adam, BL; Gao, J; Terry, AV	1
Chen, Y; Fang, L; Fang, X; Fleck, C; Gou, S; Huang, Z; Lenhardt, I; Lupp, A; Sun, Y; Zhang, Y	1
Kong, LY; Li, SY; Wang, XB; Xie, SS; Xu, ZC; Yu, WY	1
Kong, LY; Lan, JS; Li, SY; Pan, LF; Wang, XB; Xie, SS	1
Kim, JM; Kim, NJ; Lee, YH; Lee, YS; Ryu, JH; Seo, JM; Shin, MC; Shin, SY; Yun, YD	1
Bag, S; Cho, H; LeVine, H; Redjeb, H; Sood, A; Török, B; Török, M; Tulsan, R; Zhou, W	1
Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š	1
Basile, L; Gazioglu, I; Ginex, T; Guccione, S; Kucukislamoglu, M; Kurt, BZ; Sonmez, F	1
Amooru, GD; Ampasala, DR; Darla, MM; Devineni, SR; Eadlapalli, S; Kotapati, KV; Palaka, BK; Penumala, M; Shaik, JB; Vadde, R	1
Andrisano, V; Bartolini, M; Bolognesi, ML; Brand, GD; Castro, NG; da Silva Boni, M; da Silva, FMR; de Andrade Ramos, G; de Castro Couto, G; de Oliveira, AS; do Nascimento Nogueira, PC; Guimarães, MJR; Korábečný, J; Lemes, LFN; Romeiro, LAS; Romeiro, NC; Silveira, ER; Soukup, O; Souza, INO	1
Amooru Gangaiah, D; Ampasala, DR; Darla Mark, M; Eadlapalli, S; Palaka, BK; Penumala, M; Shaik, JB; Vadde, R	1
Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mobashir, M; Shandilya, A; Singh, A; Tiwari, M	1
Arantes, S; Bacalhau, P; Burke, AJ; Caldeira, AT; Goth, A; Guarda, C; Marques, CS; Martins, R; Peixoto, D; San Juan, AA; Silva, M	1
Beazely, MA; Mohamed, T; Osman, W; Rao, PP; Sit, VM; Vasefi, MS	1
Cañadas, S; García-Font, N; Iodice, C; Marco-Contelles, J; Oset-Gasque, MJ; Pejin, B; Tommonaro, G; Vitale, RM	1
Brazzolotto, X; Chan, S; De la Mora, E; Deora, GS; Dighe, SN; Nachon, F; Parat, MO; Ross, BP	1
Dikmen, M; Karaküçük-İyidoğan, A; Karaman, N; Koçyiğit-Kaymakçıoğlu, B; Oruç-Emre, EE; Öztürk, M; Sıcak, Y; Taşkın-Tok, T	1
Barbosa, FAR; Braga, AL; Canto, RFS; Rafique, J; Saba, S	1
Altomare, CD; Cellamare, S; de Candia, M; Denora, N; Majellaro, M; Tricarico, D; Zaetta, G	1
Cordier, W; Nell, M; Panayides, JL; Riley, DL; Steenkamp, V; van der Westhuyzen, C; van Greunen, DG	1
Basiri, A; Byrareddy, SN; Conda-Sheridan, M; Dutta, D; McCarthy, A; Xiao, M	1
Horton, W; Kugyela, N; Kulkarni, A; LeVine, H; Peerannawar, S; Sood, A; Soule, J; Török, B; Török, M; Tran, CD; Tulsan, R	1
Akram, MS; Rashid, U; Sadiq, A; Sarfraz, M; Sultana, N; Tariq, MI	1
Darekar, MN; Gurjar, AS; Ooi, L; Yeong, KY	1
Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S	1
Akbarzadeh, T; Amini, M; Asadi, M; Bukhari, SNA; Ghobadian, R; Khaleghzadeh-Ahangar, H; Mahdavi, M; Moradi, A; Nadri, H; Sharifzadeh, M	1
Andrisano, V; Cahlikova, L; Hostalkova, A; Hulcova, D; Jun, D; Korabecny, J; Kucera, T; Kunes, J; Marikova, J; Novakova, L; Opletal, L; Perez, DI; Siatka, T	1
Kumar, A; Mishra, P; Panda, G	1
Cai, R; Dong, YF; Geng, SQ; Liu, YM; Wang, LN; Zhu, J	1
Bartolini, M; Belluti, F; Bisi, A; Di Marzo, V; Gobbi, S; Iriepa, I; Ligresti, A; Mahmoud, AM; Montanari, S; Monti, B; Moraleda, I; Naldi, M; Petralla, S; Pruccoli, L; Rabbito, A; Rampa, A; Tarozzi, A	1
Cordier, W; Johan van der Westhuizen, C; Nell, M; Panayides, JL; Riley, DL; Stander, A; Steenkamp, V; van Greunen, DG	1
Ji, J; Peng, Y; Rakesh, KP; Wang, S; Xu, M; Zhu, L	1
Bartolini, M; Bolognesi, ML; Fernández-Bolaños, JG; Franconetti, A; Hicke, J; Lagunes, I; López, Ó; Maya, I; Monti, B; Naldi, M; Padrón, JM; Petralla, S; Poeta, E; Roldán-Peña, JM; Romero-Real, V	1
Cahlíková, L; Carmen Catapano, M; Hulcová, D; Janoušek, J; Jenčo, J; Kohelová, E; Korábečný, J; Kučera, T; Kuneš, J; Maafi, N; Maříková, J; Mecava, M; Nováková, L; Pidaný, F; Prchal, L; Schmidt, M; Shammari, LA; Špulák, M	1
Alcaro, S; Bagetta, D; Burke, AJ; Carreiro, EP; Fernández-Bolaños, JG; Hagenow, S; Leitzbach, L; López, Ó; Marques, C; Moutayakine, A; Stark, H	1
Alexandrova, A; Georgieva, A; Kalfin, R; Lazarova, M; Petkova-Kirova, P; Stefanova, M; Tancheva, L; Tsekova, D; Tsvetanova, E; Uzunova, D; Vezenkov, L	1
Celik Topkara, K; Cetinkaya, A; Demir, S; Kilinc, E; Saylan, A	1
Ai, Y; Cheng, Y; Fan, F; Liu, H; Liu, Q; Shi, X	1
Baakman, AC; Bajenaru, O; Broekhuizen, K; Camps, L; Cohen, A; de Kam, M; Gavan, C; Groeneveld, GJ; Kalisvaart, K; Lemstra, E; Scheltens, P; Schoonenboom, N; Swart, EL; van Doeselaar, L; van Gerven, J	1
Ajavakom, V; Bellingham, RK; Brown, RCD; Camp, NP; Kemp, SC; McLean, NJ; Miller, IR; Moustafa, GAI	1
Cui, Y; Ren, G; Shi, X; Xu, Z	1
Bak, SH; Byeon, GH; Byun, J; Choi, HS; Chun, IK; Heo, J; Hong, Y; Jang, JW; Jeong, CW; Kasani, PH; Kim, JA; Kim, JH; Kim, JK; Kim, KL; Kim, S; Kim, WJ; Kim, Y; Kwon, SO; Lee, DY; Lee, EJ; Lee, K; Lee, SA; Moon, KW; Nam, SJ; Park, JI; Park, SW; Park, YJ; Rhee, HY	1
Aarsland, D; Andersson, T; Berglund, A; Cummings, J; Freund-Levi, Y; Holmgren, S	1
Şahin, S	1
Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA	1
Abbasi, Z; Kalari, M; Khaleghian, A; Moosavi-Nejad, Z; Shasaltaneh, MD	1
Atanasov, A; Danalev, DL; Iwanov, I; Karadjova, V; Lozanov, V; Todorova, R; Vassilev, N; Vezenkov, LT	1
Lamba, D; Pesaresi, A	1
Allam, M; El-Ganainy, SO; Elbahnasi, AI; Ghazy, AA; Gowayed, MA; Mansour, AM; Soliman, OA	1
Atanasova, M; Berkov, S; Dimitrov, I; Doytchinova, I; Georgiev, B; Ivanov, S; Zheleva-Dimitrova, D	1
Boonprasert, R; Bunditvorapoom, D; Kaewsutthi, S; Kijsanayotin, P; Limwongse, C; Senanarong, V; Yaowaluk, T	1
Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML; Masurkar, PP; Sherer, JT	1
Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sadigh-Eteghad, S	1
Hamada, M; Murata, T	1
Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T	1
Lamba, D; Lozanov, V; Pesaresi, A; Tsekova, D; Vezenkov, L	1
Liu, C; Liu, YM; Wang, LN	1
Barić, D; Fodor, L; Horváth, O; Lasić, Z; Lovrić, MJ; Marinić, Ž; Milašinović, V; Mlakić, M; Molčanov, K; Odak, I; Škorić, I	1
Catapano, MC; Chlebek, J; Hošťálková, A; Lomozová, Z; Macáková, K; Mladěnka, P; Parvin, MS	1
Acar, OO; Deniz, FSS; Erdogan Orhan, I; Irmak, S; Luca, SV; Salmas, RE; Sen, A; Skalicka-Woźniak, K; Skiba, A; Tataringa, G; Turgut, GC; Zbancioc, AM	1
Andersen, K; Grøntved, S; Lolk, A; Nielsen, RE; Valentin, JB	1
Elhabak, M; Salama, AAA; Salama, AH	1
Arellano-Martín, I; Bastida, J; Gómez-Murillo, P; Jiménez, C; Lisa-Molina, J; Rodríguez-Escobar, ML; Tallini, LR; Torras-Claveria, L; Viladomat, F	1
Gao, F; Ji, WS; Lei, Y; Shan, LH; Wan, LX; Xiao, Y; Xu, JB; Zhang, Y; Zhou, XL	1
Fan, F; Guo, B; Luo, W; Lv, J; Wang, C; Wang, Y; Yu, H; Zhai, J; Zhang, Z; Zhao, Y	1
Blunden, G; Cahlíková, L; Vrabec, R	1
Girgin, M; Isik, S; Kantarci-Carsibasi, N	1
Achten, E; Beun, S; Clement, P; Moyaert, P	1
Yamada, M	1
Boada, M; Carnero-Pardo, C; Fortea, J; García-Ribas, G; Martínez-Lage, P; Olazarán, J; Sánchez-Juan, P; Viñuela, F	1
Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A	1
Armirotti, A; Bartolini, M; Basagni, F; Bedeschi, M; Bertorelli, R; Bertozzi, SM; Bottegoni, G; Cavalli, A; Lembo, V; Mellor, IR; Minarini, A; Ortega, JA; Rosini, M; Summa, M	1
Han, W; Liao, Y; Shi, W; Wen, J; Zhang, G	1
Antunes, CM; Burke, AJ; Carreiro, EP; Costa, AR; Ernesto, S; Pinto, F; Rodrigues, B	1
Fleet, JL; Garg, AX; McArthur, E; Montero-Odasso, M; Patel, A; Weir, MA	1
Emoto, MC; Fujii, HG; Hisahara, S; Iwahara, N; Kawamata, J; Manabe, T; Matsumura, A; Matsushita, T; Saito, T; Sato-Akaba, H; Shimohama, S; Suzuki, H; Suzuki, S; Yokokawa, K	1
Ahmed, M; Aleya, L; Ashraf, GM; Barreto, GE; Begum, MM; Kabir, MT; Mathew, B; Rahman, MS; Thangapandiyan, S; Uddin, MS	1
Correa-Basurto, J; Farfán-García, ED; Fragoso-Vázquez, MJ; García-Marín, ID; Gómez-López, M; Joseph, E; Miliar-García, Á; Rosales-Hernández, MC; Torres-Ramos, MA; Villalobos-Acosta, DMÁ	1
Sharma, P; Shrivastava, SK; Tripathi, MK	1
Chakkamparambil, B; Friedman, L; Grossberg, GT; Haake, A; Nguyen, K	1
Honjo, Y; Ide, K; Takechi, H	1
Gzielo, K; Krawczyk, M; Nikiforuk, A; Popik, P; Potasiewicz, A	1
Abdel-Daim, MM; Aleya, L; Ashraf, GM; Bin-Jumah, MN; Jeandet, P; Kabir, MT; Mamun, AA; Mansouri, RA; Mathew, B; Uddin, MS	1
Funayama, M; Kurose, S; Mimura, M; Mimura, Y; Tabuchi, H; Takata, T	1
Awasthi, A; Corrie, L; Gulati, M; Kumar Singh, S; Vishwas, S	1
Alexander, M; Ansell, D; Avillach, P; Celis-Morales, C; Collin, E; Egger, P; Gordon, MF; Grosdidier, S; Gungabissoon, U; James, G; Lawrance, M; Mosseveld, M; Mueller, A; Novak, G; Pasqua, A; Pedersen, L; Podhorna, J; Rijnbeek, P; Stewart, R; van der Lei, J; Zaremba-Pechmann, L	1
Barthold, D; Drabo, EF; Ferido, P; Gray, SL; Joyce, G; Marcum, ZA; Zissimopoulos, J	1
Ali, N; Arora, M; Ghai, R; Grover, P; Kapoor, G; Nagarajan, K	1
Alsabbagh, MW; Huang, Y	1
Atanasova, M; Atanasova, T; Doytchinova, I; Ivanov, S; Konstantinov, S; Lukarski, A; Philipova, I; Stavrakov, G; Zheleva, D; Zhivkova, ZD	1
Koola, MM	1
Amenta, F; Ben, DD; Buccioni, M; Lambertucci, C; Marucci, G; Volpini, R	1
Bhanuprakash, K; Chitumalla, RK; Karthikraj, R; Nagaveni, V; Prabhakar, S; Vairamani, M	1
Basar, MK; Baykal, AT; Coskun, J; Gurel, B; Kiris, I; Mroczek, T; Sahin, B	1
Alamiri, B; Husain, K; Naguy, A	1
Chmielewska, K; Dzierzbicka, K; Inkielewicz-Stepniak, I; Kowalski, S; Przybyłowska, M	1
Ganguly, B; Ghosh, S; Jana, K; Wakchaure, PD	1
Han, E; Kalisch Ellett, L; Lee, HJ; Lee, J; Roughead, EE	1
Chang, X; Davies, JRT; Fraser, MD; Rowlands, GE; Vallin, HE	1
Abdel-Daim, MM; Akhtar, MF; Albadrani, GM; Arya, A; Chahal, R; El-Seedi, HR; Kamel, M; Kaushik, D; Khalifa, SMA; Mittal, V; Rahman, MH; Rao, R; Saleem, A	1
Fazal, SA; Haque, SE; Iqubal, A; Iqubal, MK; Pottoo, FH	1
Halminen, O; Hörhammer, I; Linna, M; Mehtälä, J; Mikkola, T; Vesikansa, A; Virta, LJ; Ylisaukko-Oja, T	1
Dunn, T; Howlett, SE; Rockwood, K; Stanley, J	1
Bu, K; Cheng, F; Morris, R; Umeukeje, G	1
Alexandrova, AV; Dragomanova, ST; Gavrilova, PT; Georgieva, AP; Handzhiyski, YS; Kalfin, RE; Kirilov, KT; Lazarova, MI; Papazova, MG; Tancheva, LP; Tsekova, DS; Tsvetanova, ER; Uzunova, DN; Vezenkov, LT	1
Hoffman, D; Howlett, SE; Mitnitski, A; Rockwood, K; Schindler, R	1
Avila, A; Lawler, E	1
Boulouard, M; Dauphin, F; Freret, T; Hamidouche, K; Lecouflet, P; Lelong-Boulouard, V	1
Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D	1
Ribaudo, G; Zagotto, G; Zanforlin, E	1
Ali, MR; Boutajangout, A; Mezei, M; Møller, SG; Sadoqi, M	1
Kaushik, V; Mikobi, E; Raji, MA; Smith, ST	1
Naharci, MI	1
Chang, SY; Dong, L; Feng, M; Guo, X; Hügel, H; Hyde, AJ; Lu, C; May, BH; Xue, CC; Zhang, AL	1
Iyo, M; Oda, Y; Okubo, T; Sato, K; Shirayama, Y; Takahashi, M; Yoshino, K	1
Jiang, S; Lan, J; Pan, K; Yang, J; Yuan, L; Zhang, K; Zhang, Q; Zhang, T; Zhao, Y	1
Atri, A; Ballard, C; Boneva, N; Cummings, JL; Frölich, L; Molinuevo, JL; Raket, LL; Tariot, PN; Windfeld, K	1
Akilo, OD; Choonara, YE; du Toit, LC; Kumar, P; Pillay, V; Pradeep, P	1
Agrawal, M; Alexander, A; Antimisiaris, SG; Chougule, MB; Saraf, S; Shoyele, SA	1
Abe, K; Hishikawa, N; Huang, Y; Li, X; Liu, X; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Shang, J; Shi, X; Takemoto, M; Tian, F; Yamashita, T; Zhai, Y	1
Fujita, Y; Haga, Y; Hanazawa, T; Kamijo, Y; Usui, K; Yoshizawa, T	1
Mishra, DN; Singh, SK	1
Hang, L; Jia, R; Li, J; Liang, J; Wang, Y; Wu, R; Xu, Y; Zhang, H	1
Danchev, ND; Kostadinova, I; Mihaylova, R; Tsekova, DS; Vassilev, NG; Vezenkov, LT	1
Lee, KW; Park, C; Rampogu, S; Son, M; Zeb, A	1
Friedrich, L; Grisoni, F; Merk, D; Schneider, G	1
Ameen, D; Michniak-Kohn, B	1
de Andrade, JP; de Souza Borges, W; El Sohafy, SM; Shawky, E	1
Chan, TY; Chan, WC; Chiu, J; Kng, CPL; Kong, HL; Lam, LCW; Lau, KH; Law, CB; Lin, KL; Ma, SL; Poon, TK; Tam, CCW; Tang, JHY; Tang, NLS; Wat, KHY	1
Klaassen, ES; Klaassens, BL; Rombouts, SARB; van der Grond, J; van Gerven, JMA	1
Eap, CB; Noetzli, M	1
Cesario, A; Del Bufalo, A; Fini, M; Frustaci, A; Russo, P	1
Adorni, F; Caltagirone, C; Di Santo, SG; Musicco, M; Prinelli, F	1
Johnell, K; Sonde, L	1
Brown, JN; Corbo, JM; Moss, JM	1
Gard, PR; Isaac, M; Klugman, A; Richardson, C; Tabet, N	1
Droogsma, E; Huinink, EJ; Schuur, T; van Asselt, DZ; van Steijn, JH	1
Di, R; Lawton, MA; Long, C; Wang, H; Wang, Y; Wu, WH; Xin, L; Yamujala, R	1
Abe, K	1
Londos, E; Minthon, L; Paulsson, E; Wattmo, C	1
Hattori, H	1
Peters, KR	1
Bozoglu, E; Celik, T; Isik, AT; Kaptan, K	1
Birks, J; Craig, D	2
Benitez-Cardoza, CG; Correa-Basurto, J; Hernández-Rodríguez, M; Resendiz-Albor, AA; Rosales-Hernández, MC	1
Farlow, M; Ferris, SH	1
Czarnocki, Z; Granica, S; Jarończyk, M; Kiss, AK; Maurin, JK; Mazurek, AP	1
Kimura, Y; Kobayashi, T; Ohnishi, T; Okuri, Y; Saito, T; Sakiyama, Y; Sugiyama, N; Takahashi, M	1
Cumbo, E; Ligori, LD	1
Guo, T; Hu, R; Huang, H; Irwin, DM; Jin, L; Lei, Z; Li, H; Li, Z; Mao, Y; Niu, G; Song, R; Tan, H; Wang, R; Wang, X; Xu, W; Zhang, X; Zhang, Y; Zhou, N	1
Shimohama, S	3
Gaudig, M; Rettig, K; Richarz, U; Schauble, B	1
Mullangi, R; Ponnayyan Sulochana, S; Sharma, K; Sukumaran, SK	1
Ganesh, A; Ismail, Z; Jalal, H; Lau, R; Lysack, J	1
Ahn, IS; Carroll, BJ; Hwang, TY; Kang, HS; Kim, DK; Ku, HM; Lee, Y; Myung, W; Song, J; Woo, SY	1
Bhattacharya, S; Haertel, C; Maelicke, A; Montag, D	1
Hartikainen, S; Koponen, M; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM	1
Castagna, A; Cotroneo, AM; De Palo, G; Fabbo, A; Forgione, L; Gareri, P; Giacummo, A; Lacava, R; Marino, S; Putignano, D; Putignano, S; Simone, M; Zurlo, A	1
Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC	1
Flores García, JÁ; Tejera Pérez, C	1
Shoji, M	1
Allali, G; Annweiler, C; Beauchet, O; Launay, CP	1
Demir, A	1
Barré, L; Foucout, L; Gourand, F; Levacher, V; Oudeyer, S; Papamicaël, C; Petit, S; Ţînţaş, ML	1
Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A	1
Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC	1
Utsumi, K	1
Augustin, MM; Crow, JA; Kilgore, MB; Kutchan, TM; May, GD; O'Neil-Johnson, M; Starks, CM	1
Cascavilla, L; D'Onofrio, G; Fontana, A; Gravina, C; Greco, A; Paroni, G; Pellegrini, F; Pilotto, A; Seripa, D; Urbano, M	1
Jiang, D; Li, M; Wang, Y; Yang, X	1
Abe, K; Deguchi, K; Hishikawa, N; Matsuzono, K; Nakano, Y; Ohta, Y; Yamashita, T	1
Carmichael, PH; Egberts, T; Kröger, E; Souverein, P; Van Marum, R	1
Bhattacharya, S; Maelicke, A; Montag, D	1
Fujiwara, M; Mizuguchi, Y; Morimoto, T; Ohno, Y; Shimizu, S; Sobue, A	1
Ahmad, M; Basri, M; Fong Yen, W; Ismail, M	1
Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Matsuzono, K; Ohta, Y; Sato, K; Takao, Y; Tokuchi, R; Wakutani, Y; Yamashita, T	1
Buendia, I; Egea, J; León, R; López, MG; Navarro, E; Negredo, P; Parada, E	1
Ahmad, MB; Basri, M; Ismail, M; Masoumi, HR; Woo, FY	1
Hirono, N; Mimura, M; Miyata, J; Nakaaki, S; Nakagawa, A; Negi, A; Oka, M	1
Chamberlin, KW; Ehret, MJ	1
Bakalova, A; Danalev, DL; Danchev, N; Ilieva, L; Nikolova, I; Vassilev, DN; Vezenkov, LT	1
Atanasova, M; Doytchinova, I; Philipova, I; Stavrakov, G; Yordanov, N; Zheleva, D	1
Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Laroche, ML; Mouls, M; Souverein, P; van Marum, R; Wilchesky, M	1
Abe, K; Deguchi, K; Hishikawa, N; Matsuzono, K; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T	1
Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Matsuzono, K; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T	1
Fini, M; Kisialiou, A; Moroni, R; Prinzi, G; Russo, P	1
Chen, X; Cheng, X; Wu, Z; Zhang, Y; Zhao, L	1
Agarwal, S; Arora, N; Devi, CS; Mittal, N; Mohanasrinivasan, V; Priyadoss, CG; Saxena, S; Singh, B	1
Aref, H; Bassil, N; diTommaso, S; Kandiah, N; Lee, JH; Pai, MC; Srinivasan, AV; Yuksel, O	1
Abagyan, R; Ali, TB; Chen, WY; Reilly, BM; Schleret, TR	1
Lewis, SJ; Szeto, JY	1
Babri, S; Mahmoudi, J; Sadigh-Eteghad, S; Talebi, M	1
Kobayashi, H; Nakagawa, R; Ohnishi, T; Yoshizawa, K	1
Berman, A; Blautzik, J; Coates, U; Keeser, D; Kirsch, V; Meindl, T; Paolini, M; Reiser, M; Teipel, SJ	1
Badin, AS; Coen, CW; Garcia-Ratés, S; Greenfield, SA; Heffner, C; Morrill, P; Pottiez, G; Tormo-Garcia, C; Tu, H	1
Minthon, L; Wallin, ÅK; Wattmo, C	2
ElGamal, SS; Farid, RM; Hanafy, AS; Helmy, MW	1
Abe, K; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Shang, J; Yamashita, T; Zhai, Y	1
Caporaso, R; Minarini, A; Rosini, M; Simoni, E	1
Abe, K; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Sun, Z; Yamashita, T; Zhai, Y	1
Matsuda, T	1
Darwish, AS; Kamal, SM; Wahba, SM	1
Abe, K; Feng, T; Fukui, Y; Hishikawa, N; Morihara, R; Nakano, Y; Ohta, Y; Shang, J; Sun, Z; Yamashita, T; Zhai, Y	1
Kos, T; Nikiforuk, A; Popik, P; Potasiewicz, A	1
Abe, K; Fukui, Y; Hishikawa, N; Ohta, Y; Sato, K; Yamashita, T	1
Chopra, K; Medhi, B; Misra, S; Modi, M; Saikia, UN; Sehgal, R; Sinha, VR	1
Caporaso, R; Cavalli, A; Keller, E; Maurice, T; Meunier, J; Minarini, A; Reggiani, AM; Rosini, M; Simoni, E	1
Fišar, Z; Hroudová, J; Singh, N	1
Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM	1
Baseman, AS; Brashear, HR; Davis, B; Hager, K; Han, J; Nye, JS; Richards, HM; Sano, M	1
Choi, SH; Han, HJ; Kim, EJ; Kim, S; Ku, BD; Kwon, JC; Lee, AY; Lee, JH; Moon, SY; Park, JJ; Park, KW; Shim, YS	1
Abe, K; Darwish, M; Hishikawa, N; Ohta, Y; Sato, K; Takemoto, M; Yamashita, T	1
Fusek, J; Pohanka, M; Zakova, J	1
Bassett, K; Carney, G; Dormuth, CR; Fisher, A	1
Wightman, EL	1
Hattori, N; Motoi, Y; Nakanishi, A; Nakayama, S; Suda, A	1
Aarsland, D; Blennow, K; Bloniecki, V; Cummings, J; Falahati, F; Freund-Levi, Y; Winblad, B	1
Abe, K; Fukui, Y; Hishikawa, N; Ichinose, J; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T	1
Boustani, MA; Callahan, CM; Campbell, NL; Fowler, N; Gao, S; Hendrie, HC; Li, L; Perkins, AJ; Skaar, TC	1
Chen, CF; Hsu, HC; Lin, YC; Ouyang, WC	1
Battisti, WP; Berlin, JA; Brashear, HR; Dartigues, JF; Everitt, B; Feldman, HH; Kavanagh, S; Pirttila, T; Van Baelen, B	1
Cuffel, B; Del Valle, M; Mark, TL; McRae, T; Mucha, L; Shaohung, S	1
Amatniek, J; Scharre, DW; Shiovitz, T; Zhu, Y	1
Gartlehner, G; Hansen, RA; Jonas, DE; Moore, CG; Morgan, LC; Webb, AP	1
Taéron, C	1
Chankrachang, S; Nidhinandana, S; Phanthumchinda, K; Poungvarin, N; Praditsuwan, R; Senanarong, V; Tavichachart, N	1
Ellis, JR; Mulligan, RS; Nathan, PJ; Rowe, CC; Saunder, T; Savage, G; Smith, CL; Villemagne, VL; Welch, J; Wesnes, KA; Woodward, M; Young, K	1
Dartigues, JF; Everitt, B; Feldman, HH; Kavanagh, S; Pirttila, T; Schwalen, S; Van Baelen, B	1
Dewailly, P; Gaxatte, C; Huvent-Grelle, D; Puisieux, F; Roche, J	1
Bentué-Ferrer, D; Bordet, R; Förstl, H; Nieoullon, A; Tsolaki, M	1
Farlow, MR	3
Bernabei, R; Bullock, R; Burns, A; Came, E; Cruz Jentoft, AJ; Frölich, L; Hammond, GL; Hock, C; Raivio, M; Schwalen, S; Triau, E; Van Baelen, B; van Oene, JC; Vandewoude, M; Wimo, A	1
Brandt, G; Costantino, HR; Johnson, PH; Leonard, AK; Quay, SC	1
Bolognesi, ML; Cavalli, A; Melchiorre, C	1
Chaly, T; Dhawan, V; Eidelberg, D; Hermann, CR; Kramer, E; Ma, Y; Smith, GS	1
Bennett, C; Carpenter, PK; Mohan, M	1
Chen, SH; Hsieh, YH; Lin, PC; Yang, YH; Yeh, HH	1
Darreh-Shori, T; Eagle, G; Lane, R; Mousavi, M; Nordberg, A; Peskind, E; Soininen, H	1
Blais, L; Forget, A; Kergoat, MJ; Kettani, FZ; Leroux, JC; Perreault, S	1
Agostinho, P; Garção, P; Melo, JB; Oliveira, CR; Sousa, C	1
Hughes, TL; Iraqi, A	2
Fay, S; Hamilton, L; Rockwood, K	1
Errea, JM; García-Gómara, MJ; Modrego, PJ; Pérez Trullen, JM; Rios, C	1
Crutchfield, D	1
Aronson, S; Kavanagh, S; Schwalen, S; Van Baelen, B	1
Bechtel, MA; Coloe, J; Diab, M	1
Smith, DA	1
Lane, R; Venneri, A	1
Kano, M; Kurinami, H; Morishita, R; Niisato, K; Rakugi, H; Sato, N; Shinohara, M; Takeda, S; Takeuchi, D	1
Bokde, AL; Born, C; Hampel, H; Karmann, M; Lieb, M; Möller, HJ; Reiser, MF; Teipel, SJ	1
Morgan, S; Rodda, J; Walker, Z	1
Fay, S; Gorman, M; Rockwood, K	1
Binder, C; Camacho, F; Dalziel, W; Herrmann, N; Smyth, S	1
Chankrachang, S; Nidhinandana, S; Phanthumchinda, K; Poungvarin, N; Praditsuwan, R; Senanarong, V; Thavichachart, N	2
Bozoglu, E; Isik, AT	1
Bozoglu, E; Celik, T; Doruk, H; Isik, AT	1
Hoeffle-Maas, A; Jordis, U; Koepke, AK; Ludwig, J; Maelicke, A; Maus, A; Samochocki, M	1
Gavrilova, SI; Kalyn, IaB; Kolykhanov, IV; Selezneva, ND	1
Dominguez, J; Gauthier, S; Homma, A; Ikeda, M; O'Connor, D; Suh, GH; Wimo, A; Yang, BM	1
Alfonso, V; González-Adalid, M; Jiménez Caballero, PE; Sevilla, C	1
Cantor, MD; Farwell, W; Hernandez, RK; Lawler, EV	1
Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL	1
Kelly, S; Lockhart, IA; Mitchell, SA	1
Leifer, BP	1
Damulin, IV	1
Truter, I	1
Bagnoli, S; Bellavista, E; Benussi, L; Binetti, G; Chiamenti, AM; Crepaldi, G; Cruciani, G; Di Iorio, A; Feraco, E; Franceschi, C; Gabelli, C; Ghidoni, R; Gianni, W; Ginestroni, A; Grimaldi, LM; Marchegiani, F; Minicuci, N; Mishto, M; Nacmias, B; Olivieri, F; Paganelli, R; Santoro, A; Scarpino, O; Scognamiglio, M; Siviero, P; Sorbi, S	1
Ihl, R	1
Hampel, H; Pantel, J; Prvulovic, D	1
Fu, Y; Huang, F	1
Seltzer, B	1
Calciano, MA; Einstein, R; Snyder, PJ; Zhou, W	1
Formiga, F; Fort, I; Regalado, P; Robles, MJ; Rodriguez, D	1
Heinrich, M	1
Claassen, JA; Olde Rikkert, MG; Sijbesma, JC; van Beek, AH	1
Gadzhanova, S; Mackson, J; Roughead, L	1
Aguilar-Gaxiola, SA; Helfand, M; Selker, HP	1
Claassen, JA; Jansen, RW; Rikkert, MG; Sijbesma, JC; van Beek, AH	1
Londos, E; Minthon, L; Wallin, AK; Wattmo, C	1
Agius, M; Dev, H; Zaman, R	1
Borah, B; Sacco, P; Zarotsky, V	1
Dautzenberg, L; Dautzenberg, PL; Thissen, A; Wouters, CJ	1
Criado-Alvarez, JJ; Romo Barrientos, C	1
Egberts, T; Kröger, E; Souverein, P; van Marum, R	1
Fang, J; Li, Q; Wu, D; Yang, M; Zhang, L; Zhang, Y	1
Byrne, GJ; Hollingworth, SA	1
Osborn, GG; Saunders, AV	1
Fujikawa, Y; Kagitani, S; Kitamura, R; Kitamura, Y; Maelicke, A; Saeki, M; Shimohama, S; Takata, K; Taniguchi, T; Terada, M; Tomimoto, H	1
Gaudig, M; Guo, S; Hernandez, L; Wasiak, R	1
Desmarais, JE; Gauthier, S; Massoud, F	1
Forsberg, A; Kadir, A; Keller, C; Nordberg, A; Porras, O	1
Mets, T; Van Puyvelde, K	1
Brashear, HR; Howe, I; Kavanagh, S; Schwalen, S; Todd, M; van Baelen, B; Wang, D	1
Aichenbaum, S; Bentwich, J; Dobronevsky, E; Khaigrekht, M; Marton, RG; Peretz, R; Rabey, JM; Shorer, R	1
de Kanter, FJ; Giera, M; Irth, H; Lingeman, H; Maada, I; Marques, LA; Niessen, WM	1
Kinnair, D; Machili, C; Prettyman, R; Van Diepen, E	1
Bozoglu, E; Isik, AT; Kilic, S; Naharci, MI	1
Bohlken, J; Selke, GW; van den Bussche, H	1
Hüll, M; Voigt-Radloff, S	1
Adami, M; Bruno, G; Gaudig, M; Jacobs, A; Richarz, U; Scarpini, E; Schäuble, B; Zappalà, G	1
Adami, M; Delgado, A; Gaudig, M; Guzman, C; Jedenius, E; Kavanagh, S; Schäuble, B; Van Baelen, B	1
Barbujani, G; Chianella, C; Fuselli, S; Gragnaniello, D; Maisano Delser, P; Sette, E; Tola, MR; Visentini, MF	1
Abbas, SF; Baqi, Y; Chrobak, JJ; Collins, LE; Galtieri, DJ; Leser, CE; Müller, CE; Paul, NE; Podurgiel, SJ; Salamone, JD	1
Gaudig, M; Han, J; Richarz, U; Schäuble, B; Van Baelen, B	1
Butler, R; Gupta, S; Warner, JP	1
Gurkas, E; Orhan, G; Orhan, IE	1
Barone, E; Butterfield, DA; Mancuso, C; Preziosi, P; Siciliano, R	1
Yanagisawa, K	1
Buerger, K; Friese, U; Hampel, H; Likitjaroen, Y; Meindl, T; Teipel, SJ; Wagner, M	1
Okochi, M; Takeda, M; Tanaka, T	1
Bastida, J; Berkov, S; Codina, C; de Andrade, JP; Viladomat, F; Zuanazzi, JA	1
Kavanagh, S; Schäuble, B; Van Baelen, B	1
Harada, Y; Nagino, K; Saito, T; Shikinami, K	1
Andreasen, N; Davis, B; Engedal, K; Han, J; Richarz, U; Schäuble, B	1
Léger, GC; Massoud, F	1
Caraci, F; Drago, F; Fedotova, J; Leggio, GM; Salomone, S	1
Atri, A	1
Stefanacci, RG	1
Aisen, PS; Cummings, J; Schneider, LS	1
Ritter, JM	1
Isaac, M; Klugman, A; Naughton, DP; Petroczi, A; Shah, I; Tabet, N	1
Dams, J; Dodel, R; Neumann, A; Pouryamout, L; Wasem, J	1
Anderson, R; Bond, M; Davis, S; Hoyle, M; Hyde, C; Jeffreys, M; Miners, A; Moxham, T; Peters, J; Rogers, G; Thokala, P; Wailoo, A	1
Nakamura, Y	1
Ateskan, U; Bozoglu, E; Isik, AT; Soysal, P; Yay, A	1
DiBernardo, A; Farnum, M; Lobanov, V; Narayan, V; Novak, G; Raghavan, N; Samtani, MN; Schultz, T; Shi, Y; Verbeeck, R; Yang, E	1
Fesche, A; Frölich, L; Gertz, HJ; Heuser, I; Hüll, M; Jahn, H; Jessen, F; Kornhuber, J; Lorenz, D; Luckhaus, C; Maier, W; Möller, HJ; Pantel, J; Perneczky, R; Peters, O; Rüther, E; Schmidtke, K; Schröder, J; Teipel, S; Wellek, S	1
Coop, A; Cunningham, CW; Motel, WC	1
Hamuro, A	1
Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Souverein, P; van Marum, R	1
Carvajal-Varona, SM; Triana-Vidal, LE	1
Olin, J; Schneider, L	3
Caro, JJ; Garfield, FB; Getsios, D; Wimo, A; Winblad, B	1
Caro, JJ; Getsios, D; Mehnert, A; Salas, M; Ward, A	1
Maelicke, A; Weichel, C	1
Marder, K	1
Lilienfeld, S	1
Ott, BR	1
Capsoni, S; Cattaneo, A; Giannotta, S	1
Erkinjuntti, T	2
Farlow, M; Hock, C; Schwalen, S; van Baelen, B; Wilkinson, DG	1
Howard, R; Sauer, J	1
Kertesz, A	1
Lyseng-Williamson, KA; Plosker, GL	1
Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N	2
García, G; Olazarán, J	1
Carr, R; Finkel, L; Geerts, H; Spiros, A	1
Bucks, RS; Haworth, J; Joffres, C; Rockwood, K; Wilcock, GK	1
Kurz, A	1
Kurz, A; Lilienfeld, S	1
Geerts, H; Lander, C; Woodruff-Pak, DS	1
Kamei, H; Nabeshima, T; Noda, Y	1
Amici, S; Andreasen, N; Antognelli, C; Blennow, K; Davidsson, P; Gallai, V; Lanari, A; Minthon, L; Parnetti, L; Pottel, H; Romani, C	1
Houghton, PJ; Howes, MJ; Perry, NS	1
Blesa, R; Davidson, M; Kurz, A; Reichman, W; Schwalen, S; van Baelen, B	1
Bowler, JV	1
Stallard, N; Todd, S	1
Adler, G; Berger, FM; Calabrese, P; Frölich, L; Gertz, HJ; Hampel, H; Haupt, M; Jendroska, K; Kohler, J; Mielke, R; Paulus, HJ; Pilartz, H; Riepe, MW; Zedlick, D	1
Cutler, NR; Sramek, JJ; Zarotsky, V	1
Farlow, M	1
Kershaw, P; Mintzer, JE	1
Corey-Bloom, J	1
Aerssens, J; Armstrong, M; Piotrovsky, V; Van Osselaer, N; Van Peer, A	1
Lowenthal, MN	1
Bullock, R; Damaraju, CV; Erkinjuntti, T; Kurz, A; Lilienfeld, S; Small, GW	1
Caro, JJ; Getsios, D; Ishak, KJ; Migliaccio-Walle, K; O'Brien, JA; Papadopoulos, G	1
Bullock, R; Coles, H; Howe, I; Kershaw, P; Lilienfeld, S; Truyen, L; Wilcock, G; Zhu, Y	1
Bullock, R; Caro, JJ; Getsios, D; Ishak, K; O'Brien, J; Ward, A	1
Doody, RS	1
Gutterman, EM; Lilienfeld, S; Markowitz, JS; Papadopoulos, G	1
Erkinjuntti, T; Kurz, A; Lilienfeld, S; Small, G	1
Butler, R; Prabhakaran, P; Warner, J	1
Raskind, MA	1
Kavanagh, S; Sano, M; van Baelen, B; Wilcock, GK	1
Bullock, R; Erkinjuntti, T; Lilienfeld, S	1
Fuchsberger, T; Hampel, H; Möller, HJ	1
Anderson, J; Choudhury, T; Dale, MC; Libretto, SE; McCafferty, F; McWilliam, C; Patterson, C; Richardson, M	1
Alhainen, K	1
Damaraju, CR; Erkinjuntti, T; Kurz, AF; Lilienfeld, S; Small, GW	1
Goldlist, B; Gordon, M; Naglie, G	1
Kaufer, DI	1
Aarsland, D; Bahra, R; Hager, K; Jones, RW; Murthy, A; Passmore, P; Soininen, H; Zhang, R	1
Haen, E; Ibach, B	1
Alisky, JM	1
Gavrilova, SI; Zharikov, GA	1
Damaraju, CV; Kershaw, P; Peskind, ER; Raskind, MA; Truyen, L	1
Cummings, JL; Kershaw, PR; Schneider, L; Tariot, PN; Yuan, W	1
Crawford, VL; Passmore, AP; Patterson, CE	1
Rioux, S	1
Kabathova, P; Kavanagh, S	1
Dengiz, AN; Kershaw, P	1
Markowitz, JS; Papadopoulos, G; Sadik, K; Stahl, SM	1
Francis, PT; Payne-Parrish, J; Schwam, E; Wilkinson, DG	1
Heinrich, M; Lee Teoh, H	1
Kudo, T	1
Giannakopoulos, P; Monsch, AU	1
Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E	1
Galasko, D; Kershaw, PR; Schneider, L; Tariot, PN; Zhu, Y	1
Prasher, VP	1
Feldman, H; Portet, F; Reynish, E; Vellas, B; Voisin, T	1
Birks, J; Evans, JG; Wilcock, G	1
Kurz, A; Van Baelen, B	1
van Dyck, CH	1
Caramelli, P; Charchat-Fichman, H; Chaves, ML; Engelhardt, E; Machado, JC; Schultz, RR; Vale, FA	1
Caro, J; Garfield, F; Getsios, D; Migliaccio-Walle, K; Salas, M; Ward, A	1
Allgaier, C; Arendt, T	1
Dani, JA; Zhang, L; Zhou, FM	1
Herrmann, N; Lanctôt, KL; Thompson, S	1
Bernardi, G; Giordano, A; Koch, G; Marciani, MG; Palmieri, MG; Panella, M; Pierantozzi, M; Stanzione, P; Stefani, A	1
Catte, O; Cossu, G; Maccioni, E; Melis, G; Melis, M; Putzu, PF; Putzu, V	1
Loy, C; Schneider, L	2
Edwards, K; Gorman, C; Therriault O'connor, J	1
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X	1
Damaraju, CV; Pirttilä, T; Truyen, L; Wilcock, G	1
Aguglia, E; Maso, E; Onor, ML; Saina, M	1
Hammond, G; Orgogozo, JM; Schwalen, S; Small, GW; Van Baelen, B	1
Barkhof, F; Goekoop, R; Hibbel, A; Jonker, C; Knol, DL; Rombouts, SA; Scheltens, P; Truyen, L	1
Choi, S; Ho Lee, J; Hong, I; Hoon Oh, B; Ju, YS; Jung, HY; Kil Yeon, B; Nam Bae, J; Park, J; Suh, GH; Uk Lee, C; Yeon Jung, H	1
Bullock, R; Truyen, L	1
Babić, T; Mahović Lakusić, D; Petrovecki, M; Sertić, J; Stavljenić-Rukavina, A	1
Geerts, H	1
Arya, P; Butler, R; Warner, J	2
Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D	1
Garre-Olmo, J; Gelada-Batlle, E; Hernández-Ferràndiz, M; Isern-Vila, A; López-Pousa, S; Lozano-Gallego, M; Majó-Llopart, J; Morante-Muñoz, V; Pericot-Nierga, I; Turon-Estrada, A; Vilalta-Franch, M	1
Harry, RD; Zakzanis, KK	1
Chi, CW; Hong, CJ; Ko, SY; Lin, KN; Liu, HC; Liu, TY; Wang, HC; Wang, PN	1
Happich, M; Mühlbacher, A; Schweikert, B	1
Howe, I; Wilkinson, DG	1
Bullock, R	1
Ellis, JM	1
Amezcua, H; Carter, MF; Chow, G; Cummings, JL; Davoodi, P; Dinov, ID; Mega, MS; O'Connor, SM; Porter, V; Reback, E	1
Brashear, HR; Hing, JP; Kimko, H; Piotrovsky, V; Zhao, Q	1
Borson, S; Kaufer, DI; Kershaw, P; Sadik, K	1
Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N	1
Binder, C; Herrmann, N; Rabheru, K; Wang, J	1
Bullock, R; Dengiz, A	1
Brodaty, H; Corey-Bloom, J; Damaraju, CR; Gold, M; Potocnik, FC; Truyen, L	1
Aisen, PS	2
Schölzel-Dorenbos, CJ	2
Beck-Bornholdt, HP; Kaduszkiewicz, H; van den Bussche, H; Zimmermann, T	1
Chen, HZ; Dong, CZ; Ezoulin, MJ; Heymans, F; Li, J; Massicot, F; Ombetta, JE; Wu, G	1
De Deyn, PP; Van Dam, D	1
Scheltens, P; Verhey, FR; Visser, PJ	1
O'Neill, MF	1
Brashear, HR	1
Lublin, HK; Olsen, CE; Poulsen, HD	1
Cunha, L; De Deyn, PP; Gertz, HJ; Hammond, G; Schwalen, S; Vellas, B; Wesnes, K	1
Barreiro, EJ; Bolzani, Vda S; Fraga, CA; Viegas, C	1
Barkhof, F; Goekoop, R; Rombouts, SA; Scheltens, P	1
Choi, S; Hong, I; Ju, YS; Jung, HY; Kee, BS; Kim, J; Kim, YH; Ko, D; Lee, CU; Lee, N; Lee, SK; Oh, BH; Suh, GH	1
Cummings, JL	1
Jelic, V; Kivipelto, M; Winblad, B	1
Clegg, A; Green, C; Kirby, J; Loveman, E; Payne, E; Picot, J; Takeda, A	2
Castro, A; Martinez, A	1
Davis, B; Sadik, K	1
do Carmo Carreiras, M; García, AG; Marco-Contelles, J; Rodríguez, C; Villarroya, M	1
Birks, J	1
Kaduszkiewicz, H	1
Fay, S; Gorman, M; MacKnight, C; Rockwood, K; Song, X	1
Kragten, JA; Leentjens, AF	1
Lemeshko, ID; Mazal'skaia, OV; Petrukhin, AS; Pylaeva, OA; Voronkova, KV	1
Butler, R; Warner, J; Wuntakal, B	1
Cummings, JL; Ringman, JM	1
Brashear, HR; Dunbar, F; Zhu, Y	1
Hulihan, J; Spivey, JM	1
Nourhashémi, F	1
Cors, OS; Estrada, AT; Franch, JV; Gelada-Batlle, E; López-Pousa, S; Nierga, IP; Olmo, JG	1
Kloft, C; Schwalbe, O; Wunderlich, S	1
Gilbert, S; Kergoat, MJ; Kerneis, S; Legrain, S; Vantelon, C; Wolmark, Y	1
Geerts, H; Grossberg, GT	1
Edwards, KR; Grossberg, GT; Zhao, Q	1
Beck, C; Blank, K; Colenda, CC; Doraiswamy, MP; Kalunian, DA; Lyketsos, CG; Yaffe, K	1
Dybicz, SB; Erwin, WG; Keohane, DJ; McRae, T; Shah, SN	1
Plosker, GL; Robinson, DM	2
Ancoli-Israel, S; Cooke, JR; Corey-Bloom, J; Fiorentino, L; Harrison, T; Liu, L; Loredo, JS; Marler, M	1
Blennow, K; de Leon, MJ; Zetterberg, H	1
Takatori, Y	1
Sivaprakasam, K	1
Garre Olmo, J; López-Pousa, S; Pericot Nierga, I; Soler Cors, O; Turon Estrada, A; Vilalta Franch, J	1
Verhey, FR	1
Brissos, S; Dias, VV; Gorman, JM	1
Huang, J; Marszalec, W; Narahashi, T; Toth, PT; Yeh, JZ; Zhao, X	1
Johannsen, P	1
Allen, G; Barnes, N; Boundy, K; Brodaty, H; Woodward, M	1
Almkvist, O; Blomquist, G; Darreh-Shori, T; Eriksson, B; Grut, M; Kadir, A; Långström, B; Nordberg, A; Wall, A	1
Amatniek, J; Jelic, V; Kershaw, P; Winblad, B	1
Capellà, D; Vidal, X	1
Robert Brashear, H; Spivey, JM	1
Chu, LW; Chung, CP; Mok, W; Yik, PY	1
Beier, MT	1
Campanozzi, MD; Casali, E; Martini, E; Neri, M; Neviani, F	1
Ehlis, AC; Fallgatter, AJ; Herrmann, MJ; Plichta, MM; Richter, MM	1
Almkvist, O; Blomquist, G; Darreh-Shori, T; Grut, M; Kadir, A; Långström, B; Nordberg, A; Ringheim, A; Strandberg, B; Wall, A	1
Barnes, N; Boundy, K; Brodaty, H; Woodward, M	1
Asp, E; Fay, S; Jarrett, P; Rockwood, K	1
Candelise, L; Cantisani, TA; Celani, MG; Cusi, C; Incorvaia, B; Righetti, E	1
De Raedt, R; Gorus, E; Lambert, M; Mets, T	1
Forbes-McKay, KE; McGeown, WJ; Ries, M; Shanks, MF; Venneri, A; Waiter, GD	1
Albuquerque, EX; Lopes, C; Njar, V; Pereira, EF; Purushottamachar, P; Schwarcz, R; Wu, HQ	1
Aerssens, J; Alvidrez, J; Anand, R; Faison, WE; Farrer, LA; Jarvik, L; Manly, J; McRae, T; Mintzer, JE; Murphy, GM; Olin, JT; Regier, D; Sano, M; Schultz, SK	1
Egert, S; Förstl, H; Wagenpfeil, S	1
Basun, H; Cederholm, T; Eriksdotter-Jönhagen, M; Faxén-Irving, G; Freund-Levi, Y; Garlind, A; Grut, M; Palmblad, J; Vedin, I; Wahlund, LO	1
Bonham, J; Connelly, PJ; Cousland, G; Prentice, NP	1
Dai, D; Mitnitski, A; Rockwood, K	1
Amatniek, J; Coyle, JT; Geerts, H; Sorra, K	1
Baker, AS; Brandt, J; Lyketsos, CG; Mayer, LS; McNabney, M; Onyike, CU; Rosenblatt, A; Samus, QM	1
Wong, VS	1
Anghelescu, I; Heuser, I	1
Green, C	1
Agelan, A; Del Valle, L; Woodruff-Pak, DS	1
Neno, R	1
Fellgiebel, A	1
Barkhof, F; Fox, NC; Korf, ES; Scheltens, P; van de Pol, LA; van der Flier, WM	1
Lang, CJ	1
Bär, KJ; Boettger, MK; Mentzel, HJ; Sauer, H; Seidler, N; Terborg, C	1
Bajda, M; Malawska, B; Musiał, A	1
Engel, J; Hager, K; Kenklies, M; McAfoose, J; Münch, G	1
García, AG; López, MG; Marco-Contelles, J; Villarroya, M	1
Bogetto, F; Marino, F; Montemagni, C; Perrone, D; Rocca, P	1
Razay, G; Wilcock, GK	1
do Carmo Carreiras, M; Marco, L	1
Ames, D; Ashby, D; Birks, J; Kaduszkiewicz, H; van den Bussche, H; Zimmermann, T	1
Landmark, K; Reikvam, A	1
Choi, S; Jung, HY; Lee, CU; Suh, GH	1
Brashear, R; Bullock, R; Erkinjuntti, T; Gauthier, S; Hammond, G; Kurz, A; Schwalen, S; Zhu, Y	1
Brashear, HR; Feldman, H; Gauthier, S; Mayorga, AJ; Nye, JS; Scinto, L; Truyen, L; Wang, D; Wilcock, GK; Winblad, B	1
Downey, D	1
Cook, C; Fay, S; Rockwood, K	1
Allali, G; Assal, F; Beauchet, O; Herrmann, FR; Kressig, RW	1
Bahro, M; Berger, M; Gann, H; Hohagen, F; Lis, S; Riemann, D; Stadmüller, G	1
Johansson, M; Nordberg, A	1
Bores, GM; Camacho, F; Davis, L; Huger, FP; Kosley, RW; Mutlib, AE; Petko, W; Rush, DK; Selk, DE; Vargas, HM; Wolf, V	1
Benfield, P; Fulton, B	1
Mielke, R	1
Bastos, JK; Burandt, CL; McChesney, JD; Mikell, J; Moraes-Cerdeira, RM; Nanayakkara, D; Thurn, J	1
MacGowan, SH; Scott, M; Wilcock, GK	1
Brückner, A; Cvitkovich, B; Czollner, L; Fröhlich, J; Jordis, U; Kremser, L; Küenburg, B; Rizzi, A; Schuh, R	1
Havel, J; Patocka, J; Pokorná, L; Revilla, A	1
Albuquerque, EX; Maelicke, A	1
Peskind, ER; Raskind, MA; Wessel, T; Yuan, W	1
Ding, C; Kershaw, P; Lilienfeld, S; Morris, JC; Solomon, PR; Tariot, PN	1
Bucks, RS; Byrne, LM; Hughes, AO; Wilcock, GK; Wilson, PM	1
Santos, IS; Woodruff-Pak, DS	1
Maelicke, A	3
Lilienfeld, S; Parys, W	1
Cutler, NR; Frackiewicz, EJ; Sramek, JJ	1
Stahl, SM	2
Gaens, E; Lilienfeld, S; Wilcock, GK	1
Goa, KL; Scott, LJ	1
Giacobini, E	1
Kashiwagi, Y; Kudo, T; Nakamura, Y; Nishikawa, T; Shinosaki, K; Takeda, M; Tanaka, T	1
Andreasen, N; Blennow, K; Davidsson, P; Eriksson, B; Hesse, C; Minthon, L	1
Albuquerque, EX; Fehrenbacher, A; Jostock, R; Ludwig, J; Maelicke, A; Samochocki, M; Zerlin, M	1
Coyle, J; Kershaw, P	1
Thompson, CA	1
Morris, JC	1
Dunbar, F; Rasmusen, L; Robillard, A; Yan, B	1
Ferris, SH	1
Farlow, MR; Ferris, SH; Kurz, AF; Maelicke, A; Morris, JC; Rasmusen, L; Wilkinson, D; Yan, B	1
Small, G	1
Bartolucci, C; Fels, G; Lamba, D; Pilger, C; Tropsha, A	1
Hake, AM	1
Slagle, MA	1
Caro, G; Caro, JJ; Getsios, D; Ishak, K	1
Murray, J; Wilkinson, D	1
Mintzer, J; Rockwood, K; Truyen, L; Wessel, T; Wilkinson, D	1
Lee, MR	1
Tariot, PN	1
Albuquerque, EX; Alkondon, M; Maelicke, A; Pereira, EF; Santos, MD	1
Winblad, B	1
Sternon, J; Ventura, M	1
Pearson, VE	1
Schwam, EM; Subbiah, P	1
Gasser, T; Gasser, US	1
Tariot, P	1
Iyer, GR; Truyen, L; Verhaeghe, T; Zhao, Q	1
Allain, H; Bentue-Ferrer, D; Lecavorzin, P; Polard, E; Reymann, JM; Tribut, O	1
Schneider, LS	1
Bullock, R; Damaraju, CV; Erkinjuntti, T; Gauthier, S; Kurz, A; Lilienfeld, S	1
Garrido Barral, A; González Moneo, MJ	1
Robert, P	1
Dal-Bianco, P; Deecke, L; Hufgard, J; Koch, G; Lind, C; Maly, J; Marschall, I; Mraz, M; Wôber, C	1
Bickel, U; Fischer, JP; Kewitz, H; Thomsen, T	1
Kewitz, H; Thomsen, T	1

Reviews

185 review(s) available for galantamine and Alzheimer Disease

Article	Year
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018). Bioorganic & medicinal chemistry, 2019, 03-15, Volume: 27, Issue:6 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Ligands; Neuroprotective Agents	2019
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships. European journal of medicinal chemistry, 2019, Oct-15, Volume: 180 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship; Triazoles	2019
The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review. Journal of Alzheimer's disease : JAD, 2022, Volume: 85, Issue:3 Topics: Activities of Daily Living; Alzheimer Disease; Amino Acids; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Ginkgo biloba; Humans; Nootropic Agents; Patient Safety; Plant Extracts; Rivastigmine	2022
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis. Current Alzheimer research, 2022, Volume: 19, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Network Meta-Analysis; Nootropic Agents; Randomized Controlled Trials as Topic; Rivastigmine	2022
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ open, 2022, 04-26, Volume: 12, Issue:4 Topics: Adult; Alzheimer Disease; Donepezil; Galantamine; Humans; Memantine; Network Meta-Analysis; Nootropic Agents; Rivastigmine	2022
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews. European journal of clinical pharmacology, 2022, Volume: 78, Issue:10 Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Glycogen Synthase Kinase 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indans; Lithium; Melatonin; Memantine; Neurodegenerative Diseases; Rivastigmine; Systematic Reviews as Topic	2022
Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease. International journal of molecular sciences, 2023, Feb-23, Volume: 24, Issue:5 Topics: Acetylcholinesterase; Aged; Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans	2023
Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review. Journal of Alzheimer's disease : JAD, 2023, Volume: 93, Issue:4 Topics: Acetylcholinesterase; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Dementia; Galantamine; Humans; Indans; Parkinson Disease; Perfusion; Phenylcarbamates; Piperidines; Rivastigmine	2023
[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)]. Brain and nerve = Shinkei kenkyu no shinpo, 2023, Volume: 75, Issue:5 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Memantine; Receptors, N-Methyl-D-Aspartate; Rivastigmine	2023
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. Drugs & aging, 2023, Volume: 40, Issue:11 Topics: Acetylcholinesterase; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Sleep Initiation and Maintenance Disorders	2023
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning. Current pharmaceutical design, 2019, Volume: 25, Issue:33 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Repositioning; Galantamine; Humans; Rivastigmine; Tacrine	2019
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease. Expert opinion on drug safety, 2020, Volume: 19, Issue:2 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Rivastigmine	2020
Combination Drug Therapy for the Management of Alzheimer's Disease. International journal of molecular sciences, 2020, May-05, Volume: 21, Issue:9 Topics: Alzheimer Disease; Animals; Biomarkers; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Management; Disease Susceptibility; Dopamine Agents; Drug Therapy, Combination; Galantamine; Humans; Memantine	2020
Current Strategies and Novel Drug Approaches for Alzheimer Disease. CNS & neurological disorders drug targets, 2020, Volume: 19, Issue:9 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Mice; Phytotherapy; Plant Preparations; Rats; Rivastigmine	2020
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review. Pharmacology research & perspectives, 2020, Volume: 8, Issue:4 Topics: Alzheimer Disease; Animals; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Rivastigmine	2020
Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond. Psychiatry research, 2020, Volume: 293 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Humans; Memantine; Nootropic Agents; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate	2020
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology, 2021, 06-01, Volume: 190 Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Humans; Receptors, N-Methyl-D-Aspartate; Rivastigmine	2021
Galantamine beyond Alzheimer's disease-a fact or artefact? CNS spectrums, 2022, Volume: 27, Issue:3 Topics: Alzheimer Disease; Artifacts; Cholinesterase Inhibitors; Galantamine; Humans	2022
Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer's Disease Therapy. Biomolecules, 2021, 02-25, Volume: 11, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Rivastigmine; Sesquiterpenes	2021
Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease. Current molecular pharmacology, 2022, Volume: 15, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Dietary Supplements; Donepezil; Galantamine; Humans	2022
Alzheimer Disease: Monotherapy vs. Combination Therapy. American family physician, 2017, Apr-01, Volume: 95, Issue:7 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Piperidines; Rivastigmine	2017
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Expert opinion on drug safety, 2017, Volume: 16, Issue:9 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Piperidines; Rivastigmine; Severity of Illness Index	2017
An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds. Current medicinal chemistry, 2017, Nov-17, Volume: 24, Issue:34 Topics: Alzheimer Disease; Amyloid beta-Peptides; Apolipoproteins E; Biological Products; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; Receptors, Nicotinic; tau Proteins	2017
Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease. American journal of Alzheimer's disease and other dementias, 2018, Volume: 33, Issue:2 Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Comorbidity; Donepezil; Galantamine; Polypharmacy; Rivastigmine	2018
Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes. International journal of geriatric psychiatry, 2018, Volume: 33, Issue:3 Topics: Alzheimer Disease; Asia, Eastern; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Medicine, Traditional; Memantine; Nootropic Agents; Piperidines; Plant Extracts; Rivastigmine	2018
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of controlled release : official journal of the Controlled Release Society, 2018, 07-10, Volume: 281 Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier; Brain; Deferoxamine; Donepezil; Drug Carriers; Drug Liberation; Galantamine; Humans; Mucociliary Clearance; Nanoparticles; Nasal Mucosa; Nose; Olfactory Bulb; Risperidone; Tissue Distribution	2018
Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review. Clinical interventions in aging, 2018, Volume: 13 Topics: Alzheimer Disease; Antiparkinson Agents; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Rivastigmine	2018
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clinical pharmacokinetics, 2013, Volume: 52, Issue:4 Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Pharmacogenetics; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine	2013
Multitarget drugs of plants origin acting on Alzheimer's disease. Current medicinal chemistry, 2013, Volume: 20, Issue:13 Topics: Alkaloids; Alzheimer Disease; Animals; Biological Products; Cholinesterase Inhibitors; Crocus; Drug Discovery; Galantamine; Galanthus; Ginkgo biloba; Humans; Huperzia; Neuroprotective Agents; Physostigmine; Plant Extracts; Plants; Salvia; Sesquiterpenes	2013
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. Journal of Alzheimer's disease : JAD, 2013, Volume: 35, Issue:2 Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Disability Evaluation; Disease Progression; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2013
[Nicotinic acetylcholine receptor in Alzheimer's disease]. Nihon rinsho. Japanese journal of clinical medicine, 2013, Volume: 71, Issue:4 Topics: Alzheimer Disease; Galantamine; Humans; Receptors, Nicotinic; Synaptic Transmission; Thalamus; Treatment Outcome	2013
[Effectiveness and limitation of newly approved drugs for Alzheimer's disease]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2013, Volume: 115, Issue:1 Topics: Alzheimer Disease; Clinical Trials as Topic; Galantamine; Humans; Japan; Memantine; Phenylcarbamates; Quality of Life; Rivastigmine	2013
Galantamine for vascular cognitive impairment. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2006
Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors. Clinical interventions in aging, 2013, Volume: 8 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Communication Disorders; Donepezil; Galantamine; Humans; Indans; Outcome Assessment, Health Care; Phenylcarbamates; Piperidines; Rivastigmine	2013
Drugs for cognitive loss and dementia. Treatment guidelines from the Medical Letter, 2013, Volume: 11, Issue:134 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Rivastigmine	2013
[Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions]. Rinsho shinkeigaku = Clinical neurology, 2013, Volume: 53, Issue:11 Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinergic Neurons; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Molecular Targeted Therapy; Neuroprostanes; Phenylcarbamates; Piperidines; Rivastigmine	2013
Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease. Biomedical chromatography : BMC, 2014, Volume: 28, Issue:11 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tandem Mass Spectrometry	2014
Cholinesterase-inhibitor Associated Mania: A Case Report and Literature Review. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2014, Volume: 41, Issue:2 Topics: Aged; Alzheimer Disease; Bipolar Disorder; Brain; Cholinesterase Inhibitors; Female; Galantamine; Humans; Positron-Emission Tomography	2014
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Journal of Alzheimer's disease : JAD, 2014, Volume: 41, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2014
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon	2014
Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis. CNS drugs, 2014, Volume: 28, Issue:6 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Gait; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Piperidines	2014
[Progress of dementia medicine: Special reference to Alzheimer's disease]. [Hokkaido igaku zasshi] The Hokkaido journal of medical science, 2014, Volume: 89, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Magnetic Resonance Imaging; Memantine; Neurofibrillary Tangles; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Tomography, Emission-Computed, Single-Photon	2014
Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. Journal of neural transmission (Vienna, Austria : 1996), 2015, Volume: 122, Issue:8 Topics: Alzheimer Disease; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2015
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Clinical therapeutics, 2015, Volume: 37, Issue:8 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Piperidines; Rivastigmine; Treatment Outcome	2015
Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease. Current drug targets, 2017, Volume: 18, Issue:10 Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Gene Expression Regulation; Humans; Indans; Male; Pharmacogenomic Variants; Piperidines; Polymorphism, Single Nucleotide; Treatment Outcome; Up-Regulation	2017
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. Current neuropharmacology, 2016, Volume: 14, Issue:4 Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Exercise Therapy; Galantamine; Humans; Indans; Memantine; Parkinson Disease; Piperidines; Rivastigmine; Sleep Wake Disorders; Treatment Outcome	2016
The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. International journal of geriatric psychiatry, 2016, Volume: 31, Issue:8 Topics: Aged; Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Network Meta-Analysis; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2016
Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics. Future medicinal chemistry, 2016, Volume: 8, Issue:6 Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Molecular Targeted Therapy; Piperidines; Rivastigmine; Structure-Activity Relationship	2016
Psychopharmacological Studies in Mice. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2016, Volume: 136, Issue:5 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; Drug Discovery; Environment; Female; Galantamine; Indans; Male; Mental Disorders; Mice; Molecular Targeted Therapy; Motivation; Piperidines; Psychopharmacology; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1D; Receptors, Dopamine D2; Research; Rivastigmine	2016
Potential benefits of phytochemicals against Alzheimer's disease. The Proceedings of the Nutrition Society, 2017, Volume: 76, Issue:2 Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Ginkgo biloba; Humans; Melissa; Panax; Phytochemicals; Plant Extracts; Resveratrol; Rivastigmine; Salvia officinalis; Stilbenes; Terpenes	2017
Analyses of mortality risk in patients with dementia treated with galantamine. Acta neurologica Scandinavica, 2009, Volume: 119, Issue:1 Topics: Age of Onset; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Follow-Up Studies; Galantamine; Humans; Institutionalization; Male; National Institute of Neurological Disorders and Stroke (U.S.); Personality Inventory; Randomized Controlled Trials as Topic; Survival Analysis; Survivors; Time Factors; Treatment Outcome; United States	2009
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clinical interventions in aging, 2008, Volume: 3, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2008
[Relation between Pisa syndrome and choline esterase inhibitors in a cohort of Alzheimer's disease patients]. Presse medicale (Paris, France : 1983), 2009, Volume: 38, Issue:1 Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Dystonia; Galantamine; Humans; Indans; Male; Piperidines; Syndrome	2009
Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Current medical research and opinion, 2008, Volume: 24, Issue:12* Topics: Acetylcholine; Activity Cycles; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Memory; Sleep Stages	2008
Intranasal administration of acetylcholinesterase inhibitors. BMC neuroscience, 2008, Dec-10, Volume: 9 Suppl 3 Topics: Administration, Intranasal; Alzheimer Disease; Animals; Blood-Brain Barrier; Central Nervous System Diseases; Cholinesterase Inhibitors; Galantamine; Humans	2008
Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009, Volume: 6, Issue:1 Topics: Alkanes; Alzheimer Disease; Amides; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anisoles; Antioxidants; Aspartic Acid Endopeptidases; Attention; Choline; Drug Design; Ethylamines; Galantamine; Humans; Memory; Neurons; Phosphorylation; Plaque, Amyloid; Platelet Aggregation Inhibitors; tau Proteins	2009
Galantamine for dementia in people with Down syndrome. The Cochrane database of systematic reviews, 2009, Jan-21, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Down Syndrome; Galantamine; Humans	2009
Discontinuing Alzheimer's disease drug therapy: why, when, and how. Director (Cincinnati, Ohio), 2008,Winter, Volume: 16, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Approval; Drug Monitoring; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Selection; Phenylcarbamates; Piperidines; Prevalence; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Failure; United States; Withholding Treatment	2008
Treatment of Alzheimer's disease in the long-term-care setting. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, May-15, Volume: 66, Issue:10 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Humans; Indans; Long-Term Care; Memantine; Phenylcarbamates; Piperidines; Rivastigmine	2009
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. International psychogeriatrics, 2009, Volume: 21, Issue:5 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Mental Disorders; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2009
Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dementia and geriatric cognitive disorders, 2009, Volume: 28, Issue:5 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2009
[Anti-dementia drugs for dementia syndromes--just unkept promises?]. MMW Fortschritte der Medizin, 2006, May-15, Volume: Spec no. 2 Topics: Alzheimer Disease; Clinical Trials as Topic; Dopamine Agents; Galantamine; Ginkgo biloba; Humans; Memantine; Meta-Analysis as Topic; Nootropic Agents; Phytotherapy; Plant Preparations; Syndrome	2006
Galantamine for Alzheimer's disease. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:3 Topics: Alzheimer Disease; Controlled Clinical Trials as Topic; Galantamine; Humans	2010
A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Current clinical pharmacology, 2010, Volume: 5, Issue:2 Topics: Administration, Oral; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Galantamine; Half-Life; Humans; Protein Binding; Tissue Distribution	2010
Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. Clinical interventions in aging, 2010, Feb-02, Volume: 5 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double Bind Interaction; Galantamine; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Severity of Illness Index	2010
Galanthamine from Galanthus and other Amaryllidaceae--chemistry and biology based on traditional use. The Alkaloids. Chemistry and biology, 2010, Volume: 68 Topics: Alzheimer Disease; Galantamine; Galanthus; Humans; Liliaceae; Molecular Structure; Phytotherapy	2010
Current treatments for patients with Alzheimer disease. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:9 Suppl 8 Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory Amino Acid Antagonists; Galantamine; Health Status; Humans; Memantine; Neuroprotective Agents; Parasympathomimetics; Phenylcarbamates; Psychomotor Agitation; Psychotherapy; Psychotic Disorders; Rivastigmine; Time Factors; United States; United States Food and Drug Administration	2010
Switching cholinesterase inhibitors in older adults with dementia. International psychogeriatrics, 2011, Volume: 23, Issue:3 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Treatment Outcome	2011
[Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales]. Psychiatrische Praxis, 2011, Volume: 38, Issue:5 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Caregivers; Donepezil; Galantamine; Geriatric Assessment; Ginkgo biloba; Humans; Indans; Institutionalization; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine	2011
Galantamine and behavior in Alzheimer disease: analysis of four trials. Acta neurologica Scandinavica, 2011, Volume: 124, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Disorders; Randomized Controlled Trials as Topic	2011
Dementia. BMJ clinical evidence, 2010, Apr-08, Volume: 2010 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Dementia; Galantamine; Humans; Memantine	2010
An overview on natural cholinesterase inhibitors--a multi-targeted drug class--and their mass production. Mini reviews in medicinal chemistry, 2011, Volume: 11, Issue:10 Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Huperzia; Liliaceae; Sesquiterpenes	2011
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:9 Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Memantine; Neurons; Oxidative Stress; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Rivastigmine	2011
[Newly approved drugs for Alzheimer disease: effectiveness and limitation]. Brain and nerve = Shinkei kenkyu no shinpo, 2011, Volume: 63, Issue:8 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome	2011
New drugs for Alzheimer's disease in Japan. Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:5 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Japan; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine	2011
[Pharmacological and clinical profiles of galantamine (Reminyl(®))]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2011, Volume: 138, Issue:3 Topics: Acetylcholine; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Learning; Memory; Neuroprotective Agents; Randomized Controlled Trials as Topic; Receptors, Nicotinic	2011
Pharmacological treatment of Alzheimer disease. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2011, Volume: 56, Issue:10 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Neuropsychological Tests; Piperidines	2011
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. British journal of clinical pharmacology, 2012, Volume: 73, Issue:4 Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Plaque, Amyloid; Rivastigmine; tau Proteins	2012
Effective pharmacological management of Alzheimer's disease. The American journal of managed care, 2011, Volume: 17 Suppl 13 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome	2011
The costs of Alzheimer's disease and the value of effective therapies. The American journal of managed care, 2011, Volume: 17 Suppl 13 Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Health Care Costs; Health Expenditures; Humans; Indans; Medicare; Medicare Part D; Memantine; Piperidines; Psychometrics; United States	2011
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harbor perspectives in medicine, 2012, Volume: 2, Issue:3 Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Donepezil; Drug Approval; Galantamine; Ginkgo biloba; Half-Life; History, 20th Century; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Psychotropic Drugs; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Sesquiterpenes; Vitamin B Complex; Vitamin E	2012
Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs, 2012, Apr-16, Volume: 72, Issue:6 Topics: Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Drug Costs; Economics, Pharmaceutical; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Piperidines; Quality-Adjusted Life Years	2012
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health technology assessment (Winchester, England), 2012, Volume: 16, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine; Technology Assessment, Biomedical	2012
A novel subject synchronization clinical trial design for Alzheimer's disease. Journal of Alzheimer's disease : JAD, 2012, Volume: 31, Issue:3 Topics: Alzheimer Disease; Clinical Trials as Topic; Disease Progression; Galantamine; Humans; Nootropic Agents; Research Design	2012
Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease. Mini reviews in medicinal chemistry, 2013, Volume: 13, Issue:3 Topics: Allosteric Regulation; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Ligands; Opioid Peptides; Receptors, Nicotinic; Receptors, Opioid	2013
Galantamine for Alzheimer's disease. The Cochrane database of systematic reviews, 2002, Issue:3 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Galantamine; Humans; Multicenter Studies as Topic; Nootropic Agents; Randomized Controlled Trials as Topic	2002
[New theory! Galantamine and nicotinic-cholinergic transmission]. Pharmazie in unserer Zeit, 2002, Volume: 31, Issue:4 Topics: Alzheimer Disease; Animals; Galantamine; Humans; Parasympathetic Nervous System; Receptors, Nicotinic; Synaptic Transmission	2002
Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS drug reviews, 2002,Summer, Volume: 8, Issue:2 Topics: Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Caregivers; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Galantamine; Humans; Nootropic Agents; Psychiatric Status Rating Scales; Receptors, Nicotinic; Treatment Outcome	2002
Medical treatment of Alzheimer's disease: past, present, and future. Medicine and health, Rhode Island, 2002, Volume: 85, Issue:7 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome	2002
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. International journal of technology assessment in health care, 2002,Summer, Volume: 18, Issue:3 Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost of Illness; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2002
Treatment options: the latest evidence with galantamine (Reminyl). Journal of the neurological sciences, 2002, Nov-15, Volume: 203-204 Topics: Alzheimer Disease; Cerebrovascular Disorders; Dementia, Vascular; Endpoint Determination; Galantamine; Humans; Multicenter Studies as Topic; Nootropic Agents; Randomized Controlled Trials as Topic	2002
Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy. Journal of neural transmission. Supplementum, 2002, Issue:62 Topics: Aged; Alzheimer Disease; Galantamine; Humans; Nootropic Agents; Receptors, Nicotinic	2002
A novel treatment for patients with Alzheimer's disease and with vascular dementia. Annals of the New York Academy of Sciences, 2002, Volume: 977 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Galantamine; Humans; Phytotherapy	2002
Nicotinic cholinergic modulation: galantamine as a prototype. CNS drug reviews, 2002,Winter, Volume: 8, Issue:4 Topics: Acetylcholine; Allosteric Regulation; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Learning; Ligands; Memory; Models, Animal; Models, Biological; Receptors, Nicotinic; Synaptic Transmission	2002
[Anti-dementia drugs for Alzheimer disease in present and future]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2002, Volume: 120, Issue:1 Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; tau Proteins	2002
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytotherapy research : PTR, 2003, Volume: 17, Issue:1 Topics: Alkaloids; Alzheimer Disease; Estrogens, Non-Steroidal; Galantamine; Humans; Isoflavones; Physostigmine; Phytoestrogens; Phytotherapy; Plant Extracts; Plant Preparations; Plants, Medicinal; Sesquiterpenes	2003
Galantamine hydrobromide: an agent for Alzheimer's disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Mar-01, Volume: 60, Issue:5 Topics: Allosteric Regulation; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dose-Response Relationship, Drug; Formularies as Topic; Galantamine; Half-Life; Humans; Receptors, Nicotinic	2003
A clinical overview of cholinesterase inhibitors in Alzheimer's disease. International psychogeriatrics, 2002, Volume: 14 Suppl 1 Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2002
Galantamine: a review of its use in Alzheimer's disease and vascular dementia. International journal of clinical practice, 2003, Volume: 57, Issue:3 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Galantamine; Humans	2003
Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. International journal of geriatric psychiatry, 2003, Volume: 18, Issue:8 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; Female; Galantamine; Humans; Male; Models, Econometric; Nootropic Agents; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sensitivity and Specificity; United Kingdom	2003
Current treatments for Alzheimer's disease: cholinesterase inhibitors. The Journal of clinical psychiatry, 2003, Volume: 64 Suppl 9 Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2003
Dementia. Clinical evidence, 2003, Issue:9 Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phosphatidylcholines; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine; Vitamin E	2003
Update on Alzheimer drugs (galantamine). The neurologist, 2003, Volume: 9, Issue:5 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans	2003
[Current therapy of patients with dementia]. MMW Fortschritte der Medizin, 2003, May-26, Volume: 145 Suppl 2 Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dementia; Dementia, Vascular; Donepezil; Dopamine Agents; Female; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Meta-Analysis as Topic; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Plant Preparations; Prospective Studies; Rivastigmine; Tacrine; Time Factors	2003
[Mechanisms of action of Alzheimer medications]. Duodecim; laaketieteellinen aikakauskirja, 2003, Volume: 119, Issue:20 Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Rivastigmine	2003
Clinical pharmacokinetics of galantamine. Clinical pharmacokinetics, 2003, Volume: 42, Issue:15 Topics: Adult; Aged; Alzheimer Disease; Area Under Curve; Biological Availability; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Interactions; Female; Galantamine; Half-Life; Humans; Male; Middle Aged	2003
Acetylcholinesterase inhibition in Alzheimer's Disease. Current pharmaceutical design, 2004, Volume: 10, Issue:3 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine	2004
[Galantamine (reminyl) in the treatment of Alzheimer's disease and vascular dementia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2003, Volume: 103, Issue:12 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Drug Therapy, Combination; Galantamine; Humans; Treatment Outcome	2003
Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs & aging, 2004, Volume: 21, Issue:7 Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Animals; Behavioral Symptoms; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Tolerance; Galantamine; Humans; Indans; Piperidines; Rats; Receptors, Nicotinic	2004
Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. Journal of ethnopharmacology, 2004, Volume: 92, Issue:2-3 Topics: Alzheimer Disease; Animals; Biological Availability; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Galanthus; Georgia (Republic); Humans; Nootropic Agents; Treatment Outcome	2004
[Drug therapy for aged patients with Alzheimer disease]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2004, Volume: 106, Issue:1 Topics: Aged; Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Cholinesterase Inhibitors; Donepezil; Drug Design; Endopeptidases; Enzyme Inhibitors; Galantamine; Humans; Indans; Piperidines; Severity of Illness Index	2004
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. International journal of geriatric psychiatry, 2004, Volume: 19, Issue:6 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine	2004
What are the treatment options for patients with severe Alzheimer's disease? CNS drugs, 2004, Volume: 18, Issue:9 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome	2004
Evidence-based pharmacotherapy of Alzheimer's disease. The international journal of neuropsychopharmacology, 2004, Volume: 7, Issue:3 Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Research Design; Rivastigmine	2004
Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration. Dementia and geriatric cognitive disorders, 2004, Volume: 18, Issue:2 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Multicenter Studies as Topic; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2004
[Galantamine, an acetylcholinesterase inhibitor with various actions]. Medizinische Monatsschrift fur Pharmazeuten, 2004, Volume: 27, Issue:7 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans	2004
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert opinion on drug safety, 2004, Volume: 3, Issue:5 Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseases; Cholinesterase Inhibitors; Clinical Trials as Topic; Comorbidity; Donepezil; Double-Blind Method; Drug Evaluation; Drug Interactions; Female; Galantamine; Gastrointestinal Diseases; Humans; Indans; Institutionalization; Longitudinal Studies; Male; Memantine; Meta-Analysis as Topic; Mice; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Single-Blind Method; Sleep Wake Disorders; Treatment Outcome	2004
Galantamine for Alzheimer's disease. The Cochrane database of systematic reviews, 2004, Oct-18, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Galantamine; Humans; Multicenter Studies as Topic; Nootropic Agents; Randomized Controlled Trials as Topic	2004
Mechanisms of action of cognitive enhancers on neuroreceptors. Biological & pharmaceutical bulletin, 2004, Volume: 27, Issue:11 Topics: Alzheimer Disease; Animals; Donepezil; Galantamine; Humans; Indans; Nicotinic Agonists; Nootropic Agents; Piperidines; Pyrrolidinones; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic	2004
Indicators of neuroprotection with galantamine. Brain research bulletin, 2005, Jan-30, Volume: 64, Issue:6 Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Galantamine; Glutamic Acid; Humans; In Vitro Techniques; Indicators and Reagents; Models, Biological; Neuroprotective Agents; Treatment Outcome	2005
Dementia. Clinical evidence, 2004, Issue:11 Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E	2004
A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. Human psychopharmacology, 2005, Volume: 20, Issue:3 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Male; Nootropic Agents; Piperidines; Treatment Outcome	2005
Galantamine: use in Alzheimer's disease and related disorders. Expert review of neurotherapeutics, 2004, Volume: 4, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Galantamine; Humans	2004
Cholinesterase inhibitors in the treatment of dementia. The Journal of the American Osteopathic Association, 2005, Volume: 105, Issue:3 Topics: Acetylcholine; Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost of Illness; Dementia; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index	2005
Dementia. Clinical evidence, 2004, Issue:12 Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine	2004
Reduction of caregiver burden in Alzheimer's disease by treatment with galantamine. CNS spectrums, 2005, Volume: 10, Issue:6 Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cost of Illness; Depression; Employment; Galantamine; Humans; Sleep Wake Disorders	2005
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. International journal of clinical practice, 2005, Volume: 59, Issue:7 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Long-Term Care; Phenylcarbamates; Piperidines; Rivastigmine	2005
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. Journal of the American Academy of Nurse Practitioners, 2005, Volume: Suppl Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Management; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome	2005
[Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands]. Tijdschrift voor gerontologie en geriatrie, 2005, Volume: 36, Issue:3 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Galantamine; Humans; Memantine; Netherlands; Phenylcarbamates; Rivastigmine; Treatment Outcome	2005
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ (Clinical research ed.), 2005, Aug-06, Volume: 331, Issue:7512 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2005
Drug therapy of dementia in elderly patients. A review. Nordic journal of psychiatry, 2005, Volume: 59, Issue:2 Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2005
New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors. Mini reviews in medicinal chemistry, 2005, Volume: 5, Issue:10 Topics: Acetylcholine; Alzheimer Disease; Biodiversity; Brain; Cholinesterase Inhibitors; Galantamine; Humans	2005
Clinical trials in mild cognitive impairment: lessons for the future. Journal of neurology, neurosurgery, and psychiatry, 2006, Volume: 77, Issue:4 Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Lactones; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index; Sulfones; Vitamin E	2006
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. International journal of geriatric psychiatry, 2006, Volume: 21, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2006
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:1 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Galantamine; Humans; Physostigmine; Protein Conformation	2006
Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy. Dementia and geriatric cognitive disorders, 2006, Volume: 21, Issue:2 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Circadian Rhythm; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Sleep; Sleep, REM	2006
Synthesis and pharmacology of galantamine. Chemical reviews, 2006, Volume: 106, Issue:1 Topics: Alzheimer Disease; Animals; Biomimetics; Cholinesterase Inhibitors; Galantamine; Humans; Models, Chemical; Nootropic Agents	2006
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health technology assessment (Winchester, England), 2006, Volume: 10, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Evidence-Based Medicine; Female; Galantamine; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome; United Kingdom	2006
Galantamine for Alzheimer's disease and mild cognitive impairment. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Galantamine; Humans; Multicenter Studies as Topic; Nootropic Agents; Randomized Controlled Trials as Topic	2006
Galantamine for vascular cognitive impairment. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2006
Cholinesterase inhibitors for Alzheimer's disease. The Cochrane database of systematic reviews, 2006, Jan-25, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine	2006
Dementia. Clinical evidence, 2005, Issue:14 Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine	2005
Current and emerging pharmacological treatment options for dementia. Behavioural neurology, 2006, Volume: 17, Issue:1 Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine	2006
Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. Journal of clinical pharmacology, 2006, Volume: 46, Issue:7 Suppl 1 Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Memantine; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic	2006
Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. Journal of clinical pharmacology, 2006, Volume: 46, Issue:7 Suppl 1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Severity of Illness Index	2006
Alzheimer's disease. Lancet (London, England), 2006, Jul-29, Volume: 368, Issue:9533 Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Male; Molecular Biology; Phenylcarbamates; Piperidines; Plaque, Amyloid; Positron-Emission Tomography; Randomized Controlled Trials as Topic; Rivastigmine; tau Proteins	2006
[Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2006, Volume: 126, Issue:8 Topics: Alzheimer Disease; Animals; Cell Death; Cells, Cultured; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Galantamine; Glutamates; Humans; Indans; Neurons; Neuroprotective Agents; Phosphatidylinositol 3-Kinases; Piperidines; Rats; Receptors, Nicotinic; Tacrine	2006
Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation. Current medicinal chemistry, 2006, Volume: 13, Issue:18 Topics: Alkaloids; Alzheimer Disease; Amyloid; Cholinergic Fibers; Cholinesterase Inhibitors; Galantamine; Inflammation; Neurofibrillary Tangles; Plaque, Amyloid; Receptors, Nicotinic; Sesquiterpenes	2006
[Pharmacotherapy for Alzheimer's disease]. Tijdschrift voor psychiatrie, 2006, Volume: 48, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2006
[Medical treatment of Alzheimer's disease]. Ugeskrift for laeger, 2006, Oct-02, Volume: 168, Issue:40 Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2006
Galantamine extended release in Alzheimer's disease: profile report. Drugs & aging, 2006, Volume: 23, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Clinical Trials as Topic; Delayed-Action Preparations; Galantamine; Humans; Nootropic Agents; Treatment Outcome	2006
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacotherapy, 2007, Volume: 27, Issue:3 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Mental Disorders; Piperidines; Time Factors	2007
Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. International psychogeriatrics, 2007, Volume: 19, Issue:3 Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Donepezil; Ethnicity; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Thiazoles; White People	2007
[Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies]. Deutsche medizinische Wochenschrift (1946), 2007, Jun-01, Volume: 132, Issue:22 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Publication Bias; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index; Treatment Outcome	2007
Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. Journal of Alzheimer's disease : JAD, 2007, Volume: 11, Issue:4 Topics: Allosteric Regulation; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Humans; Nootropic Agents; Receptors, Nicotinic	2007
[Acetylcholinesterase inhibitors for dementia--an update]. MMW Fortschritte der Medizin, 2007, May-21, Volume: 149 Suppl 2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors	2007
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. PharmacoEconomics, 2007, Volume: 25, Issue:9 Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine	2007
[Are anti-dementia drugs worthwhile?]. MMW Fortschritte der Medizin, 2007, Sep-13, Volume: 149 Suppl 3 Topics: Activities of Daily Living; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Drug Therapy, Combination; Economics, Medical; Excitatory Amino Acid Antagonists; Galantamine; Germany; Health Policy; Humans; Indans; Memantine; Meta-Analysis as Topic; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors	2007
Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Current medicinal chemistry, 2007, Volume: 14, Issue:25 Topics: Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Indole Alkaloids; Isoquinolines; Phenylcarbamates; Physostigmine; Piperidines; Propidium; Rivastigmine; Steroids; Tacrine	2007
An update on the pharmacology of galantamine. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:12 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Neuroprotective Agents; Nootropic Agents	2007
Galantamine in Alzheimer's disease. Expert review of neurotherapeutics, 2008, Volume: 8, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans	2008
Galanthamine, a natural product for the treatment of Alzheimer's disease. Recent patents on CNS drug discovery, 2006, Volume: 1, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans	2006
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Jan-31, Volume: 128, Issue:3 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome	2008
Pharmacologic management of Alzheimer disease. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2008, Volume: 40, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; N-Methylaspartate; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine	2008
[Treatment of Alzheimer's disease: status quo and future considerations]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 131, Issue:5 Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Behavioral Symptoms; Choline; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Design; Galantamine; Glutamic Acid; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Risk Factors; Rivastigmine	2008
Pharmacokinetic studies of cholinesterase inhibitors. Acta neurologica Scandinavica. Supplementum, 1993, Volume: 149 Topics: Adult; Aged; Alzheimer Disease; Female; Galantamine; Humans; Male; Middle Aged; Physostigmine; Tacrine	1993
Galanthamine. Drugs & aging, 1996, Volume: 9, Issue:1 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans	1996
Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dementia and geriatric cognitive disorders, 2000, Volume: 11 Suppl 1 Topics: Alzheimer Disease; Cholinergic Agents; Galantamine; Humans; Receptors, Nicotinic; Synaptic Transmission	2000
Galantamine: additional benefits to patients with Alzheimer's disease. Dementia and geriatric cognitive disorders, 2000, Volume: 11 Suppl 1 Topics: Alzheimer Disease; Clinical Trials as Topic; Cognition; Galantamine; Humans; Nicotinic Agonists	2000
Review of the acetylcholinesterase inhibitor galanthamine. Expert opinion on investigational drugs, 2000, Volume: 9, Issue:10 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans	2000
Galantamine: a review of its use in Alzheimer's disease. Drugs, 2000, Volume: 60, Issue:5 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Disease Models, Animal; Galantamine; Humans	2000
Cholinesterase inhibitors stabilize Alzheimer's disease. Annals of the New York Academy of Sciences, 2000, Volume: 920 Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon	2000
Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biological psychiatry, 2001, Feb-01, Volume: 49, Issue:3 Topics: Allosteric Regulation; Allosteric Site; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Galantamine; Humans; Mice; Neurons; Nootropic Agents; Patch-Clamp Techniques; Receptors, Nicotinic	2001
Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biological psychiatry, 2001, Feb-01, Volume: 49, Issue:3 Topics: Aged; Allosteric Regulation; Allosteric Site; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Galantamine; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Receptors, Nicotinic	2001
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health technology assessment (Winchester, England), 2001, Volume: 5, Issue:1 Topics: Alzheimer Disease; Carbamates; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine	2001
Galantamine for Alzheimer's disease. The Cochrane database of systematic reviews, 2001, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2001
The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). International journal of clinical practice. Supplement, 2001, Issue:120 Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Galantamine; Humans; Nootropic Agents; Receptors, Cholinergic; Receptors, Nicotinic	2001
Use of cholinesterase inhibitors for treatment of Alzheimer disease. Cleveland Clinic journal of medicine, 2001, Volume: 68, Issue:7 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine	2001
[Anticholinesterase agents in Alzheimer's disease]. Revue medicale de Bruxelles, 2001, Volume: 22, Issue:4 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Disease Progression; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Treatment Outcome	2001
Galantamine for Alzheimer's disease. The Cochrane database of systematic reviews, 2001, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2001
Galantamine: a new alzheimer drug with a past life. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:11 Topics: Alzheimer Disease; Galantamine; Humans; Nootropic Agents	2001
Current status and new developments with galantamine in the treatment of Alzheimer's disease. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:12 Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Galantamine; Humans	2001
[Perspectives for drug treatment in Alzheimer's disease]. Annales de medecine interne, 2001, Volume: 152, Issue:8 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine	2001
[Latest therapies for treating dementia]. Atencion primaria, 2002, May-15, Volume: 29, Issue:8 Topics: Adult; Aged; Alzheimer Disease; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clinical Trials as Topic; Cognition; Cohort Studies; Controlled Clinical Trials as Topic; Dementia, Vascular; Donepezil; Female; Fluoxetine; Galantamine; Haloperidol; Hormone Replacement Therapy; Humans; Hydroxychloroquine; Indans; Middle Aged; Nootropic Agents; Piperidines; Placebos; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Trazodone	2002
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Current medical research and opinion, 2002, Volume: 18, Issue:3 Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome	2002

Trials

108 trial(s) available for galantamine and Alzheimer Disease

Article	Year
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. British journal of clinical pharmacology, 2022, Volume: 88, Issue:6 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Galantamine; Humans; Nootropic Agents; Treatment Outcome	2022
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. JAMA, 2018, 01-09, Volume: 319, Issue:2 Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitors; Cognition; Donepezil; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Indans; Indoles; Male; Middle Aged; Piperidines; Rivastigmine; Serotonin Antagonists; Treatment Failure	2018
Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease. NeuroImage, 2019, 10-01, Volume: 199 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebellum; Cerebral Cortex; Cholinesterase Inhibitors; Citalopram; Connectome; Cross-Over Studies; Double-Blind Method; Female; Galantamine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Selective Serotonin Reuptake Inhibitors; Thalamus	2019
The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. Current Alzheimer research, 2014, Volume: 11, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Galantamine; Humans; Predictive Value of Tests; Retrospective Studies; Treatment Outcome	2014
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. Journal of Alzheimer's disease : JAD, 2014, Volume: 39, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Longitudinal Studies; Male; Memantine; Mental Disorders; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine	2014
Galantamine treatment in outpatients with mild Alzheimer's disease. Acta neurologica Scandinavica, 2014, Volume: 129, Issue:6 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Female; Follow-Up Studies; Galantamine; Humans; Male; Nootropic Agents; Outpatients; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome	2014
Cognitive subdomain responses to galantamine in Alzheimer's disease. The Journal of nervous and mental disease, 2014, Volume: 202, Issue:3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Executive Function; Female; Galantamine; Humans; Male; Memory Disorders; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome	2014
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study. Journal of Alzheimer's disease : JAD, 2014, Volume: 41, Issue:2 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Comorbidity; Donepezil; Female; Galantamine; Humans; Indans; Italy; Male; Memantine; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Retrospective Studies; Rivastigmine; Time Factors; Treatment Outcome	2014
Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). Arquivos de neuro-psiquiatria, 2014, Volume: 72, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Male; Neuropsychological Tests; Nimodipine; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vasodilator Agents	2014
Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dementia and geriatric cognitive disorders, 2014, Volume: 38, Issue:3-4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Female; Galantamine; Humans; Male; Nootropic Agents; Psychomotor Agitation; Risperidone; Treatment Outcome	2014
Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2016, Volume: 26, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Female; Galantamine; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Models, Neurological; Neuropsychological Tests; Oxygen; Principal Component Analysis; Psychiatric Status Rating Scales; Rest; Time Factors	2016
Comprehensive effects of galantamine and cilostazol combination therapy on patients with Alzheimer's disease with asymptomatic lacunar infarction. Geriatrics & gerontology international, 2017, Volume: 17, Issue:10 Topics: Aged; Alzheimer Disease; Asymptomatic Diseases; Brain; Cholinesterase Inhibitors; Cilostazol; Cognition; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Galantamine; Humans; Magnetic Resonance Imaging; Male; Neuroprotective Agents; Psychiatric Status Rating Scales; Retrospective Studies; Stroke, Lacunar; Tetrazoles; Time Factors; Treatment Outcome	2017
Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimer's research & therapy, 2016, 11-15, Volume: 8, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disability Evaluation; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Longitudinal Studies; Male; Memantine; Middle Aged; Psychiatric Status Rating Scales; Retrospective Studies; Treatment Outcome	2016
Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease. Geriatrics & gerontology international, 2017, Volume: 17, Issue:10 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cerebrovascular Disorders; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Middle Aged; Surveys and Questionnaires; Treatment Outcome	2017
Galantamine Response Associates with Agitation and the Prefrontal Cortex in Patients with Alzheimer's Disease. Journal of Alzheimer's disease : JAD, 2017, Volume: 57, Issue:1 Topics: Aged; Alzheimer Disease; Behavioral Symptoms; Brain; Caregivers; Cost of Illness; Female; Galantamine; Humans; Male; Mental Status and Dementia Tests; Psychotropic Drugs; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2017
Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. Journal of Alzheimer's disease : JAD, 2017, Volume: 57, Issue:2 Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Follow-Up Studies; Galantamine; Humans; Peptide Fragments; Phosphorylation; Psychotropic Drugs; Risperidone; tau Proteins; Treatment Outcome	2017
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial. Journal of the American Geriatrics Society, 2017, Volume: 65, Issue:7 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Ethnicity; Female; Galantamine; Humans; Indans; Indiana; Male; Medication Adherence; Piperidines; Rivastigmine	2017
One-week dose titration of extended release galantamine in patients with Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2008, Volume: 4, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Galantamine; Humans; Male; Middle Aged	2008
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. The Lancet. Neurology, 2009, Volume: 8, Issue:1 Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Cognition; Double-Blind Method; Electrocardiography; Female; Galantamine; Humans; Male; Neuropsychological Tests; Nootropic Agents	2009
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Current Alzheimer research, 2009, Volume: 6, Issue:1 Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2009
Misplacing objects in mild to moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:9 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Caregivers; Data Interpretation, Statistical; Emotions; Female; Galantamine; Humans; Male; Memory; Neuropsychological Tests; Nootropic Agents; Treatment Outcome; Videotape Recording	2009
Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial. CNS drugs, 2009, Volume: 23, Issue:3 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Atherosclerosis; Carotid Artery Diseases; Cholinesterase Inhibitors; Female; Galantamine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Predictive Value of Tests; Psychiatric Status Rating Scales; Regression Analysis; Ultrasonography	2009
Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:2 Topics: Aged; Alzheimer Disease; Brain Mapping; Cholinesterase Inhibitors; Cognition Disorders; Face; Follow-Up Studies; Galantamine; Humans; Magnetic Resonance Imaging; Neuropsychological Tests; Recognition, Psychology; Visual Perception	2009
The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. International journal of geriatric psychiatry, 2010, Volume: 25, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Double-Blind Method; Female; Galantamine; Humans; Male; Neuropsychological Tests; Nootropic Agents; Severity of Illness Index	2010
Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2009, Volume: 92 Suppl 2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cohort Studies; Female; Galantamine; Humans; Male; Middle Aged; Thailand	2009
Trospium and cognition in patients with late onset Alzheimer disease. The journal of nutrition, health & aging, 2009, Volume: 13, Issue:8 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Benzilates; Cholinesterase Inhibitors; Cognition; Depression; Drug Interactions; Drug Therapy, Combination; Female; Galantamine; Geriatric Assessment; Humans; Male; Mental Health; Muscarinic Antagonists; Nocturia; Nortropanes; Patient Satisfaction; Urinary Incontinence	2009
[Galantamine (reminyl) in the treatment of severe Alzheimer's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2009, Volume: 109, Issue:7 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Galantamine; Humans; Male; Middle Aged; Severity of Illness Index; Treatment Outcome	2009
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Progress in neuro-psychopharmacology & biological psychiatry, 2010, Feb-01, Volume: 34, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cholinesterase Inhibitors; Creatine; Female; Galantamine; Glutamic Acid; Hippocampus; Humans; Inositol; Magnetic Resonance Spectroscopy; Male; Mental Status Schedule; Neuropsychological Tests; Regression Analysis	2010
Cortical oxygen supply during postural hypotension is further decreased in Alzheimer's disease, but unrelated to cholinesterase-inhibitor use. Journal of Alzheimer's disease : JAD, 2010, Volume: 21, Issue:2 Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Female; Galantamine; Humans; Hypotension, Orthostatic; Male; Microcirculation; Middle Cerebral Artery; Oxygen; Oxyhemoglobins; Spectroscopy, Near-Infrared; Ultrasonography, Doppler, Transcranial	2010
[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. Tijdschrift voor gerontologie en geriatrie, 2010, Volume: 41, Issue:3 Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Memory; Middle Aged; Phenylcarbamates; Rivastigmine; Treatment Outcome	2010
Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. Journal of Alzheimer's disease : JAD, 2011, Volume: 24, Issue:1 Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Positron-Emission Tomography; Time Factors; Treatment Outcome	2011
Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population. Geriatrics & gerontology international, 2011, Volume: 11, Issue:3 Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition; Delayed-Action Preparations; Donepezil; Female; Galantamine; Humans; Indans; Male; Patient Satisfaction; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2011
Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease. The American journal of geriatric pharmacotherapy, 2010, Volume: 8, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Bradycardia; Cholinesterase Inhibitors; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Female; Galantamine; Heart Block; Humans; Male; Nootropic Agents; Patient Dropouts	2010
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. Journal of Alzheimer's disease : JAD, 2011, Volume: 26, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Treatment Outcome; Withholding Treatment	2011
Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. Current Alzheimer research, 2011, Volume: 8, Issue:7 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Treatment Outcome	2011
Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. European archives of psychiatry and clinical neuroscience, 2012, Volume: 262, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anisotropy; Biological Availability; Cholinesterase Inhibitors; Corpus Callosum; Diffusion Tensor Imaging; Double-Blind Method; Female; Galantamine; Gyrus Cinguli; Humans; Male; Nerve Fibers, Myelinated; Neuropsychological Tests; Outcome Assessment, Health Care	2012
Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Journal of Alzheimer's disease : JAD, 2011, Volume: 27, Issue:3 Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Cognition; Cognition Disorders; Female; Follow-Up Studies; Galantamine; Humans; Internationality; Male; Retrospective Studies; Time Factors; Treatment Outcome	2011
Two galantamine titration regimens in patients switched from donepezil. Acta neurologica Scandinavica, 2012, Volume: 126, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Galantamine; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Piperidines; Treatment Outcome	2012
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. The journal of nutrition, health & aging, 2012, Volume: 16, Issue:6 Topics: Aged; Alzheimer Disease; Amnesia; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Galantamine; Germany; Humans; Male; Memantine; Middle Aged; Nootropic Agents; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate	2012
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. BMC neurology, 2012, Nov-05, Volume: 12 Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disabled Persons; Donepezil; Female; Galantamine; Humans; Indans; Linear Models; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2012
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Current neurology and neuroscience reports, 2002, Volume: 2, Issue:5 Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Galantamine; Humans; Treatment Outcome	2002
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. Current neurology and neuroscience reports, 2002, Volume: 2, Issue:6 Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Double-Blind Method; Galantamine; Humans; Nausea; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Vomiting	2002
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23 Suppl 2 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Enzyme-Linked Immunosorbent Assay; Galantamine; Humans; Indans; Peptide Fragments; Phenylcarbamates; Phosphorylation; Piperidines; Rivastigmine; tau Proteins	2002
Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dementia and geriatric cognitive disorders, 2003, Volume: 15, Issue:2 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Galantamine; Humans; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome	2003
The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. International journal of geriatric psychiatry, 2003, Volume: 18, Issue:4 Topics: Aged; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents; Parasympathomimetics; Polypharmacy; Treatment Outcome	2003
An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clinical therapeutics, 2003, Volume: 25, Issue:6 Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male	2003
Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clinical therapeutics, 2003, Volume: 25, Issue:6 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Cost Savings; Dose-Response Relationship, Drug; Female; Galantamine; Health Care Costs; Humans; Male; Models, Economic; Nursing Homes; Patient Care; Randomized Controlled Trials as Topic; Time Factors; United States	2003
A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs & aging, 2003, Volume: 20, Issue:10 Topics: Aged; Alzheimer Disease; Cognition; Donepezil; Drug Administration Schedule; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Piperidines; Time; Treatment Outcome	2003
Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. Sleep, 2003, Aug-01, Volume: 26, Issue:5 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Male; Prevalence; Severity of Illness Index; Sleep Wake Disorders	2003
Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS drugs, 2003, Volume: 17, Issue:12 Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male; Psychiatric Status Rating Scales; Treatment Outcome	2003
The effects of galantamine treatment on caregiver time in Alzheimer's disease. International journal of geriatric psychiatry, 2003, Volume: 18, Issue:10 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Female; Galantamine; Humans; Interpersonal Relations; Male; Middle Aged; Nootropic Agents; Time Factors; Treatment Outcome	2003
Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dementia and geriatric cognitive disorders, 2004, Volume: 17, Issue:1-2 Topics: Aged; Alzheimer Disease; Dementia, Vascular; Female; Galantamine; Humans; Male; Nootropic Agents; Quality of Life; Treatment Outcome	2004
Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. European journal of neurology, 2003, Volume: 10, Issue:6 Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Galantamine; Humans; Male; Neuropsychological Tests	2003
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. International journal of geriatric psychiatry, 2004, Volume: 19, Issue:1 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Attitude of Health Personnel; Attitude to Health; Caregivers; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Nootropic Agents; Piperidines; Treatment Outcome	2004
The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Archives of neurology, 2004, Volume: 61, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Double-Blind Method; Electrocardiography; Female; Galantamine; Humans; Long-Term Care; Male; Neuropsychological Tests; Psychiatric Status Rating Scales	2004
Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. The American journal of psychiatry, 2004, Volume: 161, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Caregivers; Cholinesterase Inhibitors; Cost of Illness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Male; Mental Status Schedule; Neuropsychological Tests; Psychometrics	2004
The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. CNS spectrums, 2004, Volume: 9, Issue:5 Topics: Aged; Alzheimer Disease; Cognition; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents	2004
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. Archives of gerontology and geriatrics. Supplement, 2004, Issue:9 Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index	2004
Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:7 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents; Treatment Outcome; United States	2004
Effects of galantamine on attention and memory in Alzheimer's disease measured by computerized neuropsychological tests: results of the Brazilian Multi-Center Galantamine Study (GAL-BRA-01). Arquivos de neuro-psiquiatria, 2004, Volume: 62, Issue:2B Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Brazil; Cholinesterase Inhibitors; Diagnosis, Computer-Assisted; Female; Galantamine; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Prospective Studies	2004
Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. European journal of neurology, 2004, Volume: 11, Issue:11 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Galantamine; Humans; Long-Term Care; Male	2004
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Current medical research and opinion, 2004, Volume: 20, Issue:11 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2004
Effects of galantamine in patients with mild Alzheimer's disease. Current medical research and opinion, 2004, Volume: 20, Issue:11 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Treatment Outcome	2004
Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. NeuroImage, 2004, Volume: 23, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cholinergic Fibers; Cognition Disorders; Dominance, Cerebral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Galantamine; Gyrus Cinguli; Hippocampus; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Long-Term Care; Magnetic Resonance Imaging; Male; Mental Recall; Middle Aged; Neuropsychological Tests; Pattern Recognition, Visual	2004
A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clinical therapeutics, 2004, Volume: 26, Issue:10 Topics: Aged; Alzheimer Disease; Asian People; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Korea; Male; Neuropsychological Tests; Nootropic Agents; Prospective Studies; Treatment Outcome	2004
ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study. Collegium antropologicum, 2004, Volume: 28, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Female; Galantamine; Homozygote; Humans; Male; Middle Aged; Patient Selection; Retrospective Studies	2004
Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dementia and geriatric cognitive disorders, 2005, Volume: 19, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Female; Galantamine; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Prospective Studies; Retrospective Studies; Rivastigmine; Severity of Illness Index; Time Factors	2005
Cholinesterase inhibitor affects the amyloid precursor protein isoforms in patients with Alzheimer's disease. Dementia and geriatric cognitive disorders, 2005, Volume: 19, Issue:5-6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Protein Precursor; Biomarkers; Blood Platelets; Cholinesterase Inhibitors; Female; Galantamine; Humans; Isomerism; Male; Middle Aged	2005
[Cost-effectiveness of galantamine in a german context]. Psychiatrische Praxis, 2005, Volume: 32, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Galantamine; Germany; Humans; Male; Markov Chains; Mental Status Schedule; National Health Programs; Nootropic Agents; Psychometrics; Quality-Adjusted Life Years; Statistics as Topic; Survival Rate	2005
Switching from donepezil to galantamine: a double-blind study of two wash-out periods. International journal of geriatric psychiatry, 2005, Volume: 20, Issue:5 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Indans; Male; Piperidines	2005
Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Archives of neurology, 2005, Volume: 62, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Brain; Brain Mapping; Cognition; Female; Fluorodeoxyglucose F18; Functional Laterality; Galantamine; Humans; Imaging, Three-Dimensional; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Nootropic Agents; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Treatment Outcome	2005
Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Current medical research and opinion, 2005, Volume: 21, Issue:4 Topics: Administration, Oral; Adsorption; Alzheimer Disease; Biological Availability; Capsules; Cholinesterase Inhibitors; Delayed-Action Preparations; Galantamine; Humans; Models, Theoretical; Tablets	2005
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. European journal of clinical pharmacology, 2005, Volume: 61, Issue:5-6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Italy; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome	2005
Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:6 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Delusions; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Disorders; Psychomotor Agitation; Treatment Outcome	2005
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dementia and geriatric cognitive disorders, 2005, Volume: 20, Issue:2-3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Delayed-Action Preparations; Double-Blind Method; Endpoint Determination; Female; Galantamine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales	2005
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:10 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Female; Follow-Up Studies; Galantamine; Humans; Lactones; Male; Memory Disorders; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Piracetam; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Severity of Illness Index; Sulfones	2005
Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. Dementia and geriatric cognitive disorders, 2006, Volume: 21, Issue:1 Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Delusions; Double-Blind Method; Galantamine; Hallucinations; Humans; Neuropsychological Tests; Nootropic Agents; Prospective Studies; Treatment Outcome	2006
Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, Apr-11, Volume: 174, Issue:8 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Female; Galantamine; Humans; Male; Placebos; Severity of Illness Index; Treatment Outcome	2006
Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen. International journal of clinical practice, 2006, Volume: 60, Issue:5 Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Drug Administration Schedule; Female; Galantamine; Humans; Male; Nootropic Agents; Treatment Outcome	2006
Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clinical therapeutics, 2006, Volume: 28, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antiemetics; Cholinesterase Inhibitors; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Male; Middle Aged; Nausea; Vomiting	2006
Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs & aging, 2006, Volume: 23, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Polysomnography; Rivastigmine; Sleep Stages; Sleep Wake Disorders	2006
A naturalistic study of galantamine for Alzheimer's disease. CNS drugs, 2006, Volume: 20, Issue:11 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Female; Galantamine; Humans; Interview, Psychological; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Prospective Studies; Treatment Outcome	2006
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiology of aging, 2008, Volume: 29, Issue:2 Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Humans; Immunoprecipitation; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Positron-Emission Tomography; Radiopharmaceuticals	2008
A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong. International journal of clinical practice, 2007, Volume: 61, Issue:3 Topics: Activities of Daily Living; Aged; Alzheimer Disease; China; Cholinesterase Inhibitors; Cognition; Female; Follow-Up Studies; Galantamine; Hong Kong; Humans; Male; Neuropsychological Tests; Nootropic Agents; Severity of Illness Index; Time Factors; Treatment Outcome	2007
Brain activation in elderly people with and without dementia: Influences of gender and medication. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2007, Volume: 8, Issue:1 Topics: Aged; Alzheimer Disease; Arousal; Brain; Female; Galantamine; Hemoglobin A; Hemoglobins; Humans; Male; Mental Recall; Neuropsychological Tests; Nootropic Agents; Oxyhemoglobins; Prefrontal Cortex; Reference Values; Sex Factors; Spectroscopy, Near-Infrared; Thinking; Verbal Behavior; Vocabulary	2007
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiology of aging, 2008, Volume: 29, Issue:8 Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Double-Blind Method; Enzyme Activation; Female; Galantamine; Humans; Male; Nicotine; Placebo Effect; Positron-Emission Tomography; Protein Binding; Tissue Distribution; Treatment Outcome	2008
Naturalistic treatment of Alzheimer's disease with galantamine: 12-month follow-up from the NATURE study. CNS drugs, 2007, Volume: 21, Issue:4 Topics: Alzheimer Disease; Female; Follow-Up Studies; Galantamine; Humans; Male; Mental Status Schedule; Nootropic Agents; Observation; Prospective Studies; Time Factors	2007
Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology, 2007, Apr-03, Volume: 68, Issue:14 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Communication Disorders; Diagnostic Imaging; Double-Blind Method; Female; Follow-Up Studies; Galantamine; Humans; Male; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome; Video Recording	2007
The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2 Topics: Aged, 80 and over; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Benzodiazepines; Decision Making; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Galantamine; Humans; Male; Mandelic Acids; Movement; Parasympatholytics; Patient Dropouts; Prospective Studies; Reaction Time; Selective Serotonin Reuptake Inhibitors; Task Performance and Analysis; Trazodone	2007
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International journal of geriatric psychiatry, 2008, Volume: 23, Issue:2 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Depression; Dietary Supplements; Donepezil; Double-Blind Method; Fatty Acids, Omega-3; Female; Galantamine; Genotype; Humans; Indans; Male; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine; Statistics, Nonparametric; Treatment Outcome	2008
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. International journal of geriatric psychiatry, 2008, Volume: 23, Issue:2 Topics: Aged; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Cholinesterase Inhibitors; Dietary Supplements; Donepezil; Double-Blind Method; Female; Folic Acid; Folic Acid Deficiency; Galantamine; Homocysteine; Humans; Indans; Male; Mental Status Schedule; Phenylcarbamates; Piperidines; Placebos; Rivastigmine; Treatment Outcome; Vitamin B Complex; Vitamins	2008
Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology, 2007, Oct-09, Volume: 69, Issue:15 Topics: Age Factors; Aged; Alzheimer Disease; Apolipoprotein E4; Atrophy; Biomarkers; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Galantamine; Genetic Predisposition to Disease; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Fibers, Myelinated; Neuropsychological Tests; Predictive Value of Tests; Prognosis	2007
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. Journal of neural transmission. Supplementum, 2007, Issue:72 Topics: Aged; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Long-Term Care; Male; Mental Status Schedule; Middle Aged; Oxidative Stress; Piperidines; Thioctic Acid	2007
Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study. Journal of Korean medical science, 2008, Volume: 23, Issue:1 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost of Illness; Double-Blind Method; Female; Galantamine; Health Care Costs; Humans; Male; Prospective Studies	2008
Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cerebrovascular Disorders; Cognition; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents; Psychomotor Performance; Risk Assessment	2008
Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 2008, May-27, Volume: 70, Issue:22 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Cohort Studies; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Retrospective Studies	2008
Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. International psychogeriatrics, 2008, Volume: 20, Issue:5 Topics: Activities of Daily Living; Affective Symptoms; Aged; Aged, 80 and over; Alzheimer Disease; Attitude of Health Personnel; Attitude to Health; Caregivers; Cholinesterase Inhibitors; Female; Galantamine; Health Status; Humans; Leisure Activities; Male; Middle Aged; Psychiatric Status Rating Scales; Qualitative Research; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Videotape Recording	2008
Galantamine improves gait performance in patients with Alzheimer's disease. Journal of the American Geriatrics Society, 2008, Volume: 56, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Female; Gait; Galantamine; Humans; Male; Mental Status Schedule; Neurologic Examination; Neuropsychological Tests; Nootropic Agents	2008
Cholinergic neurotransmission, REM sleep and depression. Journal of psychosomatic research, 1994, Volume: 38 Suppl 1 Topics: Adolescent; Adult; Aged; Alzheimer Disease; Brain Stem; Cholinergic Agonists; Cholinergic Fibers; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Disorders; Middle Aged; Parasympathomimetics; Physostigmine; Polysomnography; Reaction Time; Receptors, Muscarinic; Sleep Stages; Sleep Wake Disorders; Sleep, REM; Succinimides; Synaptic Transmission; Tacrine	1994
Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. International journal of geriatric psychiatry, 1998, Volume: 13, Issue:9 Topics: Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Double-Blind Method; Female; Galantamine; Genotype; Humans; Male; Sex Characteristics; Tacrine; Time Factors	1998
Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology, 2000, Jun-27, Volume: 54, Issue:12 Topics: Aged; Alzheimer Disease; Apolipoproteins E; Body Weight; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Galantamine; Humans; Male; Neuropsychological Tests; Treatment Outcome	2000
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology, 2000, Jun-27, Volume: 54, Issue:12 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavioral Symptoms; Body Weight; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome	2000
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ (Clinical research ed.), 2000, Dec-09, Volume: 321, Issue:7274 Topics: Aged; Alzheimer Disease; Double-Blind Method; Europe; Female; Galantamine; Humans; Male; Nootropic Agents; Treatment Outcome	2000
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neuroscience letters, 2001, Mar-16, Volume: 300, Issue:3 Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Biomarkers; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Indans; Male; Middle Aged; Piperidines	2001
Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. International journal of geriatric psychiatry, 2001, Volume: 16, Issue:9 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Status Schedule; Treatment Outcome	2001
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. Journal of neurology, neurosurgery, and psychiatry, 2001, Volume: 71, Issue:5 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Galantamine; Humans; Male; Neuropsychological Tests; Receptors, Nicotinic; Severity of Illness Index; Synaptic Transmission; Time Factors; Treatment Outcome	2001
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (London, England), 2002, Apr-13, Volume: 359, Issue:9314 Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male; Treatment Outcome	2002
Galanthamine treatment in Alzheimer's disease. Journal of neural transmission. Supplementum, 1991, Volume: 33 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Galantamine; Humans; Male; Middle Aged; Neuropsychological Tests; Pilot Projects	1991

Other Studies

345 other study(ies) available for galantamine and Alzheimer Disease

Article	Year
Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease. Journal of medicinal chemistry, 1995, Sep-01, Volume: 38, Issue:18 Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Aminoquinolines; Animals; Cholinesterase Inhibitors; Dementia; Drug Evaluation; Male; Mice; Rats; Scopolamine; Sesquiterpenes; Structure-Activity Relationship	1995
Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS letters, 1999, Dec-17, Volume: 463, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Cholinesterase Inhibitors; Drug Design; Galantamine; Galanthus; Hydrogen Bonding; Molecular Structure; Stereoisomerism; Torpedo; X-Ray Diffraction	1999
Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs. Proteins, 2001, Feb-01, Volume: 42, Issue:2 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Cholinesterase Inhibitors; Crystallization; Crystallography, X-Ray; Cyclohexanes; Cyclohexenes; Drug Design; Galantamine; Models, Molecular; Nootropic Agents; Protein Conformation; Structure-Activity Relationship; Torpedo	2001
Isoquinoline derivatives as potential acetylcholinesterase inhibitors. Bioorganic & medicinal chemistry letters, 2006, Apr-15, Volume: 16, Issue:8 Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Benzylisoquinolines; Binding Sites; Cholinesterase Inhibitors; Colorimetry; Humans; Isoquinolines; Structure-Activity Relationship	2006
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorganic & medicinal chemistry letters, 2006, Nov-15, Volume: 16, Issue:22 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Galantamine; Humans; Inhibitory Concentration 50; Phenylcarbamates; Physostigmine; Rivastigmine; Serotonin	2006
Methyl 2-(2-(4-formylphenoxy)acetamido)-2-substituted acetate derivatives: a new class of acetylcholinesterase inhibitors. Bioorganic & medicinal chemistry letters, 2007, Apr-15, Volume: 17, Issue:8 Topics: Acetates; Alzheimer Disease; Benzaldehydes; Cholinesterase Inhibitors; Humans; Inhibitory Concentration 50; Structure-Activity Relationship	2007
Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. Journal of medicinal chemistry, 2007, Oct-04, Volume: 50, Issue:20 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Humans; Ligands; Models, Molecular; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Polyamines; Protein Binding; Quinones; Reactive Oxygen Species; Structure-Activity Relationship; Substrate Specificity	2007
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Humans; Inhibitory Concentration 50; Memantine; Neurodegenerative Diseases; Receptors, N-Methyl-D-Aspartate	2010
Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. Journal of medicinal chemistry, 2010, Jul-22, Volume: 53, Issue:14 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Calcium; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytotoxins; Electron Transport Chain Complex Proteins; Electrophorus; Glucose; Hippocampus; Humans; Isomerism; Models, Molecular; Naphthyridines; Neuroprotective Agents; Okadaic Acid; Oligomycins; Oxygen; Peptide Fragments; Protein Binding; Protein Phosphatase 2; Rats; Rotenone; Structure-Activity Relationship	2010
Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations. Journal of enzyme inhibition and medicinal chemistry, 2011, Volume: 26, Issue:1 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Aporphines; Catalytic Domain; Cholinesterase Inhibitors; Electrophorus; Humans; Kinetics; Models, Chemical; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Protein Structure, Tertiary; Spectrophotometry; Structure-Activity Relationship	2011
Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyri Bioorganic & medicinal chemistry, 2010, Aug-15, Volume: 18, Issue:16 Topics: Acetylcholinesterase; Alzheimer Disease; Aminopyridines; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinergic Agents; Cholinesterase Inhibitors; Electrophorus; Horses; Humans; Models, Molecular; Neurons; Neuroprotective Agents; Nitriles; Pyridines; Vascular Diseases	2010
(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase. Bioorganic & medicinal chemistry letters, 2011, May-01, Volume: 21, Issue:9 Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer Simulation; Inhibitory Concentration 50; Models, Biological; Models, Molecular; Molecular Structure; Pyrans	2011
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cell Death; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Okadaic Acid; Peptide Fragments; Phenothiazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured	2011
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Crystallography, X-Ray; Dose-Response Relationship, Drug; Erythrocytes; Models, Molecular; Molecular Structure; Quinolizidines; Stereoisomerism; Structure-Activity Relationship	2011
Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease. Bioorganic & medicinal chemistry, 2011, Dec-01, Volume: 19, Issue:23 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Berberine; Cholinesterase Inhibitors; Coumaric Acids; Humans; Hydroquinones; Melatonin; Mice; Models, Molecular; Molecular Structure; Peptide Fragments; Structure-Activity Relationship	2011
Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents. Bioorganic & medicinal chemistry letters, 2012, Jul-01, Volume: 22, Issue:13 Topics: Acetylcholinesterase; Alzheimer Disease; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Humans; Indans; Kinetics; Metals; Pyridines; Structure-Activity Relationship	2012
Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template. Bioorganic & medicinal chemistry letters, 2012, Jul-15, Volume: 22, Issue:14 Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Diamines; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Retinoblastoma; Structure-Activity Relationship	2012
Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. Journal of medicinal chemistry, 2012, Nov-26, Volume: 55, Issue:22 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Proliferation; Cerebral Cortex; Cholinesterase Inhibitors; Computer Simulation; Drug Combinations; Drug Design; Feasibility Studies; Galantamine; Humans; Male; Memantine; Neuroblastoma; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate	2012
Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase. Bioorganic & medicinal chemistry, 2013, Jan-01, Volume: 21, Issue:1 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Coumarins; Horses; Humans	2013
Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease. Bioorganic & medicinal chemistry letters, 2013, May-01, Volume: 23, Issue:9 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Catalytic Domain; Cholinesterase Inhibitors; Drug Design; Flavonoids; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Structure-Activity Relationship	2013
Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease. Bioorganic & medicinal chemistry letters, 2013, May-01, Volume: 23, Issue:9 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Catalytic Domain; Chalcones; Cholinesterase Inhibitors; Coumarins; Drug Design; Humans; Molecular Docking Simulation; Structure-Activity Relationship	2013
Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease. European journal of medicinal chemistry, 2013, Volume: 64 Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Tacrine	2013
Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease. European journal of medicinal chemistry, 2013, Volume: 69 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Chelating Agents; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flavonoids; Free Radical Scavengers; Humans; Mice; Neuroblastoma; Organometallic Compounds; Oxidation-Reduction; Peptide Fragments; Picrates; Structure-Activity Relationship; Tacrine	2013
Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. European journal of medicinal chemistry, 2014, Mar-21, Volume: 75 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Carbazoles; Cell Line; Cholinesterase Inhibitors; Electrophorus; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Oxidative Stress; Tacrine	2014
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease. Bioorganic & medicinal chemistry letters, 2014, Mar-15, Volume: 24, Issue:6 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cotinine; Humans; Neurons; Neuroprotective Agents; Nicotine; Peptide Fragments; Rats; Receptors, N-Methyl-D-Aspartate	2014
Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents. European journal of medicinal chemistry, 2014, Apr-09, Volume: 76 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Drug Design; Female; Galantamine; Magnetic Resonance Spectroscopy; Microscopy, Atomic Force; Nitric Oxide; Rats; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization	2014
Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease. Bioorganic & medicinal chemistry letters, 2014, May-15, Volume: 24, Issue:10 Topics: Alzheimer Disease; Benzylisoquinolines; Cholinesterase Inhibitors; Drug Design; Humans; Models, Molecular; Structure-Activity Relationship	2014
Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease. Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Carbolines; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Electrophorus; Horses; Humans; Molecular Docking Simulation; Protein Aggregation, Pathological; Tacrine	2014
Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors. Bioorganic & medicinal chemistry, 2015, Jan-01, Volume: 23, Issue:1 Topics: Alzheimer Disease; Animals; Benzofurans; Cholinesterase Inhibitors; Male; Mice	2015
Sulfonamides as multifunctional agents for Alzheimer's disease. Bioorganic & medicinal chemistry letters, 2015, Feb-01, Volume: 25, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Donepezil; Free Radical Scavengers; Humans; Indans; Molecular Dynamics Simulation; Piperidines; Protein Binding; Sulfonamides	2015
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. Journal of natural products, 2015, Jun-26, Volume: 78, Issue:6 Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain Barrier; Cholinesterase Inhibitors; Humans; In Vitro Techniques; Molecular Structure	2015
Potential of aryl-urea-benzofuranylthiazoles hybrids as multitasking agents in Alzheimer's disease. European journal of medicinal chemistry, 2015, Sep-18, Volume: 102 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzofurans; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Dynamics Simulation; Molecular Structure; Structure-Activity Relationship; Thiazoles; Torpedo; Urea	2015
Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents. European journal of medicinal chemistry, 2016, Jan-01, Volume: 107 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Binding Sites; Butyrylcholinesterase; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Computer Simulation; Coumarins; Drug Evaluation, Preclinical; Galantamine; Humans; Hydrogen Peroxide; Male; Mice, Inbred BALB C; Models, Molecular; Neuroprotective Agents; Neurotoxicity Syndromes	2016
Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. European journal of medicinal chemistry, 2016, Jan-27, Volume: 108 Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; HT29 Cells; Humans; Molecular Structure; Phenols; Structure-Activity Relationship	2016
Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease. Chemical biology & drug design, 2016, Volume: 88, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzopyrans; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation	2016
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies. European journal of medicinal chemistry, 2016, Aug-25, Volume: 119 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Pyrimidines	2016
New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives. Bioorganic chemistry, 2016, Volume: 67 Topics: Alzheimer Disease; Azepines; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Isoquinolines; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship	2016
Structure-activity relationship studies of benzyl-, phenethyl-, and pyridyl-substituted tetrahydroacridin-9-amines as multitargeting agents to treat Alzheimer's disease. Chemical biology & drug design, 2016, Volume: 88, Issue:5 Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Binding Sites; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship	2016
Avarol derivatives as competitive AChE inhibitors, non hepatotoxic and neuroprotective agents for Alzheimer's disease. European journal of medicinal chemistry, 2016, Oct-21, Volume: 122 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Electrophorus; Hep G2 Cells; Humans; Liver; Molecular Docking Simulation; Neuroprotective Agents; Protein Conformation; Sesquiterpenes	2016
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. Journal of medicinal chemistry, 2016, 08-25, Volume: 59, Issue:16 Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship	2016
New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors. European journal of medicinal chemistry, 2016, Nov-29, Volume: 124 Topics: Acetylcholinesterase; Alzheimer Disease; Antineoplastic Agents; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Design; Humans; Hydrazones; Molecular Docking Simulation; Piperidines	2016
Synthesis and evaluation of dihydropyrimidinone-derived selenoesters as multi-targeted directed compounds against Alzheimer's disease. Bioorganic & medicinal chemistry, 2016, 11-15, Volume: 24, Issue:22 Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Esters; Humans; Molecular Structure; Organoselenium Compounds; Pyrimidinones; Structure-Activity Relationship	2016
New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity. European journal of medicinal chemistry, 2017, Jan-05, Volume: 125 Topics: Alzheimer Disease; Azepines; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Humans; Indoles; N-Methylaspartate; Neurons; Neuroprotective Agents	2017
Targeting Alzheimer's disease by investigating previously unexplored chemical space surrounding the cholinesterase inhibitor donepezil. European journal of medicinal chemistry, 2017, Feb-15, Volume: 127 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cell Line, Tumor; Cholinesterase Inhibitors; Donepezil; Esters; Humans; Indans; Inhibitory Concentration 50; Molecular Docking Simulation; Molecular Targeted Therapy; Piperidines; Protein Conformation; Structure-Activity Relationship	2017
Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors. Bioorganic & medicinal chemistry letters, 2017, 01-15, Volume: 27, Issue:2 Topics: Acetylcholinesterase; Alzheimer Disease; Cell Line, Tumor; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Piperidones; Structure-Activity Relationship	2017
Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents. Bioorganic & medicinal chemistry letters, 2017, 01-15, Volume: 27, Issue:2 Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Carbolines; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship	2017
Synthesis, biological evaluation and docking studies of 2,3-dihydroquinazolin-4(1H)-one derivatives as inhibitors of cholinesterases. Bioorganic chemistry, 2017, Volume: 70 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Electrophorus; Horses; Humans; Molecular Docking Simulation; Quinazolinones; Structure-Activity Relationship	2017
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease. Bioorganic & medicinal chemistry, 2018, 05-01, Volume: 26, Issue:8 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophorus; Female; Horses; Imidazoles; Male; Maze Learning; Memory Disorders; Mice; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship	2018
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities. European journal of medicinal chemistry, 2018, Aug-05, Volume: 156 Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines	2018
Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors. Bioorganic & medicinal chemistry, 2018, 09-15, Volume: 26, Issue:17 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Carbazoles; Cholinesterase Inhibitors; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Neuroprotective Agents; PC12 Cells; Piperidines; Rats	2018
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease. Journal of natural products, 2019, 02-22, Volume: 82, Issue:2 Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Berberis; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Isoquinolines; Magnetic Resonance Spectroscopy; Plant Exudates	2019
Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment. Bioorganic & medicinal chemistry letters, 2019, 06-01, Volume: 29, Issue:11 Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship	2019
Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. European journal of medicinal chemistry, 2019, Sep-15, Volume: 178 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzofurans; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; CHO Cells; Cholinesterase Inhibitors; Cricetulus; Drug Design; Humans; Immunologic Factors; Mice; Microglia; Molecular Docking Simulation; Neuroprotective Agents; Peptide Fragments; Protein Binding; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Small Molecule Libraries	2019
Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease. European journal of medicinal chemistry, 2019, Oct-01, Volume: 179 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Eels; Horses; Humans; Models, Molecular; Molecular Structure; Piperidines; Structure-Activity Relationship	2019
Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors. European journal of medicinal chemistry, 2019, Nov-01, Volume: 181 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antineoplastic Agents; Butyrylcholinesterase; Cell Proliferation; Cholinesterase Inhibitors; Dimerization; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Electrophorus; Horses; Humans; Ligands; Models, Molecular; Molecular Structure; Neuroprotective Agents; Phenols; Structure-Activity Relationship; Tacrine; Tumor Cells, Cultured	2019
Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study. Bioorganic & medicinal chemistry letters, 2021, 11-01, Volume: 51 Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Isoquinolines; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship	2021
Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer's disease. Bioorganic & medicinal chemistry, 2022, 08-15, Volume: 68 Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Horses; Kinetics; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship	2022
Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice. Journal of Alzheimer's disease : JAD, 2021, Volume: 84, Issue:2 Topics: Alzheimer Disease; Animals; Antioxidants; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Male; Memory, Long-Term; Memory, Short-Term; Mice; Scopolamine	2021
Therapeutic effects of carvacrol on beta-amyloid-induced impairments in in vitro and in vivo models of Alzheimer's disease. The European journal of neuroscience, 2022, Volume: 56, Issue:9 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Galantamine; Hippocampus; Humans; Memory Disorders; Neuroblastoma; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Rats; Superoxide Dismutase; Thymol	2022
Transition-Metal-Mediated Chemo- and Stereoselective Total Synthesis of (-)-Galanthamine. The Journal of organic chemistry, 2022, 01-21, Volume: 87, Issue:2 Topics: Alkaloids; Alzheimer Disease; Galantamine; Humans	2022
Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM. Scientific reports, 2022, 03-15, Volume: 12, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine	2022
Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. The Journal of neuropsychiatry and clinical neurosciences, 2022,Summer, Volume: 34, Issue:3 Topics: Alzheimer Disease; Dementia; Electroencephalography; Galantamine; Humans; Neuropsychological Tests; Risperidone	2022
A single-molecule with multiple investigations: Synthesis, characterization, computational methods, inhibitory activity against Alzheimer's disease, toxicity, and ADME studies. Computers in biology and medicine, 2022, Volume: 146 Topics: Acetylcholinesterase; Alzheimer Disease; Donepezil; Galantamine; Humans; Molecular Docking Simulation	2022
A Cobalt-Containing Compound as a Stronger Inhibitor than Galantamine to Inhibit Acetylcholinesterase Activity: A New Drug Candidate for Alzheimer's Disease Treatment. Journal of Alzheimer's disease : JAD, 2022, Volume: 87, Issue:4 Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Cobalt; Galantamine; Humans; Molecular Docking Simulation	2022
Synthesis and biological study of new galanthamine-peptide derivatives designed for prevention and treatment of Alzheimer Amino acids, 2022, Volume: 54, Issue:6 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Galantamine; Humans; Peptides; Sheep	2022
Kinetic Modeling of Time-Dependent Enzyme Inhibition by Pre-Steady-State Analysis of Progress Curves: The Case Study of the Anti-Alzheimer's Drug Galantamine. International journal of molecular sciences, 2022, May-03, Volume: 23, Issue:9 Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Kinetics	2022
Intranasal Oxytocin Attenuates Cognitive Impairment, β-Amyloid Burden and Tau Deposition in Female Rats with Alzheimer's Disease: Interplay of ERK1/2/GSK3β/Caspase-3. Neurochemical research, 2022, Volume: 47, Issue:8 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caspase 3; Cognitive Dysfunction; Disease Models, Animal; Female; Galantamine; Glycogen Synthase Kinase 3 beta; MAP Kinase Signaling System; Oxytocin; Rats; tau Proteins	2022
Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors. Molecules (Basel, Switzerland), 2022, May-13, Volume: 27, Issue:10 Topics: Acetylcholinesterase; Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Galantamine; Humans; Molecular Docking Simulation	2022
Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia. European journal of clinical pharmacology, 2022, Volume: 78, Issue:8 Topics: Alzheimer Disease; Apolipoproteins E; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Galantamine; Genotype; Humans; Treatment Outcome	2022
Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs & aging, 2022, Volume: 39, Issue:6 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Galantamine; Humans; Indans; Male; Medicare; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; United States	2022
Lemborexant add-on further improves the effect of galantamine on sleep-wake disorder in Alzheimer's disease. International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:10 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Pyridines; Pyrimidines; Sleep; Sleep Wake Disorders	2022
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Journal of Alzheimer's disease : JAD, 2022, Volume: 89, Issue:2 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine; Deglutition Disorders; Donepezil; Galantamine; Humans; Memantine; Penicillamine; Risk Management; Rivastigmine; United States; United States Food and Drug Administration	2022
Kinetic and structural studies on the inhibition of acetylcholinesterase and butyrylcholinesterase by a series of multitarget-directed galantamine-peptide derivatives. Chemico-biological interactions, 2022, Sep-25, Volume: 365 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Galantamine; Humans; Molecular Docking Simulation; Molecular Structure; Peptide Fragments; Structure-Activity Relationship	2022
Novel Morpholine-Bearing Quinoline Derivatives as Potential Cholinesterase Inhibitors: The Influence of Amine, Carbon Linkers and Phenylamino Groups. International journal of molecular sciences, 2022, Sep-23, Volume: 23, Issue:19 Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Aminoquinolines; Benzothiazoles; Carbon; Cholinesterase Inhibitors; Galantamine; Humans; Hydroxyquinolines; Kinetics; Molecular Docking Simulation; Morpholines; Structure-Activity Relationship; Sulfonic Acids	2022
Resveratrol-Maltol and Resveratrol-Thiophene Hybrids as Cholinesterase Inhibitors and Antioxidants: Synthesis, Biometal Chelating Capability and Crystal Structure. Molecules (Basel, Switzerland), 2022, Sep-27, Volume: 27, Issue:19 Topics: Alzheimer Disease; Antioxidants; Chelating Agents; Cholinesterase Inhibitors; Cholinesterases; Galantamine; Humans; Ligands; Molecular Docking Simulation; Pyrones; Resveratrol; Structure-Activity Relationship; Thiophenes; Trace Elements	2022
Interactions of Isoquinoline Alkaloids with Transition Metals Iron and Copper. Molecules (Basel, Switzerland), 2022, Sep-29, Volume: 27, Issue:19 Topics: Alzheimer Disease; Chelating Agents; Copper; Cytostatic Agents; Dimethyl Sulfoxide; Galantamine; Humans; Hydroxyl Radical; Iron; Isoquinolines; Reactive Oxygen Species; Reducing Agents; Salts	2022
Evaluation of Anti-Alzheimer Activity of Synthetic Coumarins by Combination of in Vitro and in Silico Approaches. Chemistry & biodiversity, 2022, Volume: 19, Issue:12 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumarins; Galantamine; Humans; Molecular Docking Simulation; Neuroblastoma; Structure-Activity Relationship	2022
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia. Medicine, 2022, Nov-11, Volume: 101, Issue:45 Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine	2022
Nose-to-brain delivery of galantamine loaded nanospray dried polyacrylic acid/taurodeoxycholate mixed matrix as a protective therapy in lipopolysaccharide-induced Alzheimer's in mice model. International journal of pharmaceutics, 2023, Feb-05, Volume: 632 Topics: Administration, Intranasal; Alzheimer Disease; Animals; Brain; Drug Carriers; Galantamine; Lipopolysaccharides; Mice; Nasal Mucosa; Particle Size	2023
Alkaloid Profile in Wild Autumn-Flowering Daffodils and Their Acetylcholinesterase Inhibitory Activity. Molecules (Basel, Switzerland), 2023, Jan-27, Volume: 28, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae; Amaryllidaceae Alkaloids; Cholinesterase Inhibitors; Galantamine; Narcissus	2023
Palladium-Catalyzed Synthesis, Acetylcholinesterase Inhibition, and Neuroprotective Activities of Journal of natural products, 2023, 04-28, Volume: 86, Issue:4 Topics: Acetylcholinesterase; Alzheimer Disease; Catalysis; Cholinesterase Inhibitors; Galantamine; Humans; Hydrogen Peroxide; Molecular Docking Simulation; Molecular Structure; Neuroblastoma; Neuroprotective Agents; Palladium; Structure-Activity Relationship	2023
Static Binding and Dynamic Transporting-Based Design of Specific Ring-Chain-Ring Acetylcholinesterase Inhibitor: From Galantamine to Natural Product. Chemistry (Weinheim an der Bergstrasse, Germany), 2023, May-02, Volume: 29, Issue:25 Topics: Acetylcholinesterase; Alzheimer Disease; Biological Products; Cholinesterase Inhibitors; Galantamine; Humans; Molecular Docking Simulation	2023
Proposing novel natural compounds against Alzheimer's disease targeting acetylcholinesterase. PloS one, 2023, Volume: 18, Issue:4 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Molecular Docking Simulation; Neuroblastoma; Thiamine	2023
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact. Alzheimer's research & therapy, 2023, 08-03, Volume: 15, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; COVID-19; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Pandemics; Phenylcarbamates; Piperidines; Prevalence; Retrospective Studies; Rivastigmine	2023
Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties. European journal of medicinal chemistry, 2023, Dec-05, Volume: 261 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; Mice; Receptors, N-Methyl-D-Aspartate	2023
Inhibition mechanism of fisetin on acetylcholinesterase and its synergistic effect with galantamine. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2024, Jan-15, Volume: 305 Topics: Acetylcholinesterase; Alzheimer Disease; Catalytic Domain; Cholinesterase Inhibitors; Computer Simulation; Galantamine; Humans; Molecular Docking Simulation	2024
Quercetin-1,2,3-Triazole Hybrids as Multifunctional Anti-Alzheimer's Agents. Molecules (Basel, Switzerland), 2023, Nov-09, Volume: 28, Issue:22 Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Drug Design; Galantamine; Humans; Hydrogen Peroxide; Neuroprotective Agents; Quercetin; Structure-Activity Relationship	2023
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2019, Sep-16, Volume: 191, Issue:37 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Hospitalization; Humans; Male; Ontario; Retrospective Studies; Rhabdomyolysis; Risk Assessment; Rivastigmine	2019
Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease. Free radical biology & medicine, 2019, Volume: 145 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Galantamine; Humans; Inflammation; Mice; Microglia; Oxidative Stress; Protein Aggregation, Pathological; Reactive Oxygen Species; Ribosomal Proteins; RNA-Binding Proteins	2019
Neuroprotective Effects of Apocynin and Galantamine During the Chronic Administration of Scopolamine in an Alzheimer's Disease Model. Journal of molecular neuroscience : MN, 2020, Volume: 70, Issue:2 Topics: Acetophenones; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Galantamine; Hippocampus; Male; NADPH Oxidase 2; Neuroprotective Agents; NF-kappa B; Oxidative Stress; Rats; Rats, Wistar; Scopolamine	2020
Cholinesterase as a Target for Drug Development in Alzheimer's Disease. Methods in molecular biology (Clifton, N.J.), 2020, Volume: 2089 Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Development; Galantamine; Humans; Memantine; Rivastigmine	2020
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease. Geriatrics & gerontology international, 2020, Volume: 20, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Donepezil; Female; Galantamine; Humans; Japan; Male; Memantine; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine	2020
Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats. Behavioural brain research, 2020, 05-15, Volume: 385 Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Cholinergic Antagonists; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Drug Synergism; Excitatory Amino Acid Antagonists; Galantamine; Isoxazoles; Memantine; Nootropic Agents; Phenylurea Compounds; Rats; Recognition, Psychology; Scopolamine	2020
Pisa syndrome induced by switching of a choline-esterase inhibitor treatment from donepezil to galantamine: a case report. BMC neurology, 2020, May-13, Volume: 20, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Middle Aged; Tardive Dyskinesia	2020
Multiple target-based combination therapy of galantamine, memantine and lycopene for the possible treatment of Alzheimer's disease. Medical hypotheses, 2020, Volume: 143 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Lycopene; Memantine; Piperidines	2020
Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe. Social psychiatry and psychiatric epidemiology, 2021, Volume: 56, Issue:3 Topics: Alzheimer Disease; Electronic Health Records; Europe; Galantamine; Humans; Indans; Italy; Netherlands; Phenylcarbamates; Piperidines; Retrospective Studies	2021
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities. Journal of Alzheimer's disease : JAD, 2020, Volume: 76, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Female; Galantamine; Healthcare Disparities; Humans; Male; Medicare; Memantine; Nootropic Agents; Patient Acceptance of Health Care; Rivastigmine; Treatment Outcome; United States	2020
Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors. Molecules (Basel, Switzerland), 2020, Jul-23, Volume: 25, Issue:15 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Combinatorial Chemistry Techniques; Curcumin; Galantamine; Humans; Mice; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship	2020
Gas-phase basicity and proton affinity measurements of Alzheimer's disease drugs by the extended kinetic method and a theoretical investigation. European journal of mass spectrometry (Chichester, England), 2020, Volume: 26, Issue:6 Topics: Alzheimer Disease; Curcumin; Galantamine; Humans; Neuroprotective Agents; Protons; Rivastigmine; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry	2020
Evaluation of the Therapeutic Effect of Lycoramine on Alzheimer's Disease in Mouse Model. Current medicinal chemistry, 2021, Volume: 28, Issue:17 Topics: Alzheimer Disease; Amaryllidaceae Alkaloids; Amyloid beta-Peptides; Animals; Disease Models, Animal; Galantamine; Mice; Mice, Transgenic	2021
Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. Current neuropharmacology, 2021, Volume: 19, Issue:8 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Rivastigmine; Tacrine	2021
Revealing the cholinergic inhibition mechanism of Alzheimer's by galantamine: a metadynamics simulation study. Journal of biomolecular structure & dynamics, 2022, Volume: 40, Issue:11 Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Protons	2022
Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage. European journal of clinical pharmacology, 2021, Volume: 77, Issue:6 Topics: Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Galantamine; Global Health; Humans; Memantine; Product Surveillance, Postmarketing; Republic of Korea; Rivastigmine; Universal Health Care	2021
Integrating Narcissus-derived galanthamine production into traditional upland farming systems. Scientific reports, 2021, 01-14, Volume: 11, Issue:1 Topics: Alzheimer Disease; Animals; Crop Production; Galantamine; Humans; Narcissus; Sheep	2021
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study. Journal of Alzheimer's disease : JAD, 2021, Volume: 81, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Finland; Galantamine; Humans; Male; Memantine; Nootropic Agents; Nursing Homes; Retrospective Studies; Rivastigmine; Time-to-Treatment	2021
The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021, Volume: 17, Issue:5 Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Double-Blind Method; Female; Galantamine; Humans; Male; Nootropic Agents; Patient Reported Outcome Measures; Severity of Illness Index	2021
The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System. Journal of Alzheimer's disease : JAD, 2021, Volume: 83, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Female; Galantamine; Humans; Male; Nootropic Agents; Pneumonia; Rivastigmine; Sex Factors; United States; United States Food and Drug Administration	2021
New Galantamine Derivatives with Inhibitory Effect on Acetylcholinesterase Activity. Journal of Alzheimer's disease : JAD, 2021, Volume: 83, Issue:3 Topics: Alzheimer Disease; Animals; Antioxidants; Brain; Catalase; Cholinesterase Inhibitors; Galantamine; Glutathione Peroxidase; Humans; Lipid Peroxidation; Male; Memory; Mice; Mice, Inbred ICR; Oxidative Stress; Superoxide Dismutase	2021
Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2017, Volume: 13, Issue:10 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Double-Blind Method; Female; Galantamine; Goals; Humans; Indans; Male; Multicenter Studies as Topic; Outcome Assessment, Health Care; Piperidines; Severity of Illness Index	2017
Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse. Psychopharmacology, 2017, Volume: 234, Issue:15 Topics: Allosteric Regulation; Alzheimer Disease; Aniline Compounds; Animals; Cholinesterase Inhibitors; Galantamine; Male; Memory Disorders; Mice; Nicotinic Antagonists; Piperidines; Receptors, Nicotinic; Receptors, Serotonin, 5-HT4; Scopolamine; Serotonin 5-HT4 Receptor Agonists	2017
Assessing the binding of cholinesterase inhibitors by docking and molecular dynamics studies. Journal of molecular graphics & modelling, 2017, Volume: 76 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Hydrogen Bonding; Indans; Molecular Conformation; Molecular Dynamics Simulation; Piperidines; Rivastigmine; Torpedo	2017
Could delirium and anti-dementia drugs effect the treatment of agitated nursing home residents with Alzheimer dementia? Journal of the American Medical Directors Association, 2018, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Delirium; Donepezil; Female; Galantamine; Humans; Male; Nursing Homes; Prognosis; Psychomotor Agitation; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome	2018
rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine. Brain imaging and behavior, 2019, Volume: 13, Issue:1 Topics: Aged; Alzheimer Disease; Brain; Brain Mapping; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognitive Dysfunction; Cross-Sectional Studies; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Imaging, Three-Dimensional; Male; Regional Blood Flow; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2019
Galantamine inhibits β-amyloid-induced cytostatic autophagy in PC12 cells through decreasing ROS production. Cell proliferation, 2018, Volume: 51, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Autophagy; Cell Proliferation; Cytostatic Agents; Drug Evaluation, Preclinical; Galantamine; NADPH Oxidase 4; PC12 Cells; Peptide Fragments; Rats; Reactive Oxygen Species	2018
Hypothesis: apo-lactoferrin-Galantamine Proteo-alkaloid Conjugate for Alzheimer's disease Intervention. Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Apoproteins; Binding Sites; Brain; Disease Management; Galantamine; Glycoconjugates; Humans; Iron; Iron Chelating Agents; Lactoferrin; Models, Molecular; Neuroprotective Agents; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; tau Proteins	2018
Acceleration of NLRP3 inflammasome by chronic cerebral hypoperfusion in Alzheimer's disease model mouse. Neuroscience research, 2019, Volume: 143 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain Ischemia; Caspase 1; Cerebral Cortex; Cerebrovascular Circulation; Collagen; Disease Models, Animal; Galantamine; Inflammasomes; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein	2019
Acute cholinergic syndrome in a patient with Alzheimer's disease taking the prescribed dose of galantamine. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2018, Volume: 18, Issue:5 Topics: Aged, 80 and over; Alzheimer Disease; Atrophy; Brain; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Galantamine; Humans; Male; Syndrome; Tomography, X-Ray Computed	2018
Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Current drug delivery, 2019, Volume: 16, Issue:1 Topics: Acetylcholinesterase; Adhesiveness; Administration, Intranasal; Administration, Oral; Alzheimer Disease; Animals; Behavior, Animal; Biological Availability; Blood-Brain Barrier; Chitosan; Cholinesterase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Galantamine; Humans; Male; Maze Learning; Mice; Nanoparticles; Nasal Mucosa; Nootropic Agents; Piracetam; Scopolamine; Treatment Outcome	2019
Synthesis of New Galanthamine-Peptide Derivatives Designed for Prevention and Treatment of Alzheimer's Disease. Current Alzheimer research, 2019, Volume: 16, Issue:3 Topics: Alzheimer Disease; Animals; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Galantamine; Humans; Mice; Peptides	2019
Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease. International journal of molecular sciences, 2019, Feb-25, Volume: 20, Issue:4 Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Databases, Chemical; Donepezil; Drug Discovery; Galantamine; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Quantitative Structure-Activity Relationship; Sesquiterpenes	2019
Design of Natural-Product-Inspired Multitarget Ligands by Machine Learning. ChemMedChem, 2019, 06-18, Volume: 14, Issue:12 Topics: Acetylcholinesterase; Alzheimer Disease; Biological Products; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Drug Evaluation, Preclinical; Galantamine; Humans; Ligands; Machine Learning; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Stereoisomerism	2019
Development and in vitro evaluation of pressure sensitive adhesive patch for the transdermal delivery of galantamine: Effect of penetration enhancers and crystallization inhibition. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2019, Volume: 139 Topics: Adhesives; Administration, Cutaneous; Aged; Alzheimer Disease; Cadaver; Crystallization; Diffusion; Drug Carriers; Drug Evaluation, Preclinical; Drug Liberation; Female; Galantamine; Humans; Limonene; Male; Medication Adherence; Nootropic Agents; Oleic Acid; Permeability; Polymers; Pressure; Skin; Skin Absorption; Spectroscopy, Fourier Transform Infrared; Transdermal Patch	2019
Profiling of acetylcholinesterase inhibitory alkaloids from some Natural product research, 2021, Volume: 35, Issue:5 Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amaryllidaceae; Amaryllidaceae Alkaloids; Catalytic Domain; Cholinesterase Inhibitors; Computer Simulation; Crinum; Galantamine; Gas Chromatography-Mass Spectrometry; Humans; Molecular Docking Simulation; Multivariate Analysis; Plant Extracts; Plant Leaves; Plant Roots	2021
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease. American journal of Alzheimer's disease and other dementias, 2019, Volume: 34, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Donepezil; Female; Follow-Up Studies; Galantamine; Genotype; Hong Kong; Humans; Male; Pharmacogenetics; Pharmacogenomic Testing; Rivastigmine	2019
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres. PloS one, 2013, Volume: 8, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galantamine; Humans; Indans; Male; Medical Records; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Retrospective Studies; Rivastigmine; Sweden; Treatment Outcome	2013
Galantamine-associated nightmares and anxiety. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2013, Volume: 28, Issue:4 Topics: Aged, 80 and over; Alzheimer Disease; Anxiety; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Dreams; Galantamine; Humans; Male; Quality of Life; Recurrence	2013
Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors. International journal of geriatric psychiatry, 2013, Volume: 28, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Donepezil; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Humans; Indans; Interleukin-1beta; Interleukin-6; Male; Phenylcarbamates; Piperidines; Rivastigmine; Sex Factors; Tumor Necrosis Factor-alpha	2013
Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia. The journal of nutrition, health & aging, 2013, Volume: 17, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Body Weight; Caregivers; Cholinesterase Inhibitors; Female; Galantamine; Humans; Longitudinal Studies; Male; Netherlands; Retrospective Studies; Sex Factors; Weight Loss	2013
Acetylcholineestarase-inhibiting alkaloids from Lycoris radiata delay paralysis of amyloid beta-expressing transgenic C. elegans CL4176. PloS one, 2013, Volume: 8, Issue:5 Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Gene Expression; Humans; Longevity; Lycoris; Oxidative Stress; Paralysis; Peptide Fragments; Phenanthridines	2013
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy. Clinical interventions in aging, 2013, Volume: 8 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Home Care Services; Humans; Indans; Linear Models; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivastigmine; Treatment Outcome	2013
Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease. Journal of the American Geriatrics Society, 2013, Volume: 61, Issue:7 Topics: Aged; Alzheimer Disease; Area Under Curve; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2013
Effect of galantamine on platelet functions in healthy elderly people. The Indian journal of medical research, 2013, Volume: 137, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Cardiovascular Diseases; Female; Galantamine; Healthy Volunteers; Humans; Male; Platelet Aggregation	2013
In silico and in vitro studies to elucidate the role of Cu2+ and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process. Protein science : a publication of the Protein Society, 2013, Volume: 22, Issue:10 Topics: Alzheimer Disease; Amino Acid Sequence; Amino Acids; Amyloid; Amyloid beta-Peptides; Circular Dichroism; Copper; Galantamine; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Sequence Data; Peptide Fragments; Protein Folding; Protein Structure, Secondary; Spectrometry, Fluorescence	2013
Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors. Archiv der Pharmazie, 2013, Volume: 346, Issue:11 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Furocoumarins; Galantamine; Molecular Docking Simulation; Structure-Activity Relationship	2013
An over expression APP model for anti-Alzheimer disease drug screening created by zinc finger nuclease technology. PloS one, 2013, Volume: 8, Issue:11 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; BALB 3T3 Cells; Base Sequence; Cholinesterase Inhibitors; Deoxyribonucleases; DNA Cleavage; Donepezil; Drug Evaluation, Preclinical; Galantamine; Gene Expression; Genetic Engineering; Green Fluorescent Proteins; Homologous Recombination; Humans; Ibuprofen; Indans; Mice; Molecular Sequence Data; Peptide Fragments; Piperidines; Recombinant Proteins; Zinc Fingers	2013
Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. PloS one, 2014, Volume: 9, Issue:2 Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Female; Galantamine; Male; Maze Learning; Mice; Neurons; Plaque, Amyloid; Sex Factors	2014
Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study. International clinical psychopharmacology, 2014, Volume: 29, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Donepezil; Drug Monitoring; Drug Prescriptions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Finland; Follow-Up Studies; Galantamine; Guideline Adherence; Humans; Indans; Male; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Proportional Hazards Models; Registries; Rivastigmine	2014
[Dementia solved with surgery: report of a case]. Medicina clinica, 2015, Jan-20, Volume: 144, Issue:2 Topics: Alzheimer Disease; Consciousness Disorders; Delayed Diagnosis; Dementia; Diagnostic Errors; Diagnostic Imaging; False Negative Reactions; Female; Galantamine; Humans; Hyperinsulinism; Hypoglycemia; Insulinoma; Middle Aged; Nootropic Agents; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Weight Gain	2015
Medical Resource Value Appraisal for Leucojum aestivum in Turkey. American journal of Alzheimer's disease and other dementias, 2014, Volume: 29, Issue:5 Topics: Alzheimer Disease; Amaryllidaceae; Cholinesterase Inhibitors; Galantamine; Humans; Plants, Medicinal; Turkey	2014
New developments in redox chemical delivery systems by means of 1,4-dihydroquinoline-based targetor: application to galantamine delivery to the brain. European journal of medicinal chemistry, 2014, Jun-23, Volume: 81 Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Drug Delivery Systems; Galantamine; Humans; Molecular Structure; Oxidation-Reduction; Quinolines	2014
Cloning and characterization of a norbelladine 4'-O-methyltransferase involved in the biosynthesis of the Alzheimer's drug galanthamine in Narcissus sp. aff. pseudonarcissus. PloS one, 2014, Volume: 9, Issue:7 Topics: Alkaloids; Alzheimer Disease; Amino Acid Sequence; Cloning, Molecular; DNA, Complementary; Escherichia coli; Galantamine; Humans; Narcissus; Protein O-Methyltransferase	2014
FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease. Clinical interventions in aging, 2014, Volume: 9 Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Galantamine; Gene Frequency; Genetic Loci; Genotype; Haplotypes; Humans; Indans; Male; Oxidative Stress; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine	2014
Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. Journal of Alzheimer's disease : JAD, 2015, Volume: 45, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Galantamine; Humans; Indans; Japan; Male; Memantine; Neuropsychological Tests; Piperidines; Psychiatric Status Rating Scales	2015
Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiology and drug safety, 2015, Volume: 24, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Cross-Over Studies; Databases, Factual; Female; Follow-Up Studies; Galantamine; Humans; Longitudinal Studies; Male; Netherlands; Risk Factors; Rivastigmine; Treatment Outcome; Urinary Incontinence	2015
Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice. Journal of Alzheimer's disease : JAD, 2015, Volume: 46, Issue:1 Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cholinesterase Inhibitors; Conditioning, Psychological; Disease Models, Animal; Fear; Galantamine; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Muscle Strength; Mutation; Plaque, Amyloid; Presenilin-1; Prodrugs	2015
Interaction between anti-Alzheimer and antipsychotic drugs in modulating extrapyramidal motor disorders in mice. Journal of pharmacological sciences, 2015, Volume: 127, Issue:4 Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Interactions; Galantamine; Haloperidol; Hypokinesia; Indans; Male; Mice, Inbred Strains; Nootropic Agents; Piperidines; Receptor, Serotonin, 5-HT1A; Receptors, Muscarinic; Serotonin Agents	2015
Formulation and evaluation of galantamine gel as drug reservoir in transdermal patch delivery system. TheScientificWorldJournal, 2015, Volume: 2015 Topics: Administration, Cutaneous; Alzheimer Disease; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Galantamine; Gels; Humans; In Vitro Techniques	2015
Cognitive and affective benefits of combination therapy with galantamine plus cognitive rehabilitation for Alzheimer's disease. Geriatrics & gerontology international, 2016, Volume: 16, Issue:4 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognitive Behavioral Therapy; Female; Follow-Up Studies; Galantamine; Humans; Male; Physical Therapy Modalities; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome	2016
Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures. Molecular neurobiology, 2016, Volume: 53, Issue:5 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antioxidants; Cell Death; Galantamine; Hippocampus; Melatonin; Models, Biological; Neuroprotective Agents; Okadaic Acid; Phosphorylation; Protein Aggregates; Rats, Sprague-Dawley; tau Proteins; Tissue Culture Techniques	2016
Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer's disease. International journal of nanomedicine, 2015, Volume: 10 Topics: Administration, Cutaneous; Alzheimer Disease; Delayed-Action Preparations; Ethanolamines; Galantamine; Gels; Humans; Hydrogen-Ion Concentration; Models, Chemical; Polyvinyls; Reproducibility of Results; Software; Transdermal Patch	2015
Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 2016, Volume: 16, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apathy; Cholinesterase Inhibitors; Donepezil; Executive Function; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Piperidines; Prospective Studies; Tomography, Emission-Computed, Single-Photon	2016
Synthesis of New Peptide Derivatives of Galanthamine Designed for Prevention and Treatment of Alzheimer's Disease. Protein and peptide letters, 2015, Volume: 22, Issue:10 Topics: Alzheimer Disease; Animals; Galantamine; Humans; Mice; Peptides	2015
Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity. Bioorganic & medicinal chemistry, 2015, Sep-01, Volume: 23, Issue:17 Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Drug Design; Galantamine; Humans; Indoles; Liliaceae; Molecular Docking Simulation; Structure-Activity Relationship	2015
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:11 Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Galantamine; Humans; Indans; Male; Medication Errors; North America; Pharmacovigilance; Piperidines; Rivastigmine; World Health Organization	2015
Long-Term Efficacy of Galantamine in Alzheimer's Disease: The Okayama Galantamine Study (OGS). Journal of Alzheimer's disease : JAD, 2015, Volume: 47, Issue:3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Female; Galantamine; Humans; Japan; Male; Nootropic Agents; Psychiatric Status Rating Scales; Psychological Tests; Sex Factors; Time Factors; Treatment Outcome	2015
Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS). Journal of Alzheimer's disease : JAD, 2015, Volume: 46, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Japan; Male; Memantine; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome	2015
Galantamine attenuates amyloid-β deposition and astrocyte activation in APP/PS1 transgenic mice. Experimental gerontology, 2015, Volume: 72 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Disease Models, Animal; Galantamine; Hippocampus; Interleukin-6; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurogenesis; Tumor Necrosis Factor-alpha	2015
NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease. Current drug discovery technologies, 2015, Volume: 12, Issue:4 Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Disulfides; Drug Combinations; Galantamine; Humans; Levodopa; Plaque, Amyloid	2015
Real-world evaluation of compliance and preference in Alzheimer's disease treatment. Clinical interventions in aging, 2015, Volume: 10 Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Asia; Attitude of Health Personnel; Caregivers; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Memantine; Middle East; Patient Preference; Physicians; Piperidines; Prospective Studies; Rivastigmine	2015
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. PloS one, 2015, Volume: 10, Issue:12 Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Databases, Factual; Dementia; Donepezil; Galantamine; Humans; Indans; Pharmacovigilance; Piperidines; Rivastigmine; United States; United States Food and Drug Administration	2015
Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function. Acta cirurgica brasileira, 2015, Volume: 30, Issue:11 Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Laser-Doppler Flowmetry; Male; Memory Disorders; Mice, Inbred BALB C; Neuropsychological Tests; Neurovascular Coupling; Peptide Fragments; Quinuclidines; Recognition, Psychology; Reproducibility of Results; Time Factors; Treatment Outcome	2015
(I) Pharmacological profiling of a novel modulator of the α7 nicotinic receptor: Blockade of a toxic acetylcholinesterase-derived peptide increased in Alzheimer brains. Neuropharmacology, 2016, Volume: 105 Topics: Acetylcholinesterase; Allosteric Site; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; Cell Survival; Cholinesterase Inhibitors; Galantamine; Humans; Hydrogen Peroxide; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Peptides, Cyclic; Rats; tau Proteins; Tissue Culture Techniques	2016
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimer's research & therapy, 2016, Feb-17, Volume: 8 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Piperidines; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome	2016
Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management. Drug delivery, 2016, Volume: 23, Issue:8 Topics: Acetylcholinesterase; Administration, Intranasal; Alzheimer Disease; Animals; Brain; Chitosan; Drug Delivery Systems; Galantamine; Male; Nanoparticles; Neurons; Rats; Rats, Wistar	2016
Strong Impact of Chronic Cerebral Hypoperfusion on Neurovascular Unit, Cerebrovascular Remodeling, and Neurovascular Trophic Coupling in Alzheimer's Disease Model Mouse. Journal of Alzheimer's disease : JAD, 2016, 03-05, Volume: 52, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Cerebrovascular Disorders; Disease Models, Animal; Disease Progression; Galantamine; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Neuroprotective Agents; Neurovascular Coupling; Nootropic Agents; Receptors, Nicotinic	2016
Disruption of White Matter Integrity by Chronic Cerebral Hypoperfusion in Alzheimer's Disease Mouse Model. Journal of Alzheimer's disease : JAD, 2016, 04-12, Volume: 52, Issue:4 Topics: Alzheimer Disease; Animals; Ankyrins; Brain Ischemia; Cell Adhesion Molecules; Corpus Callosum; Disease Models, Animal; Galantamine; Male; Mice; Mice, Inbred C57BL; Myelin-Associated Glycoprotein; Nerve Growth Factors; Nootropic Agents; White Matter	2016
Ceria-containing uncoated and coated hydroxyapatite-based galantamine nanocomposites for formidable treatment of Alzheimer's disease in ovariectomized albino-rat model. Materials science & engineering. C, Materials for biological applications, 2016, Aug-01, Volume: 65 Topics: Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cerebral Cortex; Cerium; Chitosan; Chlorides; Disease Models, Animal; Drug Carriers; Durapatite; Dynamic Light Scattering; Female; Galantamine; Hippocampus; Nanocomposites; Ovariectomy; Rats; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction	2016
Chronic Cerebral Hypoperfusion Accelerates Alzheimer's Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model. Journal of Alzheimer's disease : JAD, 2016, 06-13, Volume: 53, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Carotid Stenosis; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Gene Expression Regulation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Models, Cardiovascular; Plaque, Amyloid; Postural Balance; Psychomotor Performance; Receptors, Nicotinic; White Matter	2016
The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors. Behavioural brain research, 2016, 10-15, Volume: 313 Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Galantamine; Male; Memantine; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic	2016
Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer's disease. Regenerative medicine, 2016, Volume: 11, Issue:7 Topics: Adrenergic beta-Agonists; Alzheimer Disease; Animals; Behavior, Animal; Cells, Cultured; Combined Modality Therapy; Galantamine; Inflammation Mediators; Isoproterenol; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Nanoparticles; Parasympathomimetics; Rats; Rats, Wistar	2016
In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease. Scientific reports, 2016, 09-09, Volume: 6 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Galantamine; Memantine; Mice; Mice, Transgenic; Peptide Fragments	2016
In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity. Molecular neurobiology, 2017, Volume: 54, Issue:8 Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Indans; Memantine; Mitochondria; Monoamine Oxidase; Nootropic Agents; Oxygen Consumption; Piperidines; Rivastigmine; Swine	2017
Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease. Annals of medicine, 2017, Volume: 49, Issue:3 Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Finland; Galantamine; Hospitalization; Humans; Indans; Male; Memantine; Middle Aged; Piperidines; Pneumonia; Risk; Rivastigmine	2017
Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease. Geriatrics & gerontology international, 2017, Volume: 17, Issue:11 Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Substitution; Galantamine; Humans; Retrospective Studies; Rivastigmine; Treatment Outcome	2017
Galantamine has impact on immunity in mice exposed to keyhole limpet hemocyanin. Bratislavske lekarske listy, 2017, Volume: 118, Issue:1 Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Animals; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Hemocyanins; Immunoglobulins; Inflammation Mediators; Macrophages; Mice; Mice, Inbred BALB C; Receptors, Nicotinic	2017
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching. Drugs & aging, 2017, Volume: 34, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Tolerance; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Piperidines; Rivastigmine	2017
Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity. Geriatrics & gerontology international, 2017, Volume: 17, Issue:11 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Male; Memantine; Nootropic Agents; Rivastigmine; Severity of Illness Index; Treatment Outcome; White Matter	2017
Galantamine-induced pisa syndrome: memantine as an alternative. International journal of geriatric psychiatry, 2008, Volume: 23, Issue:6 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dystonic Disorders; Female; Galantamine; Humans; Memantine; Syndrome	2008
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. Journal of managed care pharmacy : JMCP, 2008, Volume: 14, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Drug Costs; Female; Follow-Up Studies; Galantamine; Health Care Costs; Humans; Indans; Male; Multivariate Analysis; Patient Compliance; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Retrospective Studies; Rivastigmine	2008
[Galantamine]. Revue de l'infirmiere, 2008, Issue:143 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Contraindications; Drug Monitoring; Galantamine; Humans; Nootropic Agents; Nurse's Role; Patient Education as Topic; Patient Selection; Risk Factors	2008
The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:9 Topics: Aged; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Female; Galantamine; Health Status Indicators; Humans; Male; Risk Factors; Sleep; Sleep Wake Disorders; Thailand	2008
Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. Psychopharmacology, 2009, Volume: 202, Issue:1-3 Topics: Aged; Alzheimer Disease; Arousal; Azetidines; Cognition; Female; Fluorine Radioisotopes; Galantamine; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Nootropic Agents; Positron-Emission Tomography; Psychomotor Performance; Pyridines; Radiopharmaceuticals; Reaction Time; Receptors, Nicotinic; Space Perception	2009
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. International journal of geriatric psychiatry, 2009, Volume: 24, Issue:5 Topics: Aged; Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Female; Follow-Up Studies; Galantamine; Humans; Institutionalization; Long-Term Care; Male; Nursing Homes; Severity of Illness Index; Statistics as Topic; Time Factors; Treatment Outcome	2009
The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease. The Lancet. Neurology, 2009, Volume: 8, Issue:1 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Clinical Trials as Topic; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic	2009
Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain : a journal of neurology, 2009, Volume: 132, Issue:Pt 2 Topics: Aged; Alzheimer Disease; Area Under Curve; Biomarkers; Brain; Case-Control Studies; Cholinesterase Inhibitors; Citalopram; Drug Synergism; Female; Galantamine; Glucose; Humans; Male; Positron-Emission Tomography; Prolactin; Selective Serotonin Reuptake Inhibitors	2009
Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease. Electrophoresis, 2009, Volume: 30, Issue:4 Topics: Adult; Alzheimer Disease; Benzylamines; Buffers; Cholinesterase Inhibitors; Chromatography, Micellar Electrokinetic Capillary; Drug Monitoring; Galantamine; Humans; Male; Phenethylamines; Phenols; Phenylcarbamates; Phosphoric Acids; Reproducibility of Results; Rivastigmine; Sensitivity and Specificity; Solvents; Surface-Active Agents	2009
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:2 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine	2009
Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. The European journal of neuroscience, 2009, Volume: 29, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cells, Cultured; Cerebral Cortex; Cholinesterase Inhibitors; Cytoprotection; Dose-Response Relationship, Drug; Galantamine; Glutathione; Lipid Peroxidation; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Plaque, Amyloid; Rats	2009
An unusual case of nightmares with galantamine. Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:3 Topics: Aged; Alzheimer Disease; Delayed-Action Preparations; Disease Progression; Dreams; Galantamine; Humans; Male; Neuropsychological Tests; Nootropic Agents	2009
Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs & aging, 2009, Volume: 26, Issue:3 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Neuropsychological Tests; Randomized Controlled Trials as Topic; Treatment Outcome	2009
Bullous pemphigoid precipitated by galantamine hydrobromide. Cutis, 2009, Volume: 83, Issue:3 Topics: Aged; Alzheimer Disease; Diagnosis, Differential; Female; Galantamine; Humans; Nootropic Agents; Pemphigoid, Bullous	2009
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport, 2009, Feb-18, Volume: 20, Issue:3 Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Cytoprotection; Disease Progression; Donepezil; Drug Synergism; Drug Therapy, Combination; Female; Galantamine; Humans; Image Processing, Computer-Assisted; Indans; Magnetic Resonance Imaging; Male; Nerve Fibers, Myelinated; Neural Pathways; Neuroprotective Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2009
Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain research, 2009, Jul-14, Volume: 1280 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Ventricles; Cognition Disorders; Disease Models, Animal; Galantamine; Hippocampus; Injections, Intraventricular; Long-Term Potentiation; Male; Memory; Memory Disorders; Mice; Mice, Inbred C57BL; Neurotoxins; Nootropic Agents; Peptide Fragments	2009
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs & aging, 2009, Volume: 26, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Delayed-Action Preparations; Dementia; Donepezil; Follow-Up Studies; Galantamine; Humans; Indans; Medication Adherence; Phenylcarbamates; Piperidines; Rivastigmine	2009
Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease. International psychogeriatrics, 2009, Volume: 21, Issue:6 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Blood Glucose; Brain; Cholinesterase Inhibitors; Female; Galantamine; Geriatric Assessment; Humans; Insulin Resistance; Male; Mental Status Schedule; Nootropic Agents; Psychometrics	2009
Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. Journal of molecular neuroscience : MN, 2010, Volume: 40, Issue:1-2 Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Brain Chemistry; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Ferrets; Galantamine; Gastrointestinal Diseases; Humans; Mice; Scopolamine; Synaptic Transmission; Treatment Outcome	2010
International price comparisons of Alzheimer's drugs: a way to close the affordability gap. International psychogeriatrics, 2009, Volume: 21, Issue:6 Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Developing Countries; Donepezil; Drug Costs; Economics; Galantamine; Humans; Income; Indans; India; Memantine; Mexico; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United States	2009
Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients? Dementia and geriatric cognitive disorders, 2009, Volume: 28, Issue:3 Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Patient Compliance; Patient Satisfaction; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Rivastigmine; Socioeconomic Factors; Spain; Surveys and Questionnaires	2009
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:11 Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Galantamine; Heart Rate; Hospitals, Veterans; Humans; Incidence; Indans; Massachusetts; Nootropic Agents; Phenylcarbamates; Piperidines; Risk; Rivastigmine; Veterans	2009
Alzheimer's disease: Seeing the signs early. Journal of the American Academy of Nurse Practitioners, 2009, Volume: 21, Issue:11 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Primary Health Care; Psychometrics; Rivastigmine; Time Factors	2009
[The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2009, Volume: 109, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Data Interpretation, Statistical; Dementia, Vascular; Double-Blind Method; Female; Galantamine; Humans; Male; Middle Aged; Nootropic Agents; Placebos; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome	2009
Prescribing of drugs for Alzheimer's disease: a South African database analysis. International psychogeriatrics, 2010, Volume: 22, Issue:2 Topics: Aged; Alzheimer Disease; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Donepezil; Drug Prescriptions; Female; Galantamine; Humans; Indans; Male; Memantine; Nootropic Agents; Piperidines; Practice Patterns, Physicians'; Retrospective Studies; South Africa	2010
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS drugs, 2010, Volume: 24, Issue:2 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Genetic Variation; Genotype; Humans; Indans; Italy; Male; Outcome Assessment, Health Care; Phenylcarbamates; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome	2010
Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2010, Volume: 6, Issue:5 Topics: Alzheimer Disease; Analysis of Variance; Blood Cells; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Gene Expression Regulation; Genome-Wide Association Study; Humans; Indans; Microarray Analysis; Phenylcarbamates; Piperidines; Principal Component Analysis; Rivastigmine; RNA	2010
Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease. Dementia and geriatric cognitive disorders, 2010, Volume: 29, Issue:3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Drug Utilization; Female; Galantamine; Geriatric Assessment; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychotropic Drugs; Rivastigmine; Socioeconomic Factors	2010
Galantamine does not cause aggravated orthostatic hypotension in people with Alzheimer's disease. Journal of the American Geriatrics Society, 2010, Volume: 58, Issue:2 Topics: Aged; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Female; Galantamine; Hemodynamics; Humans; Hypotension, Orthostatic; Male; Netherlands; Syncope, Vasovagal	2010
Anticholinesterase duration in the Australian veteran population. The Australian and New Zealand journal of psychiatry, 2010, Volume: 44, Issue:5 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Medication Adherence; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Time Factors; Treatment Outcome; Veterans	2010
Comparative effectiveness research: an approach to avoiding "overgeneralized medicine". Clinical and translational science, 2009, Volume: 2, Issue:6 Topics: Alzheimer Disease; Clinical Trials as Topic; Comparative Effectiveness Research; Financing, Government; Galantamine; Healthcare Disparities; Humans; Treatment Outcome	2009
Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. The Gerontologist, 2011, Volume: 51, Issue:1 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Kaplan-Meier Estimate; Male; Middle Aged; Nursing Homes; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivastigmine; Severity of Illness Index; Sex Factors; Sweden	2011
The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease. Psychiatria Danubina, 2010, Volume: 22, Issue:2 Topics: Alzheimer Disease; England; Female; Follow-Up Studies; Galantamine; Humans; Mental Status Schedule; Middle Aged; Nootropic Agents; State Medicine	2010
Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Current medical research and opinion, 2010, Volume: 26, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Insurance Claim Review; Logistic Models; Male; Medication Adherence; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Predictive Value of Tests; Retrospective Studies; Rivastigmine; Treatment Outcome	2010
[Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease]. Neurologia (Barcelona, Spain), 2010, Volume: 25, Issue:4 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Observer Variation; Phenylcarbamates; Piperidines; Plant Extracts; Rivastigmine; Spain; Substance-Related Disorders	2010
Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study. Drugs & aging, 2010, Aug-01, Volume: 27, Issue:8 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Medication Adherence; Netherlands; Phenylcarbamates; Retrospective Studies; Rivastigmine	2010
Galantamine inhibits calpain-calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells. Neuroscience letters, 2010, Aug-23, Volume: 480, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Calcineurin; Calcineurin Inhibitors; Calpain; Cell Line, Tumor; Cholinesterase Inhibitors; Galantamine; Humans; Nerve Degeneration; Neuroblastoma; Peptide Fragments; Signal Transduction	2010
Prescribing trends in cognition enhancing drugs in Australia. International psychogeriatrics, 2011, Volume: 23, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Nootropic Agents; Piperidines; Practice Patterns, Physicians'; Sex Factors	2011
Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. The Journal of biological chemistry, 2010, Dec-17, Volume: 285, Issue:51 Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antibodies, Monoclonal; Binding Sites; Calcium Signaling; Calmodulin; Cells, Cultured; Choline; Cholinesterase Inhibitors; Disease Models, Animal; Female; Galantamine; Hippocampus; Humans; Male; Microglia; Nootropic Agents; Phagocytosis; Rats; Rats, Wistar; Receptors, Nicotinic	2010
Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany. Journal of medical economics, 2010, Volume: 13, Issue:4 Topics: Aged, 80 and over; Alzheimer Disease; Caregivers; Disease Progression; Female; Galantamine; Germany; Ginkgo biloba; Humans; Long-Term Care; Male; Models, Economic; Nootropic Agents; Severity of Illness Index	2010
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. Current Alzheimer research, 2011, Volume: 8, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Galantamine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome	2011
Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; Galantamine; Humans; Male; Middle Aged; Practice, Psychological; Psychiatric Status Rating Scales; Transcranial Magnetic Stimulation; Treatment Outcome	2011
Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide. Journal of pharmaceutical and biomedical analysis, 2011, Apr-28, Volume: 55, Issue:1 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Chromatography, High Pressure Liquid; Drug Stability; Galantamine; Hot Temperature; Hydrogen-Ion Concentration; Kinetics; Light; Magnetic Resonance Spectroscopy; Oxidation-Reduction; Photolysis; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism; Tandem Mass Spectrometry; Technology, Pharmaceutical	2011
Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability. International journal of geriatric psychiatry, 2011, Volume: 26, Issue:3 Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Multivariate Analysis; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine	2011
[Prescription differences of dementia drugs in urban and rural areas in Germany]. Psychiatrische Praxis, 2011, Volume: 38, Issue:5 Topics: Aged; Alzheimer Disease; Ambulatory Care; Donepezil; Galantamine; General Practice; Germany; Humans; Indans; Medically Underserved Area; Memantine; Neuropsychiatry; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Rivastigmine; Rural Population; Urban Population; Workforce	2011
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. European journal of clinical pharmacology, 2011, Volume: 67, Issue:11 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Cytochrome P-450 CYP2D6; Donepezil; Female; Galantamine; Genetic Association Studies; Genetic Variation; Genotype; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome	2011
Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. Pharmacology, biochemistry, and behavior, 2011, Volume: 99, Issue:3 Topics: Alzheimer Disease; Animals; Cholinergic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Electromyography; Galantamine; Jaw; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome; Tremor	2011
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. Prescrire international, 2011, Volume: 20, Issue:115 Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk; Rivastigmine	2011
Alkaloids from Hippeastrum papilio. Molecules (Basel, Switzerland), 2011, Aug-18, Volume: 16, Issue:8 Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Chromatography, Thin Layer; Galantamine; Humans; Liliaceae; Magnetic Resonance Spectroscopy; Plant Extracts; Plant Leaves	2011
Drugs for Alzheimer's disease. British journal of clinical pharmacology, 2012, Volume: 73, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Design; Excitatory Amino Acid Antagonists; Galantamine; Humans; Memantine; Plaque, Amyloid	2012
Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors. Journal of Alzheimer's disease : JAD, 2012, Volume: 30, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Catalase; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Glutathione Reductase; Humans; Indans; Male; Oxidative Stress; Phenylcarbamates; Piperidines; Rivastigmine	2012
[New anti-AD drugs--their possibilities and issues]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2012, Volume: 114, Issue:3 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; N-Methylaspartate; Phenylcarbamates; Rivastigmine	2012
Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease? American journal of Alzheimer's disease and other dementias, 2012, Volume: 27, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Heart; Humans; Indans; Male; Phenylcarbamates; Piperidines; Rivastigmine	2012
[Galantamine]. Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 10 Pt 2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans	2011
Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease. The Australian and New Zealand journal of psychiatry, 2013, Volume: 47, Issue:6 Topics: Alzheimer Disease; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Memantine; Middle Aged; Parasympathomimetics	2013
Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands. The American journal of geriatric pharmacotherapy, 2012, Volume: 10, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrioventricular Block; Cholinesterase Inhibitors; Cohort Studies; Cross-Over Studies; Databases, Factual; Female; Galantamine; Hospitalization; Humans; Incidence; Male; Netherlands; Phenylcarbamates; Poisson Distribution; Proportional Hazards Models; Risk; Rivastigmine; Syncope	2012
Protective effect of galantamine against oxidative damage using human lymphocytes: a novel in vitro model. Archives of medical research, 2013, Volume: 44, Issue:2 Topics: Alzheimer Disease; Apoptosis; Cell Culture Techniques; Cell Survival; Cells, Cultured; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Galantamine; Humans; Hydrogen Peroxide; Lymphocytes; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species	2013
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. PharmacoEconomics, 2002, Volume: 20, Issue:9 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clinical Trials as Topic; Cost of Illness; Disease Progression; Drug Costs; Galantamine; Health Care Costs; Health Services Needs and Demand; Health Services Research; Humans; Institutionalization; Long-Term Care; Models, Econometric; Nootropic Agents; Probability; Sensitivity and Specificity; Sweden	2002
Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dementia and geriatric cognitive disorders, 2002, Volume: 14, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Health Care Costs; Humans; Models, Economic; Netherlands; Nursing Homes; Prognosis; Severity of Illness Index	2002
Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, Sep-17, Volume: 99, Issue:19 Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antibodies; Choline O-Acetyltransferase; Cholinergic Agonists; Disease Models, Animal; Entorhinal Cortex; Galantamine; Humans; Mice; Mice, Knockout; Mice, Transgenic; Nerve Degeneration; Nerve Growth Factor; Phenotype; Phosphorylation; Recombinant Proteins; tau Proteins	2002
Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine. European journal of neurology, 2002, Volume: 9, Issue:5 Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Galantamine; Humans; Treatment Outcome	2002
Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months. International journal of clinical practice, 2002, Volume: 56, Issue:7 Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Chronic Disease; Clinical Trials, Phase III as Topic; Cognition; Female; Galantamine; Humans; Male; Nootropic Agents; Randomized Controlled Trials as Topic; Treatment Outcome	2002
The impact of journal advertisements on prescribers of cholinesterase inhibitors. International journal of geriatric psychiatry, 2002, Volume: 17, Issue:10 Topics: Advertising; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Publishing; Random Allocation; Rivastigmine	2002
Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease. PharmacoEconomics, 2002, Volume: 20, Issue:13 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Costs and Cost Analysis; Galantamine; Humans	2002
[Galantamine: a novel cholinergic agent for Alzheimer's disease]. Neurologia (Barcelona, Spain), 2002, Volume: 17, Issue:8 Topics: Acetylcholine; Allosteric Regulation; Alzheimer Disease; Cell Line; Cholinesterase Inhibitors; Cognition; Galantamine; Humans; Molecular Structure; Parasympathomimetics; Treatment Outcome	2002
Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. Dementia and geriatric cognitive disorders, 2003, Volume: 15, Issue:1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Galantamine; Humans; Interview, Psychological; Male; Middle Aged; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome	2003
Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease treated with galantamine. Annals of the New York Academy of Sciences, 2002, Volume: 977 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; Galantamine; Humans; Phytotherapy; Research Design; Time Factors	2002
Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Stroke, 2003, Volume: 34, Issue:2 Topics: Alzheimer Disease; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Piperidines; Severity of Illness Index; Terminology as Topic; Treatment Outcome	2003
Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in medicine, 2003, Mar-15, Volume: 22, Issue:5 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cognition; Computer Simulation; Data Interpretation, Statistical; Drug Approval; Galantamine; Humans; Research Design	2003
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office]. Fortschritte der Medizin. Originalien, 2002, Dec-05, Volume: 120, Issue:4 Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihydroergotoxine; Donepezil; Family Practice; Female; Follow-Up Studies; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nimodipine; Nootropic Agents; Phenylcarbamates; Piperidines; Piracetam; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Time Factors; Vasodilator Agents	2002
Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. Journal of clinical pharmacology, 2003, Volume: 43, Issue:5 Topics: Adult; Aged; Algorithms; Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Clinical Trials as Topic; Computer Simulation; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Liver Diseases; Male; Middle Aged; Models, Biological; Population; Reproducibility of Results; Sex Characteristics; Software	2003
Galantamine. The Israel Medical Association journal : IMAJ, 2003, Volume: 5, Issue:5 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Approval; Galantamine; Humans; Israel	2003
Clinical experience of galantamine in dementia: a series of case reports. Current medical research and opinion, 2003, Volume: 19, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Female; Galantamine; Humans; Male; Middle Aged; Nootropic Agents	2003
Galantamine vs donepezil in the treatment of Alzheimer's disease. Drugs & aging, 2003, Volume: 20, Issue:15 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Piperidines	2003
Pharmacologic treatment expectations in the management of dementia with Lewy bodies. Dementia and geriatric cognitive disorders, 2004, Volume: 17 Suppl 1 Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brain; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome	2004
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease. Journal of Alzheimer's disease : JAD, 2003, Volume: 5, Issue:6 Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine	2003
Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease. Prescrire international, 2003, Volume: 12, Issue:68 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; France; Galantamine; Humans; Indans; Piperidines; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Tacrine; Treatment Outcome	2003
A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease. International journal of clinical practice, 2004, Volume: 58, Issue:2 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Galantamine; Humans; Male; Middle Aged; Nootropic Agents; Treatment Outcome	2004
[Acetylcholinesterase inhibitors]. Revue medicale de la Suisse romande, 2003, Volume: 123, Issue:7 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Galantamine; Humans; Phenylcarbamates; Rivastigmine	2003
Drug therapy for Alzheimer's disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2004, Apr-27, Volume: 170, Issue:9 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans	2004
Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current medical research and opinion, 2004, Volume: 20, Issue:4 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dreams; Galantamine; Humans; Nootropic Agents; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders	2004
Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Current medical research and opinion, 2004, Volume: 20, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Female; Galantamine; Humans; Male; Mental Disorders; Middle Aged; Nootropic Agents; Switzerland	2004
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease. CNS spectrums, 2004, Volume: 9, Issue:7 Suppl 5 Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome	2004
Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs & aging, 2004, Volume: 21, Issue:10 Topics: Alzheimer Disease; Australasia; Canada; Cost-Benefit Analysis; Delivery of Health Care; Europe; Galantamine; Humans; Long-Term Care; Models, Economic; Placebos	2004
Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Molecular pharmacology, 2004, Volume: 66, Issue:3 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinergic Agents; Cholinesterase Inhibitors; Donepezil; Dopamine; Dose-Response Relationship, Drug; Galantamine; Indans; Mice; Piperidines; Receptors, Nicotinic	2004
Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2004, Volume: 115, Issue:10 Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Dementia; Electromagnetic Fields; Electromyography; Evoked Potentials, Motor; Female; Frontal Lobe; Functional Laterality; Galantamine; Humans; Male; Middle Aged; Neuroprotective Agents; Temporal Lobe	2004
Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:10 Topics: Aged; Alzheimer Disease; Botulinum Toxins, Type A; Cholinesterase Inhibitors; Cognition Disorders; Dystonia; Female; Galantamine; Humans; Neuromuscular Agents; Neuropsychological Tests; Severity of Illness Index; Syndrome	2004
Switching from donepezil or rivastigmine to galantamine in clinical practice. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:11 Topics: Alzheimer Disease; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine	2004
Not all head-to-head trials are created equal: results from an open-label, short-term study seem inconsistent with previous donepezil literature. International journal of geriatric psychiatry, 2005, Volume: 20, Issue:1 Topics: Aged; Alzheimer Disease; Caregivers; Cognition; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Piperidines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome	2005
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology, 2005, Volume: 180, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Male; Memantine; Mice; Mice, Mutant Strains; Phenylcarbamates; Piperidines; Rivastigmine; Sensitivity and Specificity	2005
Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells. Neuroscience letters, 2005, Dec-02, Volume: 389, Issue:2 Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Encephalitis; Furans; Galantamine; Glutathione; Humans; Inflammation Mediators; Interleukin-1; Lipopolysaccharides; Mitochondria; Neuroblastoma; Neurons; Neuroprotective Agents; Oxidative Stress; Platelet Activating Factor; Reactive Oxygen Species	2005
Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Excitatory Amino Acid Antagonists; Galantamine; Humans; Maze Learning; Memantine; Mice; Mice, Transgenic; Motor Activity; Neuropsychological Tests; Random Allocation; Reaction Time; Time Factors	2006
UK government guidance on Alzheimer's drugs postponed. Drug discovery today, 2005, Sep-01, Volume: 10, Issue:17 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Excitatory Amino Acid Antagonists; Federal Government; Galantamine; Government Regulation; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United Kingdom	2005
Galantamine in the treatment of vascular dementia. International psychogeriatrics, 2003, Volume: 15 Suppl 1 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Galantamine; Humans	2003
Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Current medical research and opinion, 2005, Volume: 21, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Caregivers; Cholinesterase Inhibitors; Europe; Female; Galantamine; Humans; Male; Middle Aged; Treatment Outcome	2005
Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. Brain : a journal of neurology, 2006, Volume: 129, Issue:Pt 1 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Chi-Square Distribution; Cholinesterase Inhibitors; Cognition Disorders; Female; Galantamine; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests	2006
Behavioral and neuropsychiatric outcomes in Alzheimer's disease. CNS spectrums, 2005, Volume: 10, Issue:11 Suppl 1 Topics: Aged; Alzheimer Disease; Brain; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Humans; Mental Disorders; Phenylcarbamates; Prevalence; Rivastigmine	2005
A case report of paranoid delusion with galantamine use. Journal of the American Geriatrics Society, 2005, Volume: 53, Issue:11 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Delusions; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Galantamine; Humans; Male; Paranoid Disorders; Recurrence	2005
An innovative approach to involve patients in measuring treatment effects in drug trials. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2006, Apr-11, Volume: 174, Issue:8 Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Endpoint Determination; Galantamine; Goals; Humans; Psychometrics; Randomized Controlled Trials as Topic; Treatment Outcome	2006
[Complete atrioventricular block during galantamine therapy]. Nederlands tijdschrift voor geneeskunde, 2006, Mar-11, Volume: 150, Issue:10 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Electrocardiography; Galantamine; Heart Block; Humans; Male; Pacemaker, Artificial	2006
[Use of reminyl (galantamine) in the treatment of dementia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2006, Volume: 106, Issue:3 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Female; Galantamine; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome	2006
Alzheimer's disease: beware of interactions with cholinesterase inhibitors. Prescrire international, 2006, Volume: 15, Issue:83 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Treatment Outcome	2006
Once-daily formulation of galantamine. Journal of the American Medical Directors Association, 2006, Volume: 7, Issue:5 Topics: Aged; Alzheimer Disease; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Delayed-Action Preparations; Galantamine; Humans; Nursing Homes; Patient Selection; Severity of Illness Index	2006
[Advances in Alzheimer's disease treatment]. La Revue de medecine interne, 2006, Volume: 27, Issue:8 Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine	2006
Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age and ageing, 2006, Volume: 35, Issue:4 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Cholinesterase Inhibitors; Cohort Studies; Comorbidity; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Piperidines; Retrospective Studies; Treatment Outcome	2006
[Pharmacotherapy of a patient with Alzheimer's disease: interactions with the antidementive galantamine]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:6 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Interactions; Female; Galantamine; Humans; Nootropic Agents	2006
[Cholinesterase inhibitor therapy in long term care settings]. La Revue de medecine interne, 2006, Volume: 27, Issue:8 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Follow-Up Studies; Galantamine; Humans; Indans; Long-Term Care; Neuroprotective Agents; Nootropic Agents; Patient Selection; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Time Factors	2006
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:7 Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Geriatric Psychiatry; Health Services for the Aged; Humans; Phenylcarbamates; Professional-Family Relations; Rivastigmine; Sesquiterpenes; Tacrine; United States	2006
Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis. The American journal of geriatric pharmacotherapy, 2006, Volume: 4, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Utilization; Female; Galantamine; Homes for the Aged; Humans; Indans; Male; Middle Aged; Nursing Homes; Phenylcarbamates; Piperidines; Polypharmacy; Retrospective Studies; Rivastigmine	2006
Galantamine extended release. CNS drugs, 2006, Volume: 20, Issue:8 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Administration Routes; Drug Administration Schedule; Galantamine; Humans; Inhibitory Concentration 50	2006
[Mortality-associated factors in patients with Alzheimer's disease treated with galantamine]. Medicina clinica, 2006, Jul-08, Volume: 127, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Retrospective Studies	2006
Adjuvant galantamine for cognitive dysfunction in a patient with bipolar disorder. Journal of psychiatric practice, 2006, Volume: 12, Issue:5 Topics: Alzheimer Disease; Antimanic Agents; Bipolar Disorder; Cholinesterase Inhibitors; Cognition Disorders; Diagnosis, Differential; Female; Galantamine; Humans; Middle Aged; Neuropsychological Tests; Severity of Illness Index	2006
In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology, 2006, Volume: 51, Issue:7-8 Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Bicuculline; Calcium Signaling; Cells, Cultured; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Drug Evaluation, Preclinical; Drug Synergism; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Galantamine; Glycine; In Vitro Techniques; Inhibitory Concentration 50; Memantine; Nerve Tissue Proteins; Neuroprotective Agents; Nicotinic Agonists; Patch-Clamp Techniques; Perfusion; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Strychnine; Synaptic Transmission; Therapeutic Irrigation	2006
[Complete atrioventricular block during galantamine therapy]. Nederlands tijdschrift voor geneeskunde, 2006, Apr-29, Volume: 150, Issue:17 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Heart Block; Humans; Quality of Life	2006
Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials. Drugs & aging, 2007, Volume: 24, Issue:1 Topics: Aged; Alzheimer Disease; Cognition Disorders; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Galantamine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nootropic Agents	2007
Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine. Age and ageing, 2007, Volume: 36, Issue:2 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Piperidines	2007
Galantamine and QTc prolongation. The Journal of clinical psychiatry, 2007, Volume: 68, Issue:1 Topics: Alzheimer Disease; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Galantamine; Humans; Long QT Syndrome; Schizophrenia; Sick Sinus Syndrome	2007
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl). Archives of gerontology and geriatrics, 2007, Volume: 44 Suppl 1 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Mental Disorders; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index	2007
Anti-Alzheimer drugs: life-threatening adverse effects. Prescrire international, 2007, Volume: 16, Issue:87 Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; France; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines	2007
Galantamine for Alzheimer's disease and mild cognitive impairment. Neuroepidemiology, 2007, Volume: 28, Issue:2 Topics: Alzheimer Disease; Cognition Disorders; Delayed-Action Preparations; Galantamine; Humans; Nootropic Agents; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome	2007
Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease. Magnetic resonance imaging, 2007, Volume: 25, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinergic Agents; Dementia; Female; Galantamine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parasympathomimetics; Reproducibility of Results	2007
Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 322, Issue:1 Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Atropine; Cells, Cultured; Choline; Corpus Striatum; Dopamine; Galantamine; Kynurenic Acid; Male; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic	2007
Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. International journal of geriatric psychiatry, 2008, Volume: 23, Issue:2 Topics: Aged; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Cognition; Disease Progression; Europe; Female; Follow-Up Studies; Galantamine; Humans; Logistic Models; Male; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome	2008
Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. International journal of geriatric psychiatry, 2008, Volume: 23, Issue:2 Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Assisted Living Facilities; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Administration Schedule; Female; Galantamine; Health Surveys; Homes for the Aged; Humans; Indans; Male; Mental Status Schedule; Neuropsychological Tests; Phenylcarbamates; Piperidines; Retention, Psychology; Rivastigmine; Survival Analysis; Treatment Outcome	2008
Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology, 2007, Aug-21, Volume: 69, Issue:8 Topics: Alzheimer Disease; Caregivers; Clinical Trials as Topic; Disability Evaluation; Galantamine; Humans; Memory Disorders; Neuropsychological Tests; Nootropic Agents; Outcome Assessment, Health Care; Quality of Life; Respiratory Tract Infections; Risk Assessment; Speech Disorders; Treatment Outcome; Verbal Behavior; Vomiting	2007
A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels. Journal of Alzheimer's disease : JAD, 2007, Volume: 11, Issue:3 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blinking; Cerebellum; Cholinesterase Inhibitors; Cognition Disorders; Conditioning, Classical; Disease Models, Animal; Galantamine; Hippocampus; Male; Neurons; Neuropsychological Tests; Rabbits; tau Proteins	2007
NICE judgement leaves behind a nasty taste. Nursing older people, 2007, Volume: 19, Issue:7 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Formularies as Topic; Galantamine; Humans; Indans; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Jurisprudence; Phenylcarbamates; Piperidines; Rivastigmine; State Medicine; Time Factors; United Kingdom	2007
[Alzheimer drugs for mild cognitive impairment]. Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater, 2007, Volume: 21, Issue:3 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Early Diagnosis; Galantamine; Humans; Memantine; Neuropsychological Tests; Nootropic Agents; Treatment Failure	2007
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease. Prescrire international, 2007, Volume: 16, Issue:91 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dystonia; France; Galantamine; Humans; Indans; Lewy Body Disease; Parkinson Disease; Phenylcarbamates; Piperidines; Tremor	2007
Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Stroke, 2007, Volume: 38, Issue:12 Topics: Acetylcholinesterase; Adult; Aged; Alzheimer Disease; Carbon Dioxide; Case-Control Studies; Cerebrovascular Disorders; Cholinesterase Inhibitors; Dementia, Vascular; Female; Galantamine; Humans; Male; Middle Aged; Nervous System; Spectroscopy, Near-Infrared; Ultrasonography, Doppler	2007
Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study. Psychiatry and clinical neurosciences, 2007, Volume: 61, Issue:6 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Behavior; Benzodiazepines; Cognition; Data Interpretation, Statistical; Dibenzothiazepines; Donepezil; Endpoint Determination; Female; Galantamine; Humans; Indans; Long-Term Care; Male; Neuropsychological Tests; Nootropic Agents; Olanzapine; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Retrospective Studies; Risperidone; Rivastigmine; Treatment Outcome	2007
For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? International psychogeriatrics, 2008, Volume: 20, Issue:2 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Piperidines; Severity of Illness Index; Treatment Outcome	2008
Treatment for MCI: is the evidence sufficient? Neurology, 2008, May-27, Volume: 70, Issue:22 Topics: Alzheimer Disease; Clinical Trials as Topic; Cognition Disorders; Galantamine; Humans	2008
Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. The Journal of pharmacology and experimental therapeutics, 1996, Volume: 277, Issue:2 Topics: Alzheimer Disease; Animals; Avoidance Learning; Body Temperature; Cholinesterase Inhibitors; Galantamine; Humans; Male; Mice; Rats; Rats, Sprague-Dawley; Rats, Wistar; Scopolamine	1996
[Neuroprotective therapy of Alzheimer's disease?]. Deutsche medizinische Wochenschrift (1946), 1996, Nov-29, Volume: 121, Issue:48 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Neuroprotective Agents; Physostigmine; Piracetam; Tacrine	1996
Evaluation of four Narcissus cultivars as potential sources for galanthamine production. Planta medica, 1997, Volume: 63, Issue:5 Topics: Alzheimer Disease; Galantamine; Humans; Plant Roots; Plants, Medicinal	1997
Enantiomeric resolution of galanthamine and related drugs used in anti-Alzheimer therapy by means of capillary zone electrophoresis employing derivatized cyclodextrin selectors. Journal of chromatography. B, Biomedical sciences and applications, 1999, Jul-09, Volume: 730, Issue:2 Topics: Alzheimer Disease; Electrophoresis, Capillary; Galantamine; Galanthus; Humans; Nootropic Agents; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism	1999
Capillary zone electrophoresis determination of galanthamine in biological fluids and pharmaceutical preparatives: experimental design and artificial neural network optimization. Electrophoresis, 1999, Volume: 20, Issue:10 Topics: Alzheimer Disease; Body Fluids; Cholinesterase Inhibitors; Electrophoresis, Capillary; Galantamine; Humans; Hydrogen-Ion Concentration; Neural Networks, Computer; Pharmaceutical Preparations; Regression Analysis; Reproducibility of Results	1999
Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. European journal of pharmacology, 2000, Mar-30, Volume: 393, Issue:1-3 Topics: Allosteric Regulation; Alzheimer Disease; Animals; Cells, Cultured; Cholinergic Agents; Cholinesterase Inhibitors; Cognition; Galantamine; Humans; Learning; Neurotransmitter Agents; PC12 Cells; Rats; Receptors, Nicotinic	2000
The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease. International journal of geriatric psychiatry, 2000, Volume: 15, Issue:7 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Clinical Trials as Topic; Female; Galantamine; Humans; Male; Mental Status Schedule; Middle Aged; Nootropic Agents; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Sensitivity and Specificity; Tacrine	2000
Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease. Behavioural brain research, 2000, Volume: 113, Issue:1-2 Topics: Age Factors; Alzheimer Disease; Animals; Association Learning; Cholinesterase Inhibitors; Conditioning, Classical; Conditioning, Eyelid; Disease Models, Animal; Female; Galantamine; Humans; Mental Recall; Nootropic Agents; Rabbits; Receptors, Nicotinic	2000
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:10 Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine; Tacrine	2000
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:11 Topics: Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine	2000
[Treatment of the elderly dementia patients]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2000, Volume: 37, Issue:11 Topics: Aged; Alzheimer Disease; Benzazepines; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Piperidines; Tacrine; Trichlorfon	2000
FDA approves galantamine for Alzheimer's disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, Apr-15, Volume: 58, Issue:8 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Approval; Galantamine; Humans; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration	2001
Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Introduction. Clinical therapeutics, 2001, Volume: 23 Suppl A Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans	2001
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Clinical therapeutics, 2001, Volume: 23 Suppl A Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Sleep	2001
Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Clinical therapeutics, 2001, Volume: 23 Suppl A Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Administration Schedule; Galantamine; Humans; Indans; Piperidines	2001
Switching previous therapies for Alzheimer's disease to galantamine. Clinical therapeutics, 2001, Volume: 23 Suppl A Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans	2001
Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers. Clinical therapeutics, 2001, Volume: 23 Suppl A Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans	2001
Pharmacokinetic rationale for switching from donepezil to galantamine. Clinical therapeutics, 2001, Volume: 23 Suppl A Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Models, Biological; Piperidines	2001
Meeting the challenges of vascular dementia. Introduction. International journal of clinical practice. Supplement, 2001, Issue:120 Topics: Alzheimer Disease; Dementia, Vascular; Galantamine; Humans; Nootropic Agents	2001
Galantamine (reminyl) for Alzheimer's disease. The Medical letter on drugs and therapeutics, 2001, Jun-25, Volume: 43, Issue:1107 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Diarrhea; Dizziness; Dose-Response Relationship, Drug; Galantamine; Humans; Nausea; Vomiting	2001
Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking. Journal of molecular graphics & modelling, 2001, Volume: 19, Issue:3-4 Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Catalytic Domain; Cholinesterase Inhibitors; Computer Simulation; Crystallography, X-Ray; Galantamine; Humans; Models, Molecular; Molecular Conformation; Nootropic Agents; Protein Conformation; Software; Torpedo	2001
Featured CME topic: dementia. Medication update. Southern medical journal, 2001, Volume: 94, Issue:7 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Contraindications; Donepezil; Drug Interactions; Ergoloid Mesylates; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plants, Medicinal; Rivastigmine	2001
Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology, 2001, Sep-25, Volume: 57, Issue:6 Topics: Aged; Aged, 80 and over; Alzheimer Disease; Canada; Clinical Trials as Topic; Cost Control; Disease Progression; Female; Galantamine; Health Services Needs and Demand; Humans; Long-Term Care; Male; Models, Economic; Nootropic Agents	2001
The snowdrop (Galanthus nivalis): from Odysseus to Alzheimer. Proceedings of the Royal College of Physicians of Edinburgh, 1999, Volume: 29, Issue:4 Topics: Alzheimer Disease; Botany; Folklore; Galantamine; Galanthus; History, Ancient; History, Modern 1601-; Humans	1999
Maintaining cognitive function in Alzheimer disease: how effective are current treatments? Alzheimer disease and associated disorders, 2001, Volume: 15 Suppl 1 Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Galantamine; Humans; Neuropsychological Tests; Nootropic Agents; Treatment Outcome	2001
Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer disease and associated disorders, 2001, Volume: 15 Suppl 1 Topics: Acetylcholine; Activities of Daily Living; Aged; Alzheimer Disease; Animals; Brain; Clinical Trials as Topic; Galantamine; Humans; Neuropsychological Tests; Nootropic Agents; Receptors, Nicotinic	2001
Maintaining functional and behavioral abilities in Alzheimer disease. Alzheimer disease and associated disorders, 2001, Volume: 15 Suppl 1 Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Treatment Outcome	2001
Galantamine hydrobromide. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, Nov-15, Volume: 58, Issue:22 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Interactions; Galantamine; Humans	2001
Unsafe prescription medication switching recommendations. Clinical therapeutics, 2001, Volume: 23, Issue:12 Topics: Alzheimer Disease; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Nootropic Agents; Piperidines	2001
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]. MMW Fortschritte der Medizin, 2001, Dec-13, Volume: 143, Issue:51-52 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Confidence Intervals; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Rivastigmine	2001
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease. Prescrire international, 2001, Volume: 10, Issue:56 Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; France; Galantamine; Indans; Tacrine; Treatment Outcome	2001
Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. Journal of clinical pharmacology, 2002, Volume: 42, Issue:4 Topics: Adolescent; Adult; Aged; Alzheimer Disease; Analysis of Variance; Area Under Curve; Cholinesterase Inhibitors; Female; Galantamine; Humans; Liver Diseases; Male; Middle Aged; Protein Binding; Statistics, Nonparametric	2002
Galantamine for vascular dementia: some answers, some questions. Lancet (London, England), 2002, Apr-13, Volume: 359, Issue:9314 Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia, Vascular; Galantamine; Humans; Treatment Outcome	2002
Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. European journal of clinical pharmacology, 1990, Volume: 39, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Galantamine; Humans; Male; Stereoisomerism; Structure-Activity Relationship	1990
Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life sciences, 1990, Volume: 46, Issue:21 Topics: Administration, Oral; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Erythrocytes; Galantamine; Galanthus; Humans; In Vitro Techniques	1990